RePORT India...RePORT INDIA OVERVIEW 2 Parent Protocol data and samples at their respective India-based institutions. Below are the CRUs and their Parent Protocols: 1. BMMRC and U

RePORT India 7TH ANNUAL JOINT LEADERSHIP MEETING CATALYZING DISCOVERIES TOWARD TB ELIMINATION

15–17 FEB 2018

Hosted by Government of India, Department of Biotechnology International Centre for Genetic Engineering and Biotechnology (ICGEB)

Aruna Asaf Ali Marg, Jawaharlal Nehru University

New Delhi, Delhi 110067, INDIA

Key Partners

Bhagwan Mahavir Medical Research Center (BMMRC)

Byramjee Jeejeebhoy Government

Medical College (BJGMC)

Boston University/Boston Medical Center (BU/BMC)

Christian Medical College, Vellore

(CMC)

CRDF Global

Jawaharlal Institute of Postgraduate Medical Education

and Research (JIPMER)

Johns Hopkins University (JHU)

M. Viswanathan Diabetes Research Center (MVDRC)

National Institute for Research In

Tuberculosis (NIRT)

PD Hinduja Hospital

PPD

RePORT International

Coordinating Center (RICC)

Rutgers University

University of Cambridge

University of Massachusetts (UMass)

University of Texas Health Science

Center at Tyler

Contents prepared February 2018

Contents

RePORT India Overview .......................................................................................... 1

Data Tables Available Upon Request

Young Investigator Abstracts .................................................................................. 4

Publications ............................................................................................................... 19

Lectures & Presentations......................................................................................... 27

Grants & Substudies ................................................................................................. 38

Conference Agenda .................................................................................................. 45

Speaker Biographies ................................................................................................. 51

This page is intentionally blank

RePORT India

Overview

RePORT India 7TH ANNUAL JOINT LEADERSHIP MEETING CATALYZING DISCOVERIES TOWARD TB ELIMINATION NEW DELHI | 15–17 FEB 2018


RePORT INDIA OVERVIEW

1

BACKGROUND RePORT India (Regional Prospective Observational Research for Tuberculosis (TB)) is a bilateral, multi-

organizational, collaborative research effort established in 2013 under the Indo-US Vaccine Action Program

(VAP). The consortium aims to address the threat of TB to the people of India and across the globe, a disease

which also poses an increased risk for persons living with HIV or other immunocompromised conditions.

RePORT India is one of six regional consortia—China, Brazil, Indonesia, Philippines, and South Africa are also

undertaking multi-organizational TB research efforts. Each RePORT consortium is designed to support in-

country data collection, specimen biorepositories, and associated research with the goal of adding additional

regional consortia to encourage worldwide TB prevention and treatment research.

RePORT INDIA MISSION RePORT India is charged with:

1. Advancing regional TB science in India;

2. Strengthening TB research capacity and infrastructure; and

3. Fostering research collaboration within India and with other countries with an aim of carrying out a wide

range of basic and clinical research that can lead to clinically important biomarkers, vaccines, drugs, and

diagnostics.

COHORT RESEARCH UNITS (CRUs) RePORT India consists of six distinct TB Cohort Research Units (CRUs) at seven Indian clinical sites located in

Western and Southern India. Each CRU is partnered with a US-based Principal Investigator (PI) and an academic

institution. CRUs consist of one or more clinical sites where participants are enrolled and where data and

samples are collected for research. There are two prospective observational cohorts of participants from whom

specimens are collected:

Cohort A: Participants who have active pulmonary TB. Studies involving this cohort of patients focus

on TB diagnosis and treatment outcomes.

Cohort B: Participants who are household contacts (HHCs) of an active case of TB. Studies involving

this cohort of patients focus on risk of infection and TB disease after exposure.

COMMON PROTOCOL (RePORT INDIA-WIDE OBJECTIVE) All CRUs collaborate to implement a RePORT India Common Protocol to establish an Indian biorepository of

well-characterized and standardized specimens with associated clinical data for future TB research. The

Common Protocol was launched in April 2017. The central repository for specimen storage is located at the

National Institute of Research in Tuberculosis (NIRT) in Chennai, a statistical and data management center is

housed at the Society for Applied Studies (SAS)-Centre for Health Research and Development (CHRD) in New

Delhi, and a US coordination and support center is located at PPD.

The primary objective of the Common Protocol is to collect specimens and make them available to Indian

biomarker researchers and collaborators over the next decade to achieve a better understanding of: 1) the

prognosis of TB disease; and 2) the pathogenesis of progression from TB exposure to disease.

PARENT PROTOCOLS (CRU-SPECIFIC OBJECTIVES) Prior to commencing the Common Protocol, and as early as 2014, CRUs began implementing individual “Parent

Protocols” with distinct research objectives. Each CRU is connected to one or more laboratories where

samples are processed for storage and specified for both protocol and future testing. The CRUs house their


2

Parent Protocol data and samples at their respective India-based institutions. Below are the CRUs and their

Parent Protocols:

1. BMMRC and U of Texas, Tyler

Study: Immunologic Markers of Persons at Highest Risk of Progression of Latent TB Infection to TB

India PI: Dr. Vijaya Valluri, Bhagawan Mahavir Medical Research Centre (BMMRC), Hyderabad, India

US PI: Dr. Krishna Vankayalapati, University of Texas Health Science Center, Tyler, TX, USA

Participating Patient Cohort: Cohort B

2. BJGMC, NIRT, and JHU

Study: Host and Microbial Factors Associated with Poor Treatment Response and Progression to

Active TB (C-TRIUMPH)

India PIs: Drs. Vidya Mave, Shashikala Sangle, and Sanjay Gaikwad, Byramjee Jeejeebhoy Government

Medical College (BJGMC), Pune, India and Dr. Padma Chandrasekaran, National Institute for Research in

TB (NIRT), Chennai, India

US PI: Dr. Amita Gupta, Johns Hopkins University, Baltimore, MD, USA

Participating Patient Cohorts: Cohort A (Adult Pulmonary TB, Pediatric TB, and Extrapulmonary

TB) and Cohort B

3. CMC Vellore and U of Wash/U of Cambridge

Topic Study: Host Determinants in the Eicosanoid Pathway that Modulate the Inflammatory Response,

Disease Outcome, and Treatment Responsiveness in TB

India PI: Dr. DJ Christopher, Christian Medical College (CMC), Vellore, India

US PI: Dr. Lalitha Ramakrishnan, University of Washington/University of Cambridge, UK

Participating Patient Cohort: Cohort A (Adult Pulmonary TB and TB Meningitis)

4. Hinduja and JHU

Topic of Study: MDR-TB Treatment Outcomes, Adverse Effects, Mtb Genotyping, and

Pharmacokinetic Testing

India PIs: Drs. Zarir F. Udwadia, Tester F. Ashavaid, and Camilla Rodrigues; PD Hinduja Hospital,

Mumbai, India

US PI: Dr. Amita Gupta, Johns Hopkins University, Baltimore, MD, USA

Participating Patient Cohorts: Cohort A (Adult/Adolescent MDR-TB) and Cohort B

5. JIPMER, BMC, and Rutgers

Topic of Study: Biomarkers for Risk of TB and for TB Treatment Failure and Relapse

India PIs: Drs. Subhash Parija, Gautam Roy, and Sonali Sarkar, Jawaharlal Institute of Postgraduate

Medical Education and Research (JIPMER), Puducherry, India

US PI: Dr. Jerrold Ellner, Boston Medical Center (BMC), Boston, MA, USA, and Dr. Padmini Salgame,

Rutgers University, Bridgeton, NJ, USA

Participating Patient Cohorts: Cohort A (Adult Pulmonary TB and Pediatric TB) and Cohort B

6. MVDRC and UMass

Topic of Study: Effects of Diabetes and Prediabetes on TB Severity

India PI: Dr. Vijay Viswanathan, MV Diabetes Research Centre (MVDRC), Chennai, India

US PI: Dr. Hardy Kornfeld, University of Massachusetts Medical School, Boston, USA

Participating Patient Cohort: Cohort A (Adult Pulmonary TB)


3

RePORT INDIA SUBTUDIES

A complete list of RePORT-related grants and substudies can be found on page 53 of this booklet. Consortium-

wide RePORT India studies include:

1. TST Comparison Study

The consortium received funding to conduct a TST comparison study with PIs Dr. DJ Christopher and Andrea

DeLuca, MHS. The study objective is to compare the performance of latent TB diagnostics PPD and Quantiferon

(QFT) among populations of interest, including children and immunocompromised adults. This study began in

spring 2016.

2. TB Vaccine Trial

The consortium is collaborating with Serum Institute of India Pvt. Ltd. (SIIPL) and VPM, Germany, on a multicenter

phase III double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of VPM1002, a new

recombinant BCG vaccine, in the prevention of TB recurrence in HIV uninfected adults after successful pulmonary

TB Treatment in India. The study began in January 2018.

RePORT INDIA ADMINISTRATION The RePORT India Consortium’s primary governance body is the Executive Committee, whose mission is to:

Set research priorities for the consortium and guide scientific activities;

Ensure coordination of TB research; and

Provide administrative and logistics support.

The consortium is currently governed by Dr. D.J. Christopher (India Chair), Dr. Vijaya Valluri (India Co-Chair),

Dr. Amita Gupta (US Chair), and Dr. Hardy Kornfeld (US Co-Chair). The Executive Committee convenes a

monthly teleconference. The consortium has several active working groups including: Operations, Basic Science,

Clinical Epidemiology, Behavioral Science, and Data Management. The Common Protocol leadership also

convene on a monthly basis. Consortium operations are facilitated by a RePORT India Coordinator located in

India in Chennai and a US Secretariat located in the US at Johns Hopkins University.

FUNDING The RePORT Indian Consortium is supported with funding from the Government of India’s (GOI) Department

of Biotechnology (DBT) as the primary GOI sponsor, the Indian Council of Medical Research (ICMR), and the

US National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID), Division

of AIDS (DAIDS), and Office of AIDS Research (OAR). CRDF Global administers and oversees the funding from

the US government. Supplemental funding through RePORT has been made available in 2016-2017 with

additional awards forthcoming in 2018.

Data Available Upon Request

Young Investigator

Abstracts


YOUNG INVESTIGATOR ABSTRACTS

4

Poster

Number Title

Presenter/

Submitting Author

Bhagwan Mahavir Medical Center 1 NK Cells and Memory-like NK Cells as Immunological Markers of

Protection against Latent TB Conversion in Household Contacts of TB

Patients

Devalraju Kamakshi

Prudhula

2 CD14+ CD16+ cells as Immunological Marker for Protection in

Household Contacts with Latent Tuberculosis Infection

Venkata Sanjeev Kumar

Neela

Byramjee Jeejeebhoy Government Medical College 3 Interleukin-6, Interleukin-13 and Interferon-γ as Potential Biomarkers for

Treatment Failure in Pulmonary Tuberculosis

Akshay Gupte

4 Poor Understanding of TB Infection among At-risk Tuberculin Skin-test

Positive Household Contacts of Pulmonary TB Cases in Pune, India

Gauri Dhamal

5 Incidence of Mycobacterium Tuberculosis Infection among Household

Contacts of Adult Pulmonary Tuberculosis Cases in India

Mandar Paradkar

N/A The Effect of HIV on the Immune Response to Myobacterium

Tuberculosis in Pregnant Women from Pune, India

Jyoti Mathad

N/A Drug Susceptibility of Rifampin-resistant Tuberculosis using Whole

Genome Sequencing to Identify Genes of Interest in Pune, India

Jeff Tornheim

Christian Medical College Vellore 6 Profile of Indian Patients with Tubercular Meningitis in the CMC, Vellore

Cohort

Samuvel S.

7 Are non-Tuberculous Disorders being Treated as Smear Negative

Pulmonary Tuberculosis?

Allan Deepak Ilangovan/

Samuvel S.

8 Factors Affecting Time to Sputum Smear and Culture Conversion in

Adults with Pulmonary Tuberculosis: A Prospective Cohort Study from

CMC RePORT Data

Deepa Shankar

N/A Prevalence of Latent TB Infection (LTBI) among Undergraduate Nursing

Trainees in a Rural Secondary Care Hospital in Southern India

Allan Deepak Ilangovan

Jawaharlal Institute of Postgraduate Medical Education and Research 9 Effect of Malnutrition on Tuberculosis Mycobacterial Burden and Chest

Radiographic Findings

Kacie Hoyt

10 Alcohol Use and Clinical Presentation of Tuberculosis at Time of

Diagnosis in Puducherry and Tamil Nadu, India

Megan Forsyth

11 Evaluation of Factors Influencing Mycobacterium Tuberculosis Complex

Recovery and Contamination Rates in MGIT 960

Kalaiarasan Ellappan

N/A Influence of Type of Tobacco Product on Chest X-ray findings in

Pulmonary Tuberculosis Patients in India

Nicole Schenk

N/A Wood Fuel Usage Is Associated with a Higher Leukocyte Count in

Pulmonary Tuberculosis Patients

Divya Reddy

M. Viswanathan Diabetes Research Centre 12 Effect of Anti-tuberculosis Treatment on the Systemic Levels of Tissue

Inhibitors of Metalloproteinases in Tuberculosis–Diabetes Co-morbidity

Kadar Moideen

13 Effect of Standard Tuberculosis Treatment on Circulating Levels of

Monocyte Activation Markers and RAGE Ligands in Tuberculosis–

Diabetes Co-morbidity

Pavan Kumar

14 Impact of Metformin Use on TB Severity in Diabetes Basavaradhya S. Shruthi

National Institute for Research on Tuberculosis 15 Risk Factors Associated with Unfavorable Outcomes in a Cohort of

Pulmonary TB Patients

Kavitha Dhanasekaran


5

Poster

Number Title

Presenter/

Submitting Author

PD Hinduja Hospital 16 Implications of Acetylator Genotype on Plasma Rifampicin and Isoniazid

Levels

Ishita Gajjar/

Prerna K. Chawla

17 Linezolid Experience among MDR-TB Patients in Mumbai Jeff Tornheim

POSTER 1: NK Cells and Memory-like NK Cells as Immunological Markers of Protection

against Latent TB Conversion in Household Contacts of TB Patients Authors: Devalraju KP, Neela VSK, Chaudhury A, Vankayalapati R, Valluri VL

Background: House hold contacts (HHCs) of TB patients are at an increased risk of developing LTBI (Latent

TB Infection) because of their continuous exposure to the bacteria. With new candidate vaccines aimed at

either prevention of infection (POI) or prevention of disease (POD), there is a need for biomarkers and

correlates of protection. Identification of immune biomarkers and correlates of protection would allow focused

immunoprophylaxis to persons with increased risk. We determined if biomarkers can predict development of

LTBI in these individuals.

Subjects: Individuals living with TB cases for at least 6 months from the date of diagnosis were enrolled as

HHCs. Study was approved by institutional ethical committee. HHCs were screened for HIV and an in-house

QuantiFERON test was performed to determine latent TB. Subjects were evaluated after every 4 months for 2

years.

Results: These observations were made regarding IL-17 levels in stimulated culture supernatants The baseline

levels in LTBI- HHCs who converted to LTBI+ during follow-up were significantly high compared to those who

did not (p=0.02, n=25). (b) The levels were high in LTBI+ HHCs who did not develop active tuberculosis when

compared to those who did (p=0.01, n=6). Baseline CD16+CD56+ and CD3-CD56+CD27+CCR7+ cell

numbers were significantly high in LTBI- individuals who never converted to LTBI+ compared to those did

(p=0.002, n=15).

Conclusion: High IL-17 production at baseline by T-cells from HHCs who convert to latent or active TB

indicates an ongoing inflammation and can be used as an early marker of conversion to latent/ active TB. We

also could demonstrate differences in memory like NK cell percentages as potential markers of protection and

might serve as a tool to identify individuals at risk for conversion and in need for immuno-prophylaxis. Future

studies include determining the mechanisms involved in expansion of the above identified cell population using

microarray, multiplex and siRNA technologies.

POSTER 2: CD14+ CD16+ cells as Immunological Marker for Protection in Household

Contacts with Latent Tuberculosis Infection Submitting Author: Venkata Sanjeev Kumar Neela

Background: One-third of the global population is estimated to have Latent TB Infection (LTBI). Biomarkers

can be used to identify both; persons who are at great risk for development of active TB disease and those who

are resistant to TB having significant exposure. Monocytes play a pivotal role as cellular component of the innate

immune response also influence the process of adaptive immunity due to their role in antigen presentation. The

CD14+CD16+ cells were found to secrete pro-inflammatory cytokines for arresting bacterial growth and


6

activation of T cells. Monitoring these cells with the cytokines levels in HHCs would be informative and

indicative of either TB protection or progression. HIV negative household contacts (HHCs) of active pulmonary

TB patients visiting clinics of Mahavir hospital and LEPRA were enrolled for the study after written and informed

consent.

Methods: PBMCs from the venous blood (20ml) were isolated by density gradient centrifugation.

Immunophenotyping of circulating CD14+CD16+ cells was performed by flow cytometry. PBMCs were cultured

with CFP10+ESAT6 antigens for 96 hours. The IFN-γ levels in culture supernatants were assessed by ELISA and

the levels were used to determining latency. Above experiments were repeated after every 4 months for 2

years.

Results: The baseline CD14+CD16+ cells were significantly high (p=0.03) in non-progressors (HHCs who

remained LTBI+ on follow up) when compared to TB progressors (HHCs who progressed to active TB on

follow up) (fig. 1a). PBMCs from non progressors expressed significantly lower levels of CFP+ESAT6 specific

IFN-γ (p=0.003) when compared to TB progressors at baseline. The levels of IFN-γ significantly increased in

non-progressors (p=0.0004) and decreased (p=0.01) in TB progressors on follow up (fig 1b). Conclusion: High

percentages of CD14+CD16+ cells in non progressors indicates robust innate immune system and can be used

as an immune correlate of protection against TB in high risk HHCs.

POSTER 3: Interleukin-6, Interleukin-13 and Interferon-γ as Potential Biomarkers for Treatment Failure in Pulmonary Tuberculosis Authors: Gupte A, Andrade B, Kumar P, Selvaraju S, Lokhande R, Kulkarni V, Paradkar M, Kohli R, Thiru K, Shivakumar

SVBY, Gupte N, Babu S, Golub J, Mave V, Chandrasekaran P, Gupta A

Background: Biomarkers are needed for the early identification of tuberculosis cases at risk of treatment

failure.

Methods: New adult (>18 years) drug-sensitive pulmonary tuberculosis cases were enrolled at or within 1

week of treatment initiation and, prospectively evaluated at 8 weeks and 24 weeks for plasma concentrations of

20 cytokines linked to the host immune response in tuberculosis in Pune and Chennai, India. Cytokine

concentrations were evaluated, in duplicates, using multiplex ELISA according to manufacturer protocols.

Markers associated with treatment failure, defined as Mycobacterium tuberculosis growth on liquid or solid culture

at 24 weeks of treatment, were identified using non-parametric tests. Cytokine concentrations were log2

transformed and z-score normalized across study groups for analysis. P-values were adjusted for multiple

comparisons using the Benjamini-Hochberg procedure and considered significant at α<0.05.

Results: Of the 30 participants enrolled, 20 (74%) were male, 7 (26%) had diabetes (defined as HbA1c>6.5%)

and 2 (7%) had HIV-coinfection. The median (IQR) age and BMI at enrollment was 36 (28-50) years and 18 (16-

20) kg/m2, respectively. Four (13%) participants failed treatment; none had diabetes or HIV-coinfection. While

plasma cytokine concentrations significantly declined with treatment, TIMP-4 and TNF-α were overexpressed at

8 weeks and 24 weeks of treatment relative to their baseline levels, respectively. Participants who failed

treatment had significantly higher plasma concentrations of IL-6 (p<0.001), IL-13 (p<0.001) and IFN-γ (p<0.001)

at treatment initiation compared to those who were cured, however this difference was not statistically

significant at 8 and 24 weeks of treatment.

Conclusion: Overexpression of circulating IL-6, IL-13 and IFN-γ at treatment initiation may be associated with

treatment failure among drug-sensitive pulmonary tuberculosis cases. Well powered validation studies should be

undertaken to evaluate the performance of these biomarkers, individually or in combination, for predicting

unfavorable tuberculosis treatment outcomes.


7

POSTER 4: Poor Understanding of TB Infection among At-risk Tuberculin Skin-test

Positive Household Contacts of Pulmonary TB Cases in Pune, India Authors: Dhumal G, DeLuca A, Paradkar M, Suryavanshi N, Mave V, Kohli R, Shivakumar SVBY, Kadam D, Gupta A

Background: Recent studies on contacts of tuberculosis (TB) cases in India have found TB infection (TBI)

prevalence of 40-50% among people living in the same household. Previous research has shown the barriers to

TB prevention are widespread, even in countries with strong policies. We evaluated knowledge and

understanding of TBI and IPT among tuberculin skin-test positive (TST+) household contacts (HHCs) of recently

diagnosed pulmonary TB (PTB) cases, and their preference for receiving information about TB.

Methods: This was a sub-study of CTRIUMPH, a cohort study enrolling TB patients and their HHCs that is part

of RePORT-India. We approached TST+ HHCs of adult PTB, to administer a validated questionnaire on TB

knowledge, and also asked open-ended questions on understanding of TBI and their preference to receive

information about TBI and its prevention. Over one year, 100 adult HHCs were enrolled at a tertiary teaching

hospital in Pune, India.

Results: General awareness of how TB is transmitted was low among HHCs, with a majority of participants

believing that you can get TB from sharing dishes (70%) or touching something that has been coughed on (52%).

Understanding of TBI was also low, with 42% believing that being TST+ means you have disease, and 88%

reporting that they did not understand the difference between TBI and active disease. Median age of the

participants was 35.5 years. Ninety-five (98%) participants preferred to receive TBI and its prevention

information from doctor, with pamphlets in their mother tongue (n=75, 77%) or a video/DVD (n=74, n=76%)

being the other methods preferred for receiving health information. Participants who are aware of IPT (n=4), all

were willing to opt it.

Conclusions: Due to poor understanding of TB transmission and infection, adoption of health messaging in

video or pamphlet form in Marathi may help to improve TB knowledge. Whenever possible, study physicians

should communicate information about TB transmission to household contacts.

POSTER 5: Incidence of Mycobacterium tuberculosis Infection among Household Contacts

of Adult Pulmonary Tuberculosis Cases in India Authors: Paradkar M, Dhanasekaran K, Kinikar A, Kulkarni R, Bharadwaj R, Gaikwad S, Lokhande R, Meshram S, Dolla CK,

Selvaraju S, Murali L, Thiruvengadam K, Jain D, Rajagopal S, Kulkarni V, Pradhan N, John S, Kohli R, Nayagam R, Shivakumar

SVBY, Suryavanshi N, Cox S, Gupte A, Gupte A, Chandrasekaran P, Mave V, Gupta A for the CTRIUMPh Study Team

Background: Evaluating incident tuberculosis infection (TBI) in household contacts (HHC) of tuberculosis (TB)

cases in high burden settings such as India is vital for TB biomarker and vaccine development.

Methods: CTRIUMPH study prospectively enrolled HHCs of (adults/children living in same house with adult

pulmonary TB case) in Pune and Chennai, India. Tuberculin skin test (TST, 5TUs) and Quantiferon Gold-In Tube

test (QGIT) were performed at enrollment, and at 4 and 12 months among HHCs without previous TBI.

Incident TBI was defined as TST induration ≥5mm or positive QGIT (>0.35 IU/mL) at follow up. We calculated

incidence rates by Poisson regression and Kaplan-Meier estimate for cumulative incidence, for TST, QGIT and

either. We performed Cox proportional hazards regression to assess the risk factors and McNemar’s test to

compare the age-specific incidence by TST and QGIT.


8

Results: 706/999 (70.6%) HHCs enrolled had TBI at baseline. 219 HHCs without baseline TBI completed 12

months follow-up and 87/219 (40 %) seroconverted by either or both tests within 12 months (Table 1). TBI

incidence by QGIT, TST and either test was 288, 502and 642 per 1000 person-years respectively. Cumulative

TBI incidence was stratified by age and index microbiological status (Figure 1). Risk factors independently

associated with TBI were- HHC age 25-45 years by TST (aHR 2.81,CI 0.98-8.01,p=0.05), by QGIT (aHR

12.75,CI 1.64-98.83,p=0.02) and TST and/or QGIT (aHR 4.11,CI 1.63-10.37,p=0.003); HHC age>45 years by

TST (aHR 5.98,CI 1.83-19.53,p=0.003) and TST and/or QGIT (aHR 5.15,CI 1.73-15.29,p=0.003); index age 18-25

years (aHR 2.98,CI 1.04-8.52,p=0.04) and high TB exposure score (aHR 2.70,CI 1.17-6.25,p=0.02) by QGIT;

Peri-urban residence by TST (aHR 4.68,CI 2.05-10.07,p<0.001) and by TST and/or QGIT (aHR 2.91,CI 1.41-

6.02,p=0.004). TBI was higher by TST than QGIT in HHCs aged 15-<25 (p-0.002) and <45 years (p=0.008).

Conclusion: Among our cohort of Indian HHCs recently exposed to TB, incidence of TBI was impacted by

type of TBI test used, HHC age, index age, peri-urban residence and by TB exposure score.

TITLE: The Effect of HIV on the Immune Response to Myobacterium tuberculosis in

Pregnant Women from Pune, India Authors: Mathad J, Alexander M, Bhosale R, Naik S, Suryavanshi N, Mave V, Deshpande P, Balasubramanian U, Kulkarni V,

Kumar P, Babu S, Gupte N, Nevrekar N, Patil S, Chandanwale A, Gupta A

Background: The incidence of active tuberculosis (TB) in women is highest during pregnancy and postpartum,

making it a leading cause of maternal mortality. We sought to understand the impact of HIV on the immune

response to M. tuberculosis in pregnant women in India.

Methods: We are conducting a longitudinal study of pregnant women with and without HIV in Pune. Women

with a positive interferon gamma release assay (IGRA) are enrolled. From the IGRA supernatant, we measured

Th1 and Th2 cytokines (e.g. IFN-g, IL-4) using the multiplex ELISA Luminex platform. Repeat IGRA testing was

done at delivery.

Results: We enrolled 198 women; 45 HIV-infected, 153 HIV-uninfected. Among HIV-infected, the median CD4

count was 425 cells/mm3 (IQR: 399-602) and 80% of them had undetectable viral loads. At delivery, 68% of HIV-

uninfected women remained IGRA-positive versus only 43% of HIV-infected women (p=0.002). Compared to

HIV-uninfected women, HIV-infected women had significantly lower IFN- g levels in response to MTB antigen

stimulation at entry (5.4 IU/mL vs. 2.47 IU/mL, p=0.0004) and delivery (2.23 IU/mL vs. 1.1 IU/mL, p=0.004). In

contrast, HIV-infected women had significantly higher IL-6 than HIV-uninfected women at entry (355.5 pg/mL vs.

48.8 pg/mL, p=0.02) and delivery (1499 pg/mL vs. 235 pg/mL, p=0.002). Levels of IL-2 and IL-4 decreased

significantly between entry and delivery (IL-2: 23.5 pg/mL vs. 14.3 pg/mL, p=0.02; IL-4: 20.8 pg/mL vs. 2.07 pg/mL,

p=0.0001) in all women.

Conclusions: Compared to HIV-uninfected women, women with HIV experience a greater suppression of their

immune response to MTB during pregnancy. This is not related to increased IL-4 levels as IL-4 unexpectedly

decreased in both HIV-infected and HIV-uninfected women. The suppressed IFN-g may, however, be related to

higher IL-6 in HIV-infected women, which increased as pregnancy progressed. Our study provides novel insight

into the pathogenesis of TB in HIV-infected pregnant women.


9

TITLE: Drug Susceptibility of Rifampin-resistant Tuberculosis using Whole Genome

Sequencing to Identify Genes of Interest in Pune, India Authors: Tornheim JA, Madugundu AK, Pradhan N, Bharadwaj R, Mave V, Golub J, Pandey A, Gupta A

Background and Rationale: India has the world’s largest tuberculosis (TB) burden. Recent expansion of

molecular drug susceptibility testing (DST) is revealing more drug resistance than previously identified. In many

parts of India, resistance to second-line drugs needs further study. We performed whole genome sequencing

(WGS) to evaluate the frequency of resistance mutations found among rifampin-resistant isolates from Pune,

India, a city of 7 million people.

Methods: Samples were collected at a public hospital in Pune, India. Pulmonary TB patients provided spot and

morning sputum samples for Xpert MTB/RIF, culture, and phenotypic DST. Samples with positive or

indeterminate rpoB mutation results were included and were analyzed by patient. Phenotypic DST was

performed for isoniazid, rifampin, ethambutol, and streptomycin. Raw WGS data were submitted to an analytic

pipeline using BWA aligner, GATK, and snpEff to generate annotated variant call files. Identified variants were

compared to genes of interest reported from the ReSeqTB Data Platform. Analysis was duplicated by multiple

bioinformatic pipelines.

Results: From 2015-2016, 104 participants met inclusion criteria, and 32 had sufficient culture material for

further analysis. Most were smear positive (84.4%), and all were culture positive, though 3 samples had

insufficient growth for phenotypic DST. On average, WGS produced 8.6 million reads (5.1-31.2 million) per

sample with 94.9% (77.0-98.5%) mapping to M. tuberculosis. This identified an average of 1,847 genetic variants

per isolate. East Asian lineage was most common (40.6%) followed by Central Asian (31.3%). Phenotypic and

genotypic tests for rifampin were concordant in 66.7% of cases. While injectable drug resistance was not

identified, WGS frequently identified fluoroquinolone resistance among MDR-TB isolates.

Conclusions and Recommendations: WGS for DST of resistant TB isolates in the Indian public sector

identified high rates of fluoroquinolone resistance. DST using WGS and published genes of interest can be

performed in India and may help guide treatment guidelines, particularly with respect to fluoroquinolones.

POSTER 6: Profile of Indian Patients with Tubercular Meningitis in the CMC, Vellore

Cohort Authors: Christopher DJ, Thangakunam B, Samuvel S, Mathuram A, David T, Satheyendra S, Abraham OC, Ramya

Introduction: Tubercular meningitis (TBM) is one of the severe forms of tuberculosis with high morbidity and

mortality. There are challenges in diagnosis and managing patients with tuberculosis. We have established a

cohort of such patients as part of RePORT India consortium.

Materials & Methods: We analysed the clinical, laboratory, and radiological variables of the first 151 TBM

patients in our cohort. We have compared the variables of these patients with the other large published

cohorts.

Results: Of the 151 TBM patients, 62% were males and 42% were from the state of Tamil Nadu. Around 29%

of patients did not have formal school education and 81% of patients were never smokers.

At presentation, 93% had fever, 43% had weight loss, 78% had headache and 60% had confusion. GCS score of

59% of the patients was normal. Past history of tuberculosis was reported by 7% of the patients, 13% were sero

positive for HIV and 16% had diabetes mellitus. Definite, possible and probable TBM were diagnosed in 25%,


10

34% and 40% of patients respectively. At presentation the MRC clinical severity was stage 1 in 40%, stage 2 and

3 were 44% and 17% respectively.

MRI Brain showed hydrocephalus in 17%, Basilar Meningeal Enhancement in 40%, Tuberculoma in 7%, Infarct in

5%. Normal Chest X-ray was reported in 69% and 5 % of patients had cavitary lesions on CXR.

In all 34 patients have succumbed to the disease (mortality rate -23%).Among patients who are alive, 38 have

completed 1 yr of treatment and are under follow up. The clinical and laboratory profiles of the patients was

similar to other TBM cohorts.

Conclusion: Definite diagnosis of TBM has been possible in only 25% of the patients. The clinical severity of the

majority of patients fell in MRC stage 2. Basilar meningeal enhancement is the commonest MRI finding. While

the clinical and laboratory profiles of the patients were similar to other cohorts, the mortality rate was only

23%, which is lower than other cohorts.

POSTER 7: Are Non-tuberculous Disorders being Treated as Smear Negative Pulmonary

Tuberculosis? Authors: Oliver A, Samuvel S, Shankar D, Thangakunam B, Christopher DJ

Background: In most of the countries in the world, diagnosis of pulmonary tuberculosis (PTB) is primarily

based on smear microscopy. Some patients, who have negative by sputum smears, end up being treated as

smear negative TB on the basis of symptomatology and or chest x-ray which have poor specificity, and some

patients are inappropriately prescribed anti-TB treatment.

Very few studies have looked at patients diagnosed to have smear negative Pulmonary TB (SNPTB) in detail to

identify the precise etiology and also estimate the quantum of mis-diagnosis, this study was designed to address

this question.

Methods: Consecutive consenting patients who were diagnosed as SNPTB under the Revised National TB

control programme (RNTCP), of the city were recruited. The subjects were sequentially subjected to the

following investigations: repeat AFB smears (twice), Gene Xpert (CB-NAAT) and MGIT culture on sputum

samples, chest x-ray, CT Thorax, bronchoscopy, pulmonary function tests and other investigations as required,

to arrive at specific diagnosis.

Results: A total of 102 patients were enrolled. Repeat sputum smears & CBNAAT confirmed PTB in 31(30%)

subjects. The other 71 patients were recommended further evaluation but 25 dropped out at various stages and

were excluded. Among the 46 who completed evaluation, 5(11%) more were diagnosed as PTB from

bronchoscopy samples.

The others patients had non PTB diagnosis: COPD-8, bronchiectasis-6, sequel of healed PTB-6, bronchial

asthma-5, bacterial pneumonia-4, gastro-oesophageal reflux disease-3, adenocarcinoma-1, cryptogenic organizing

pneumonia-1, bacterial pyo-pneumothorax-1.

Conclusions: Of the 102 patients diagnosed to have SNPTB who were re-evaluated, only 41% turned out to

have a confirmed diagnosis of PTB. The rest had non-TB causes for their symptoms. Use of CB-NAAT on smear

negative cases identified most of true PTB. However expert evaluation and use of expensive technology may be

required for the rest.


11

POSTER 8: Factors Affecting Time to Sputum Smear and Culture Conversion in Adults

with Pulmonary Tuberculosis: A Prospective Cohort Study from CMC RePORT Data Authors: Christopher DJ, Shankar D, Thangakunam B, Ramakrishnan L

Background: In patients with pulmonary tuberculosis (PTB), shortening the time of sputum smear and culture

conversion is a challenge but is most enviable. Reduction in time to conversion leads to less mycobacterium

transmission. Persistent positive sputum culture after 2 months of treatment is mostly associated to symptoms,

high smear grading, grade of severity on chest x-ray, diabetes mellitus, smoking, alcohol, low BMI and lower

socio-economic strata. Very few studies have done periodic microbiologic examination to identify the precise

duration to sputum conversion and correlated this with the risk factors for delay in sputum conversion.

Methods: This study is an observational prospective study done in a tertiary care centre in southern India. All

new sputum smear & or Genexpert positive pulmonary TB patients (& subsequently culture +ve),presenting to

the Pulmonary medicine OPD & DOTS clinic of CMC, Vellore were included, if they were willing to participate

in the RePORT observational study titled ‘Host determinants in the eicosanoid pathway modulate the

inflammatory response, disease outcome, and treatment responsiveness in TB’and fulfillthe requirements of the

study, including providing weekly sputum samples for microbiologic examination for the first 2 months and if

they remained +ve at the end of 2 months,until sputum cultures became negative. They were all treated with

DOTS treatment under RNTCP. The following risk factors were evaluated: Symptoms, diabetes, smoking,

alcohol, low BMI, socioeconomic status, chest x-ray severity scores and high AFB load.

Results: The data of the first 80 recruited patients was analyzed, 56.7% of the subjects were smear –ve by 2

months and 71% culture –ve. The median time to sputum smear conversion was 5.8 weeks and sputum culture

conversion 6.3 weeks. Smoking and high AFB load showed a trend towards delayed sputum smear and culture

conversion

Conclusion: The time to culture conversion correlates with various risk factors and could be helpful in

predicting response to treatment.

TITLE: Prevalence of Latent TB Infection (LTBI) among Undergraduate Nursing

Trainees in a Rural Secondary Care Hospital in Southern India Authors: Christopher SA, Ilangovan AD, Shankar D, Thangakunam B, Christopher DJ

Objectives: To estimate the prevalence of LTBI among nursing trainees in a rural secondary care hospital and

asses various factors contributing to LTBI.

Secondary objective is to compare the prevalence of LTBI among undergraduate nursing trainees between a

Rural Secondary care Centre and Urban Tertiary care centre.

Methods: This is a Cross Sectional Observational Study done in Christian Fellowship hospital, Oddanchatram.

From January 2017 – March 2017, 98 healthy Nursing students across 3 yrs had given informed consent to

participate. All participants completed a questionnaire, underwent a physical examination and a TST to assess

latent TB status that was read after 48 hours. The results were stratified by Age, year of course study, total

length of work in health care, BMI, BCG vaccination status and presence of BCG scar to see if these factors

affected TST results. The results were compared with a our previous study done in Christian Medical College

Hospital, Vellore to ascertain if working in a Rural Hospital Centre made significant difference to Latent TB

status.


12

Results: Among the 98 students enrolled, 100% were females. Mean age of the Cohort was 19.84 years with

56.12% being ≥ 20 years age. BMI was < 19 in 40.82% and 69.39% of students had BCG scar. A total of 80.61%

students recalled work related exposure to TB patients and TST was positive in 40.82%. Significant association

of positive TST was seen with low BMI <19 (p=0.002) and contact with TB patients (p=0.05) and not with

presence of BCG scar. 40.82% of Undergraduate nurses in the Rural Hospital, Oddanchatram tested TST

positive compared to 45.22% of Undergraduate nurses in CMC, Vellore.

Conclusions: First study on LTBI in a rural secondary care hospital. A total of 80.61% Students had been

exposed to TB and 40.82% had evidence of Latent TB. The major contributing factors were found to be low BMI

and increased exposure to TB patients. The prevalence of LTBI was lower than that in Urban Tertiary care

Hospital.

POSTER 9: Effect of Malnutrition on Tuberculosis Mycobacterial Burden and Chest

Radiographic Findings Authors: Hoyt K, White L, Sarkar S, Pleskunas J, Zhou T, Noyal J, Muthuraj M, Vinod K, Roy G, Ellner JJ, Horsburgh CR,

Hochberg NS

Background: The relationship between malnutrition and tuberculosis (TB) severity is understudied. We aimed

to investigate the effect of malnutrition on mycobacterial burden and chest radiograph findings.

Methods: Subjects included newly diagnosed, smear-positive, culture-confirmed, pulmonary TB cases enrolled

in the Regional Prospective Observational Research for TB (RePORT) cohort in Puducherry and two districts of

Tamil Nadu, India. Multivariate negative binomial and linear regression were used to evaluate the relationship

between body mass index (BMI) and mycobacterial growth indicator tube (MGIT) time to positive (TTP) at start

of treatment and percentage of lung affected, respectively. Severe malnutrition was defined as BMI<16.5 kg/m2,

moderate malnutrition as 16.5-18.4kg/m2, and “normal”/overweight as ≥18.5 kg/m2.

Results: Of 776 subjects, 599 (77%) were male. The median age was 45 years (range 15-82); 222 (29%) had

severe malnutrition and 271 (35%) moderate malnutrition. Median MGIT TTP was 195 hours. Compared to

those with normal BMI, MGIT TTP was not statistically different for individuals with severe and moderate

malnutrition (aRR=1.05 [95% CI 0.97-1.15] and aRR=1.03 [95% CI,0.96-1.12], respectively), after adjusting for

confounders. Among 173 subjects with chest x-ray data, 132 (76%) had cavitation including 37/42 (88%) and

45/58 (78%) severely malnourished and malnourished cases, respectively. Median percentage of lung affected was

32%. Severe malnutrition was associated with more lung affected (46%) compared to moderate malnutrition

(30%) and normal BMI (24%). Percentage of lung affected in those with severe malnutrition was, on average,

10.9% greater than those with normal BMI (p=0.004).

Conclusion: This study found no significant association between BMI and MGIT TTP but did detect an

association between malnutrition and percentage of lung affected. These findings suggest that malnutrition might

affect long-term pulmonary sequelae of TB.

POSTER 10: Alcohol use and clinical presentation of tuberculosis at time of diagnosis in

Puducherry and Tamil Nadu, India Authors: Forsyth M, Ragan EJ, Sahu S, Jenkins HE, Sarkar S, Horsburgh CR, Roy G, Ellner JJ, Hochberg NS, Jacobson KR

Background: Alcohol use increases the risk of developing tuberculosis (TB) disease and is associated with

worse TB treatment response. Whether alcohol use affects disease severity at diagnosis has not been


13

investigated. Our objective was to assess the association between alcohol use and TB disease burden and

presentation at diagnosis.

Methods: Study participants were smear-positive TB patients enrolled prospectively in the Indian states of

Puducherry and Tamil Nadu. TB disease severity was assessed four ways: 1) high (2+ and 3+) versus low (1+)

smear grade, 2) time to positivity (TTP) on culture, 3) cavitation on chest x-ray (CXR), and 4) percent lung

affected on CXR. Alcohol use was assessed using the Alcohol Use Disorders Identification Test (AUDIT-C).

Exposure was categorized as 1) alcohol drinker versus non-drinker, and 2) at risk for alcohol use disorders

(AUD) versus not at risk (included non-drinkers). Associations were studied through univariate and multivariate

analysis, controlling for known risk factors. Final multivariate models were determined using backward selection

at p≤0.20.

Results: High smear grade (aOR 1.11, 95% CI: 0.77, 1.56), cavitation (aOR 0.97, 95% CI 0.34, 2.74), and TTP

(mean difference 0.43 days, p=0.15) did not differ between drinkers and non-drinkers, nor between those at risk

for AUD compared to those not at risk (smear: OR a0.95, 95% CI 0.68, 1.33; cavitation: aOR 1.07, 95% CI 0.42,

2.70; TTP: mean difference 0.04 days, p=0.89). Drinkers had greater percent lung affected than non-drinkers

(adjusted mean difference 11.83% p<0.001), but this did not differ by risk for AUD (adjusted mean difference

5.51%, p=0.088).

Conclusion: Alcohol drinkers had significantly greater percent lung affected on CXR at time of diagnosis than

non-drinkers. Although there were no differences for other clinical characteristics, our findings warrant further

investigation of potential biologic or behavioral pathways between alcohol use and TB disease.

POSTER 11: Evaluation of Factors Influencing Mycobacterium tuberculosis Complex

Recovery and Contamination Rates in MGIT 960 Authors: Ellappan K, Datta S, Muthuraj M, Joseph NM, Subitha L, Pleskunas JA, Horsburgh CR, Salgame P, Hochberg N,

Sarkar S, Ellner JJ, Roy G

Background: Tuberculosis (TB) is a major public health problem. The contamination rate and poor recovery of

Mycobacterium tuberculosis complex (MTBC) in MGIT960 culture may affect the early diagnosis of TB. Evidence

is needed to determine the factors associated with contamination rates and MTBC recovery.

Objectives: To determine the factors affecting the MTBC culture positivity and contamination rates using

MGIT960.

Methodology: Newly diagnosed, smear-positive, active pulmonary TB notified to DOTS centres were enrolled

in RePORT study since May 2014. Repeat smear examination and sputum culture using MGIT960 were done for

these patients. Chi-square test was performed to study the impact of sputum appearance, volume, transport

duration, smear grading, location of residence, age and gender on the culture positivity and contamination rate.

Results: Of the 849 cases studied, 95.5% (811/849) were culture positive for MTBC, 2.7% (23/849) were

culture negative and 1.8% (15/849) were contaminated. Salivary sputum showed significantly less culture

positivity (91.4%) compared to mucopurulent/blood stained samples (96.6%) (p 0.003). Sputum from individuals

<20 years of age and those ≥60 showed lower culture positivity of 89.8% and 91.3%, respectively, compared to

those aged 20-39yr (97.1%) and 40-59yr (96.7%) (p 0.007). Based on smear grading, negative, scanty and positive

(1+/2+/3+) samples showed a culture positivity of 79.8%, 91.7% and 98.2%, respectively (p <0.0001).

Contamination rates were higher in smear negatives (6.0%), compared to scanty (2.1%) and smear positives

(1.1%) (p 0.007). Transport duration (3.2% vs. 1.4% for samples transported > 3hr and < 3 hr, respectively, p


14

0.090) and sputum appearance (3.4% vs. 1.3% for mucopurulent/blood stained and salivary sputum, respectively,

p 0.059) also influenced the contamination rates.

Conclusion: Sputum appearance and smear grading were the most important factors influencing both culture

positivity and contamination. Transport duration affected the contamination rates. Awareness of these factors

may improve the diagnostic performance of MGIT960.

TITLE: Influence of Type of Tobacco Product on Chest X-ray findings in Pulmonary

Tuberculosis Patients in India Authors: Schenk NM, Sahu S, Roy G, Ellner JJ, Horsburgh Jr CR, Kumar V, Amsaveni S, Pleskunas J, Sarkar S, Hochberg

NS, Reddy D

Background and Rationale: Tobacco smoking is associated with increased morbidity and mortality in

pulmonary tuberculosis (PTB) disease. Bidis, commonly smoked in India, are unprocessed cigarettes that contain

less tobacco but more harmful chemicals. This study aims to assess the influence of the type of tobacco product

used on chest x-ray (CXR) findings in PTB patients.

Methods: Data from PTB cases enrolled in the Regional Prospective Observational Research for TB (RePORT)

cohort in Puducherry and Tamil Nadu, India were analyzed. Smoking was self-reported through standardized

questionnaires and defined as ever (current or former) and never smokers. CXRs were obtained prior to

initiation of PTB treatment and were read by trained clinicians. Univariate associations were examined using the

chi-square, two-sample t-test and analysis of variance test.

Results: Among 161 newly diagnosed smear-positive, culture-confirmed PTB cases with CXRs, 119 (73.9%)

were male, the median age was 45 years, and 71/161 (44.1%) were ever smokers. Of the 71 smokers, 39 (54.9%)

smoked bidis and 23 (32.9%) smoked cigarettes. On univariate analysis, ever smokers were more likely to have

bilateral infiltrates (OR=3.7; 95% CI 1.4 – 9.7; p=0.005) and upper zone involvement (OR=3.3; 95% CI 1.2 -9.4;

p=0.020) on CXRs compared to never smokers. Further investigation revealed that those who smoked bidis

were significantly more likely than never smokers to have bilateral infiltrates on CXR (OR=6.4; 95% CI 1.4 -28.5;

p=0.007), but those who smoked cigarettes were not (OR=2.3; 95% CI 0.6 -8.4; p=0.203).

Conclusion and Recommendations: Bidis are the preferred form of tobacco among PTB patients in this

cohort in southern India. Initial univariate analyses suggest that PTB patients who smoke are more likely to have

more severe lung disease on CXR; the effects were particularly notable for bidi smokers. Additional multivariate

analyses are ongoing to control for potential confounders.

TITLE: Wood Fuel Usage Is Associated with a Higher Leukocyte Count in Pulmonary

Tuberculosis Patients Authors: Eisenberg RE, Mowry WB, Sahu S, Roy G, Ellner JJ, Pleskunas J, Amsaveni S, Sarkar S, Hochberg NS, Reddy D

Background: Toxic environmental exposures such as wood fuel and tobacco smoke have been associated with

neutrophil dysfunction. Studies also suggest an association between neutrophils and tuberculosis (TB) pathology,

higher bacterial burden, and more extensive lung destruction. This study aims to looks at the effect of wood fuel

use on leukocyte counts in pulmonary tuberculosis (PTB) patients.

Methods: Data from newly diagnosed, culture-confirmed, HIV-uninfected PTB cases enrolled in the Regional

Prospective Observational Research for TB (RePORT) cohort in Puducherry and Tamil Nadu, India were


15

analyzed. Standardized questionnaires were used to obtain demographic and socioeconomic data at enrollment;

complete blood counts were measured. The main outcomes of interest were total leukocyte, absolute

neutrophil and lymphocyte count. T-tests and Pearson’s chi-squared tests were used to compare groups. Linear

regression and logistic regression were used to adjust for potential confounders including age, sex, poverty,

crowding, location of care, tobacco and alcohol use, and duration of illness.

Results: Of 344 PTB patients with household data, 262 (76%) were male and the median age was 44 years

(range 14 ─77). 166/344 (48%) used wood fuel for cooking. Compared to non-wood fuel users, wood fuel users

had a significantly higher leukocyte count (mean: 10,981 vs 10,014; p = 0.01) and this association remained

significant after adjusting for potential confounders (mean difference: 795 ± 392; p = 0.04). Wood fuel users had

a higher proportion of high (vs. normal) absolute neutrophil count (91% vs. 83%; p = 0.03) compared to non-

wood fuel users and this association was borderline significant (OR 1.95; 95%CI 0.98-3.85; p = 0.056) with

adjustment.

Conclusion: Wood fuel usage in PTB patients is associated with a significantly higher leukocyte count and

borderline significant higher absolute neutrophil count. Further studies looking at the mechanism behind this

association and its effect on PTB severity are underway.

POSTER 12: Effect of Anti-tuberculosis Treatment on the Systemic Levels of Tissue

Inhibitors of Metalloproteinases in Tuberculosis–Diabetes Co-morbidity Authors: Moideen K, Viswanathan V, Shruthi BS, Sivakumar S, Menon PA, Kornfeld H, Babu S, Kumar NP

Background: Matrix metalloproteinases (MMPs) are considered to be key mediators of tuberculosis (TB)

pathology and tissue inhibitors of metalloproteinases (TIMPs) facilitate the remodeling and repair of tissue

following destruction by MMPs but their role in tuberculosis – diabetes comorbidity (TB-DM) is not well

understood. We have previously described elevation of TIMP levels in TB-DM and hence in this study sought to

evaluate the effect of anti-TB treatment on TIMP levels in TB-DM.

Methods: The systemic levels of TIMP 1, 2, 3, 4 were measured by multiplex ELISA in individuals with either TB

alone or TB-DM at baseline and at 6 months of anti-TB treatment.

Results: Circulating levels of TIMP 1, 3, 4 were significantly higher in TB-DM compared to TB at baseline and 6

months post treatment. Moreover, the levels of TIMP 1, 3, 4 were significantly higher in TB-DM individuals with

bilateral and cavitary disease and also exhibited a significant positive relationship with bacterial burdens at

baseline. Moreover, TIMP 3 and 4 levels exhibited a positive relationship with HbA1c levels. In addition, among

the TB-DM group, individuals with a known history of DM (KDM) displayed enhanced levels of TIMP 1, 2, 3 and

4 compared to newly diagnosed DM (NDM) at baseline. Finally, known diabetic patients who are taking

metformin treatment showed decreased levels of TIMP 1, 2 and 4 at baseline compared to patients who are on

non-metformin anti –DM drugs.

Conclusions: Therefore, our results imply that TIMP upregulation is a characteristic feature of TB-DM and

more specifically, TB with known history of DM, perhaps as a response to MMP upregulation. Our data also

suggest that MMP inhibition or promoting TIMP function might be a useful host directed therapy (HDT) in TB-

DM patients.


16

POSTER 13: Effect of Standard Tuberculosis Treatment on Circulating Levels of

Monocyte Activation Markers and RAGE Ligands in Tuberculosis-diabetes Co-morbidity Authors: Kumar NP, Moideen K, Viswanathan V, Shruthi BS, Sivakumar S, Menon PA, Kornfeld H, Babu S

Background: Type 2 diabetes mellitus (DM) is a major risk factor for the development of active pulmonary

tuberculosis (PTB), However, the effect of anti-TB treatment (ATT) on monocyte activation markers and RAGE

ligands in TB-DM co-morbidity is not well understood. We have previously shown an effect of anti-TB treatment

on the circulating levels of monocyte subsets in TB DM comorbidity. Hence, we wanted to examine the

association of monocyte activation markers and RAGE ligands in TB-DM comorbidity.

Methods: To identify the influence of DM on circulating monocyte activation markers and RAGE ligands in TB

disease, ELISA was performed to examine the systemic levels of monocyte activation markers - sCD14, sCD163,

C-reactive protein(CRP), soluble tissue factor(sTF) and RAGE ligands - soluble receptor for advanced glycation

end product(sRAGE), advanced glycation end products(AGE), S100A12 and high mobility group protein

B1(HMGB-1) in TB patients with DM(TB-DM) and without DM(TB-NDM) at baseline and at 2nd and 6th month

of ATT.

Results: TB-DM is characterized by elevated levels of monocyte activation markers, sCD14, sCD163, CRP and

sTF in comparison to TB Non-DM before, during and after completion of ATT. Similarly, TB-DM is

characterized by elevated levels of RAGE ligands, AGE, sRAGE, S100A12 but not HMGB-1 in comparison to TB-

NDM before, during and after completion of ATT. Finally, TB-DM is characterized increased levels of sCD14,

sCD163 and AGE and decreased levels of CRP and S100A12 were observed at the successful completion of

ATT. Among the monocyte activation markers and RAGE ligands, only sCD14, CRP and sRAGE exhibited a

highly significant area under the curve during ROC calculations to discriminate TB-DM from TB-NDM.

Conclusion: Our data demonstrate that TB-DM is associated with heightened levels of monocyte activation

and RAGE ligands, indicating an association with disease severity and potentially contributing to increased

immune pathology in tuberculosis-diabetes co-morbidity.

POSTER 14: Impact of Metformin Use on TB Severity in Diabetes Authors: Shruthi BS, Liu J, Kumar NP, Babu S, Sivakumar S, Menon PA, Sathyavani K, Kornfeld H, Viswanathan V

Background: Diabetes mellitus (DM) is a major TB risk factor, with South India among the most affected

regions. The anti-diabetic drug metformin has been studied as an adjuvant therapy for TB based on its

immunomodulatory activity. Among EDOTS study participants reporting DM history at enrolment, DM

treatment data is available. We aim to compare TB disease severity at presentation and response to TB

treatment in diabetic participants treated with metformin vs non-metformin regimens. Data collection is ongoing

with final analysis pending. Here we present preliminary findings.

Methods: Data will be obtained from EDOTS study participants with DM diagnosed prior to incident TB,

classified as self-reported metformin users or non-users. Baseline variables including HbA1c, symptom score,

sputum score and radiographic severity score will be compared. Treatment response will be assessed by time to

sputum conversion, change in radiographic score, TB treatment outcome and TB recurrence within 12 months.

Linear regression models will be used to compare the differences in TB outcomes by metformin use status, with

and without adjustment for covariates.

Results and Conclusion: Preliminary analysis of baseline data from 133 eligible diabetic participants identified

87 (65%) as metformin-users. There were no significant differences in median HbA1c, BMI, demographic or


17

lifestyle characteristics between metformin-users and non-users. This suggests that major potential confounders

will not seriously limit interpretation once longitudinal data are available from all participants. Preliminary

comparison of baseline chest X-rays showed no difference in median severity score or lung cavitation by

metformin use status. Preliminary results suggest no benefit of metformin on baseline TB severity. Final results,

when available, will reveal any differences in treatment response or outcomes in diabetic participants attributable

to metformin exposure prior to incident TB. A negative outcome would not necessarily predict the results of a

randomized, prospective clinical trial in diabetic or non-diabetic TB patients.

POSTER 15: Risk Factors Associated with Unfavorable Outcomes in a Cohort of


Authors: Dhanasekaran K, Chandrasekaran P, Paradkar M, Marinaik SB, Gupte A, Dolla CK, Joseph B, Subramanyam B,

Sivaramakrishnan GR, Thiruvengadam K, Gupte N, Rajagopal S, Pradhan N, Selvaraju S, Kulkarni V, Hannah LE, Nayakam R,

Suryavanshi N, Shivakumar SVBY, Mave V, Thomas B, Bharadwaj R, Gaikwad S, Meshram S, Lokhande R, Kinikar A, Daware

R, Murali L, Swaminathan S, Gupta A

Background: India accounts for 25%of the global tuberculosis (TB) burden. Vaccines for treatment shortening,

prevention of recurrence require precise estimates of treatment failure, death and recurrence to adequately

power clinical trials. We sought to determine prevalence of these outcomes and risk factors associated with

treatment failure in a cohort of pulmonary TB (PTB) patients.

Methods: C-TRIUMPH is a multi-centric, prospective ongoing study enrolling drug-sensitive PTB patients with

24 months of follow-up post-treatment initiation. Outcomes are defined as-Confirmed failure -Positive on 2

cultures (MGIT or LJ) at 6 months; Probable failure –1positive culture and symptomatic; Possible failure-Positive

on culture/smear but asymptomatic; Cure-2successive culture negatives; Treatment complete-1culture negative

and no subsequent cultures. Death, recurrence were also documented. Uni variable and multi variable Poisson

regression was performed to assess factors associated with treatment failure in PTB patients

Results: Of 476 enrolled, the characteristics were: median age 32, (61%) male, (31%) diabetic or (24%) pre-

diabetes, (6%) HIV infected, 25%smokers, 24% with alcohol dependence (AUDIT scale>8), (64%) with BMI<18.5,

(41%) with cavity and 59% with smear positive. (86%) had favorable outcome & (14%) treatment failure (23%

confirmed, 58% probable, 19% possible), 20(4%) recurrence/relapse, (4%) deaths. Excluding the possible failure,

Alcoholics (aRR1.88, 95%CI: 1.06-3.33), smokers (RR2.52, 95%CI: 1.43–4.42), low BMI (aRR2.45, 95%CI: 1.19–

5.05) culture positivity at baseline with high smear grade (RR6.83, 95% CI: 2.13–21.91) had a higher risk of failing

treatment

Conclusion: Smoking, alcohol use, malnutrition, and anemia play pivotal role in emergence of failures. Early

diagnosis and nutrition supplement for undernourished will decrease failure. Counseling and intervention for

smokers and alcoholics will enhance successful outcomes in Management of TB.

POSTER 16: Title: Implications of Acetylator Genotype on Plasma Rifampicin and

Isoniazid Levels Authors: Chawla PK, Lokhande RV, Naik PR, Dherai AJ, Udwadia ZF, Mahashur AA, Soman R, Patel J, TF Ashavaid

Background: Rifampicin(Rif) and Isoniazid(Inh) exhibit wide inter-individual variability. Factors like inadequate

absorption, inaccurate dosing(as per mg/kg), drug–drug interactions or acetylator status of the individual etc.

may interfere with drug exposure thus altering the bioavailability of these drugs. The present study aims to

assess plasma Rif and Inh levels & correlate them with the human acetylator status and other factors

contributing to sub-optimal levels.


18

Methods: In-house validated HPLC methods were used for plasma Rif and Inh level estimation. Allelic variants

from human NAT2 gene(*4,*6,*11, *12 and*13)were genotyped by conventional PCR. Detailed clinical & drug

history was obtained from 168 clinically proven Rif susceptible TB patients.

Results: Among the study population, 100 patients(59%) had Rif levels in the sub-therapeutic range while 2

patients(1%) had toxic levels. Isoniazid levels observed in 107 patients showed a sub-optimal & variable trend

with 34 patients(33%) having sub-therapeutic levels & 24 patients(23%) had toxic levels. Among the NAT2

polymorphisms available for 75 patients so far, about 45%(n=34) were slow acetylators(carriers of NAT2*6

allele) & 39%(n=29) were intermediate acetylators(carriers of *11, *12 & *13 alleles) while remaining 16%(n=12)

were rapid acetylators. Most of the slow acetylators had isoniazid levels at a higher side as compared to the

intermediate and rapid acetylators. Plasma rifampicin levels were inversely proportional to the acetylator status.

Thus most rapid acetylators had high rifampicin and low isoniazid levels.

Conclusions: Sub-optimal levels of rifampicin and isoniazid are common and warrant attention. A high

prevalence of slow or intermediate acetylators suggests the importance of assessment of NAT2 gene

polymorphisms prior to dose initiation. Monitoring drug levels is necessary to optimize drug doses & achieve

therapeutic efficacy & desired patient outcome.

Recommendations: Therapeutic Drug Monitoring of Rifampicin and isoniazid is recommended in all slow

responders. Determination of acetylator status before treatment will help clinicians titre isoniazid doses.

POSTER 17: Title: Linezolid Experience Among MDR-TB Patients in Mumbai Authors: Tornheim JA, Ganatra S, Deluca A, Banka R, Rodrigues C, Gupta A, Udwadia ZF

Background and Rationale: India has 25% of the world’s tuberculosis. Mumbai is home to

12% of India’s cases that are resistant to rifampin and isoniazid (MDR-TB), but they are often resistant to

standard treatment. Linezolid (LZD) resistance is rare, but toxicity limits widespread use.

Methods: From October 2015–November 2016, MDR-TB patients were recruited from a Mumbai chest clinic

for a prospective cohort. Medical history and side-effects were evaluated by structured questionnaires. Odds

ratios (ORs) and differential time to culture conversion were determined by logistic regressions and t-tests.

Results: Of 286 participants, 105 had LZD resistance testing, and 3 (1%) were resistant to LZD. LZD was

prescribed to 147 (51.4%) participants, and 112 (76.2%) of those still take LZD. Most received 600mg daily

(56.8%) or 300mg daily (37.1%). Mean duration of LZD was 166.3 days (8-722 days), at a mean daily dose of

12.2mg/kg (4.5-26.6mg/kg) and a mean cumulative dose of 102g (7.2–903.6g). 40 participants reported

neuropathy (27.3%), which was associated with duration of LZD (OR 1.13/month, p=0.046) but not cumulative

dose or dose per kg. Daily dose per kg was associated with a trend towards anemia (OR 1.1 per mg/kg,

p=0.124). Participants taking >10mg/kg had higher odds of anemia (OR 2.1, p-0.096). Treatment duration and

cumulative dose/kg had small associations with time to culture conversion (R-squared: 0.27, p=0.007 and 0.186,

p=0.031, respectively). Higher doses (>10mg/kg or >15mg/kg) were not associated with faster culture

conversion.

Conclusions and Recommendations: LZD has an increasing role in MDR-TB due to infrequent resistance.

Treatment approaches that maximize efficacy and minimize toxicity are urgently needed.

Publications PARENT & COMMON PROTOCOLS



PUBLICATIONS

19

RePORT India Consortium RePORT International: Advancing Tuberculosis Biomarker Research through Global

Collaboration Hamilton CD, Swaminathan S, Christopher DJ, Ellner J, Gupta A, Sterling TR, Rolla V, Srinivasan S, Karyana M, Siddiqui S,

Stoszek SK, Kim P. Clinical Infectious Diseases (CID).2015 October 15; 61(Suppl 3): S155–S159.

PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26409277

Collaborating Organizations:

Scientific Affairs, Global Health, Population and Nutrition, FHI 360

Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA

Indian Council of Medical Research and Department of Health Research, Government of India

Pulmonary Medicine, Christian Medical College, Vellore, India

School of Medicine, Boston University, MA, USA

School of Medicine, Johns Hopkins University, Baltimore, MD, USA

Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN, USA

National Institute of Infectious Diseases Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil

Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious

Diseases, National Institutes of Health

The National Institute of Research and Development, Indonesia Ministry of Health, Jakarta, Indonesia

Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious

Diseases, National Institutes of Health

Health Studies Sector, Westat, Rockville, MD, USA

1

10

9 9

0

2

4

6

8

10

12

2015 2016 2017 2018

PAPERS: 2015–PRESENT

http://www.ncbi.nlm.nih.gov/pubmed/26409277

PUBLICATIONS

20

Bhagwan Mahavir Medical Research Centre/LEPRA Society/University of

Texas Health Science Center at Tyler (CRU 107)

1. Defective MyD88 and IRAK4 but not TLR-2 expression in HIV+ individuals with latent

tuberculosis infection Devalraju KP, Neela VSK, Gaddam R, Chaudhury A, Van A, Krovvidi SS, Vankaylapati R, Valluri VL. (Cytokine.

Revision.)

2. IL-17 and IL-22 production in HIV+ individuals with latent and active tuberculosis Devalraju KP, Neela VSK, Ramaseri SS, Van A, Chaudhury A, Krovvidi SS, Vankayalapati R, Valluri VL. BMC (Infectious

Diseases. Revision.)

3. Alcohol enhances type 1 interferon-α production and mortality of young mice infected with

Mycobacterium tuberculosis Tripathi D, Welch E, Cheekatla SS, Radhakrishnan R, Venkatasubramanian S, Paidipally P, Van A, Samten B, Devalraju P,

Neela V, Valluri V, Mason C, Nelson S and Vankayalapati R. (Mucosal Immunology, under review).

4. IL-21 regulates NK cell responses during Mycobacterium tuberculosis infection Paidipally P, Tripathi D, Van A, Radhakrishnan R, Dhiman R, Venkatasubramanian S, Devalraju K, Tvinnereim A, Valluri

V, Vankayalapati R. (J Infect Dis, in press).

5. IL-21-dependent expansion of memory-like NK cells enhances protective immune responses

against Mycobacterium tuberculosis Venkatasubramanian S, Cheekatla S, Paidipally P, Tripathi D, Welch E, Tvinnereim AR, Nurieva R, Vankayalapati R.

Mucosal Immunol. 2016 Dec 7. doi: 10.1038/mi.2016.105

PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462891/


Department of Pulmonary Immunology, Center for Biomedical Research, University of Texas Health Science

Center at Tyler, Tyler, Texas, USA

2Department of Immunology, M. D. Anderson Cancer Center, Houston, Texas, USA

6. A TLR9 agonist promotes IL-22-dependent pancreatic islet allograft survival in type 1 diabetic

mice Tripathi D, Venkatasubramanian S, Cheekatla SS, Paidipally P, Welch E, Tvinnereim AR, Vankayalapati R. Nat Commun.

2016 Dec 16;7:13896. doi: 10.1038/ncomms13896.

PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27982034




7. NK-CD11c+ cell crosstalk in diabetes enhances IL-6-mediated inflammation during

Mycobacterium tuberculosis infection Cheekatla SS, Tripathi D, Venkatasubramanian S, Nathella PK, Paidipally P, Ishibashi M, Welch E, Tvinnereim AR, Ikebe

M, Valluri VL, Babu S, Kornfeld H, Vankayalapati R. PLoS Pathog. 2016 Oct 26;12(10):e1005972. doi:

10.1371/journal.ppat.1005972. eCollection 2016.


https://www.ncbi.nlm.nih.gov/pubmed/27924822

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462891/




PUBLICATIONS

21




National Institutes of Health, International Center for Excellence in Research, Chennai, India

Department of Cellular and Molecular Biology, Center for Biomedical Research, University of Texas Health

Science Center at Tyler, Tyler, Texas, USA

Blue Peter Research Center, LEPRA Society, Cherlapally, Hyderabad, India,

Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA

Byramjee Jeejeebhoy Medical College (BJGMC)/ National Institute for

Research in Tuberculosis (NIRT)/ Johns Hopkins University (JHU) (CRU 106

& 105)

1. Diabetes and Prediabetes among Household Contacts of TB Patients in India: Is it time to

screen them all? Shivakumar SVBY, Chandrasekaran P, Kumar AMV, Paradkar M, Dhanasekaran K, Suryavarshini N, Thomas B, Kohli R,

Thiruvengadam K, Kulkarni V, Hannah LE, Gomathy NS, Pradhan N, Dolla C, Gupte A, Ramachandran G, DeLuca A,

Meshram S, Bhardawaj R, Bollinger RC, Golub J, Selvaraj K, Gupte N, Swaminathan S, Mave V, Gupta A for the

CTRIUMPH- RePORT India Study Team. (Accepted for publication in Int J Tuberc Lung Dis 01/12/18.)

2. Sources of household air pollution and their association with fine particulate matter in low-

income urban homes Elf J, Kinikar A, Khadse S, Mave V, Suryvavanshi N, Gupte N, Kulkarni V, Patekar P, Raichur P, Breysse P, Gupta A,

Golub J. (Accepted for publication in J Exposure Sci Environmental Epidemiol 12/18/17.)

3. Secondhand smoke exposure and validity of self-report in low-income women and children in

India

Elf J, Kinikar A, Khadse S, Mave V, Gupte N, Kulkarni V, Patekar V, Raichur P, Cohen J, Breysse PN, Gupta A, Golub JE.

Pediatrics. 2018 Jan; 141 (Suppl 1): S118-S129. doi: 10.1542/peds.2017-1026O



Division of Infectious Disease, School of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA

Schroeder Institute for Tobacco Research and Policy Studies at Truth Initiative, Washington, DC, USA

Department of Pediatrics, Sassoon General Hospital and Byramjee Jeejeebhoy Medical College, Pune, India

Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA

4. Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children

with tuberculosis

Mave V, Kinikar A, Kagal A, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Gerona R, Wen A, Ramachandran G, Kumar H,

Bacchetti P, Dooley KE, Gupte N, Gupta A, Gandhi M. PLoS One. 2017 Dec 7;12(12):e0189101. doi:

10.1371/journal.pone.0189101.



Byramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.

Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Byramjee-Jeejeebhoy Government Medical College, Pune, India

University of California San Francisco, San Francisco, USA

National Institute of Research in Tuberculosis, Chennai, India



PUBLICATIONS

22

5. Prevalence of dysglycemia and clinical presentation of pulmonary tuberculosis in Western

India

Mave V, Meshram S, Lokhande R, Kadam D, Dharmshale S, Bharadwaj R, Kagal A, Pradhan N, Deshmukh S, Atre S,

Sahasrabudhe T, Barhwal M, Meshram S, Kakrani A, Kulkarni V, Raskar S, Suryavanshi N, Shivakoti R, Chon S, Selvin E,

Gupte A, Gupta A, Gupte N, Golub J. Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1280-1287. doi: 10.5588/ijtld.17.0474

PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29297449 Collaborating Organizations:

Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India

Johns Hopkins University School of Medicine, Baltimore, MD, USA

Dr D Y Patil Medical College, Pune, India

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

6. Isoniazid hair concentrations in children with tuberculosis: a proof of concept study Mave V, Chandanwale A, Kinikar A, Khadse S, Kagal A, Gupte N, Suryavanshi N, Nimkar S, Koli H, Khwaja S,

Bharadwaj R, Joshi S, Horng H, Benet LZ, Ramachandran G, Dooley KE, Gupta A, Gandhi M. Int J Tuberc Lung Dis.

2016 Jun; 20(6): 844–847.doi: 10.5588/ijtld.15.0882

PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889729/


Byramjee-Jeejeebhoy Medical College Clinical Trials Unit, Pune, India


University of California, San Francisco, CA, USA

National Institute of Research in Tuberculosis, Chennai, India

7. Cohort for Tuberculosis Research by the Indo-US Medical Partnership (CTRIUMPH): protocol

for a multicentric prospective observational study Gupte A, Padmapriyadarsini C, Mave V, Kadam D, Suryavanshi N, Shivakumar SVBY, Kohli R, Gupte N, Thiruvengadam

K, Kagal A, Meshram S, Bharadwaj R, Khadse S, Ramachandran G, Hanna LE, Pradhan N, Gomathy NS, DeLuca A,

Gupta A, Swaminathan S; CTRIUMPH Study Team. BMJ Open 2016 Feb 25;6(2):e010542.



Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA


National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India

Johns Hopkins Clinical Trials Unit, Byramjee Jeejeebhoy Government Medical College, Pune, Maharashtra, India

Byramjee Jeejeebhoy Government Medical College, Pune, Maharashtra, India

Indian Council of Medical Research, New Delhi, India

Christian Medical College, Vellore (CMC-Vellore)/University of Cambridge-

University of Washington (CRU 101)

1. Thoracoscopic pleural biopsy improves yield of Xpert MTB/RIF for diagnosis of pleural

tuberculosis. Christopher DJ, Dinakaran S; Gupta, R; James P; Isaac B, Thangakunam B. (Accepted for publication in Respirology

01/18.)



PUBLICATIONS

23

Jawaharlal Institute of Postgraduate Medical Education & Research

(JIPMER)/Boston Medical Center (BMC) (CRU 102) 1. Existing blood transcriptional classifiers accurately discriminate active tuberculosis from

latent infection in individuals from South India Leong, S, Yue Zhao, Joseph NM, Hochberg NS, Sarkar S, Pleskunas J, Hom D, Lakshminarayanan S, Horsburgh Jr, CR,

Roy G, Ellner JJ, Johnson WE, Salgame, P. (Accepted for publication in Tuberculosis 01/18).


Centre for Emerging Pathogens, Department of Medicine, Rutgers-New Jersey Medical School, Newark, NJ, USA

Division of Computational Biomedicine and Bioinformatics Program, Boston University, Boston, MA, USA

Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India

Boston Medical Centre, Boston, MA, USA

Boston University, School of Public Health, Boston, MA, USA

Department of Biostatistics, Boston University, Boston, MA, USA

2. Comorbidities in pulmonary tuberculosis cases in Puducherry and Tamil Nadu, India:

Opportunities for intervention Hochberg NS, Sarkar S, Horsburgh, Jr, CR, Knudsen S, Pleskunas J, Sahu S, Kubiak RW, Govindarajan S, Salgame P,

Lakshminarayanan S, Sivaprakasam A, White LF, Joseph NM, Ellner JJ, Roy G. PLoS One. 2017; 12(8): e0183195.

PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568341


Boston University School of Medicine, Boston, MA, USA

Boston University School of Public Health, Boston, MA, USA

Boston Medical Center, Boston, MA, USA

Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India

Government Chest Clinic, Puducherry, India

Rutgers University, Newark, New Jersey, USA

3. Predictors of delay to accessing care among tuberculosis patients in southern India.

(Predictors of delayed care seeking for tuberculosis in Southern India: an observational study) Van Ness SE, Chandra A, Sarkar S, Pleskunas J, Ellner JJ, Roy G, Lakshminarayanan S, Sahu S, Horsburgh Jr CR, Jenkins

HE, Hochberg NS. BMC Infect Dis. 2017 Aug 15;17(1):567. doi: 10.1186/s12879-017-2629-9.



Boston University Department of Biostatistics, Boston, MA, USA

Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India

Boston Medical Center, Boston, MA, USA

Boston University School of Medicine, Boston, MA, USA

Boston University School of Public Health, Boston, MA, USA

4. Advances in basic and translational tuberculosis research proceedings of the first meeting of

RePORT international Geadas C, Stoszek SK, Sherman D, Andrade BB, Srinivasan S, Hamilton CD, Ellner J. Tuberculosis (2016), doi:

10.1016/j.tube.2016.11.006



Boston Medical Center and Boston University School of Medicine, Department of Internal Medicine, Section of

Infectious Diseases, Boston, MA, USA

Health Studies Sector, Westat, Rockville, MD, USA

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568341



PUBLICATIONS

24

Center for Infectious Disease Research, Seattle, Washington, USA

Unidade de Medicina Investigativa, Laboratório Integrado de Microbiologia e Imunorregulação, Instituto Gonçalo

Moniz, Fundação Oswaldo Cruz, Salvador, Brazil

Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD,

USA

Scientific Affairs, Global Health, Population and Nutrition, FHI 360

Department of Medicine, Division of Infectious Diseases, Duke University, School of Medicine, Durham, North

Carolina, USA

MV Diabetes Research Centre – NIRT-NIH-ICER /University of

Massachusetts (CRU 103)

1. Heightened circulating levels of antimicrobial peptides in tuberculosis-diabetes co-morbidity

and reversal upon treatment Kumar NP, Moideen K, Viswanathan V, Sivakumar S, Menon PA, Kornfeld H, Babu S. PLoS One. 2017 Sep

14;12(9):e0184753. doi: 10.1371/journal.pone.0184753. eCollection 2017.



National Institutes of Health-NIRT-International Center for Excellence in Research, Chennai, India

Prof. M. Viswanathan Diabetes Research Center, Chennai, India

National Institute for Research in Tuberculosis, Chennai, India

University of Massachusetts Medical School, Worcester, MA, USA

LPD, NIAID, NIH, Bethesda, MA, USA

2. Systems immunology of diabetes tuberculosis comorbidity reveals signatures of disease

complications Prada-Medina CA, Fukutani KF, Kumar NP, GilSantana L, Babu S, Lichtenstein F, West K, Sivakumar S, Menon PA,

Viswanathan V, Andrade BB, Nakaya HI, Kornfeld H. Sci Rep. 2017 May 17;7(1):1999. doi: 10.1038/s41598-017-01767-

4.



Department of Pathophysiology and Toxicology, School of Pharmaceutical Sciences, University of São Paulo, São

Paulo, Brazil

Laboratório de Imunoparasitologia, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil

National Institutes of Health- NIRT - International Center for Excellence in Research, Chennai, India

Unidade de Medicina Investigativa, Laboratório Integrado de Microbiologia e Imunorregulação, Instituto Gonçalo

Moniz, Fundação Oswaldo Cruz, Salvador, Brazil

Multinational Organization Network Sponsoring Translational and Epidemiological Research, Instituto Brasileiro

para a Investigação da Tuberculose, Fundação José Silveira, Salvador, Brazil

Curso de Medicina, Faculdade de Tecnologia e Ciências, Salvador, Brazil

Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA



Universidade Salvador (UNIFACS), Laureate Universities, Salvador, Brazil

Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN,

USA

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kumar%20NP%5BAuthor%5D&cauthor=true&cauthor_uid=28910369

https://www.ncbi.nlm.nih.gov/pubmed/?term=Moideen%20K%5BAuthor%5D&cauthor=true&cauthor_uid=28910369

https://www.ncbi.nlm.nih.gov/pubmed/?term=Viswanathan%20V%5BAuthor%5D&cauthor=true&cauthor_uid=28910369

https://www.ncbi.nlm.nih.gov/pubmed/?term=Sivakumar%20S%5BAuthor%5D&cauthor=true&cauthor_uid=28910369

https://www.ncbi.nlm.nih.gov/pubmed/?term=Menon%20PA%5BAuthor%5D&cauthor=true&cauthor_uid=28910369

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kornfeld%20H%5BAuthor%5D&cauthor=true&cauthor_uid=28910369

https://www.ncbi.nlm.nih.gov/pubmed/?term=Babu%20S%5BAuthor%5D&cauthor=true&cauthor_uid=28910369



PUBLICATIONS

25

3. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes.

Part 2: Underlying biological mechanisms Ronacher K, van Crevel R, Critchley J, Bremer A, Schlesinger LS, Kapur A, Basaraba R, Kornfeld H, Restrepo BI. Chest.

2017 Jul;152(1):174-180. doi: 10.1016/j.chest.2017.02.032. Epub 2017 Apr 20.



Mater Research Institute-The University of Queensland, Translational Research Institute,

Woolloongabba, Queensland, Australia

Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB

Research/Medical Research Council Centre for Molecular and Cellular Biology, Division of Molecular Biology and

Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa

Department of Internal Medicine, Radbourd University Medical Center, Nijmegen, the Netherlands

Population Health Research Institute, St George’s, University of London, UK

Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and

Kidney Diseases, National Institutes of Health, Bethesda, MD, USA

Department of Microbial Infection & Immunity, The Ohio State University, Ohio, USA

World Diabetes Foundation, Copenhagen, Denmark

Department of Microbiology, Immunology and Pathology, Colorado State University, Colorado, USA

Department of Medicine, University of Massachusetts Medical School, USA

University of Texas Health Science Center Houston, School of Public Health, Brownsville Campus, Texas, USA

4. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes.

Part 1: Epidemiology and clinical management Critchley JA, Restrepo BI, Ronacher K, Kapur A, Bremer AA, Schlesinger LS, Basaraba R, Kornfeld H, van Crevel R.

Chest. 2017 Jul;152(1):165-173. doi: 10.1016/j.chest.2017.04.155. Epub 2017 Apr 20.



Population Health Research Institute, St George’s, University of London, UK

University of Texas Health Science Center Houston, School of Public Health, Brownsville

Campus, Texas, USA

Mater Research Institute – The University of Queensland, Translational Research Institute, Woolloongabba,

Queensland, Australia

World Diabetes Foundation, Copenhagen, Denmark

Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and

Kidney Diseases, National Institutes of Health, Bethesda, MD, USA

Department of Microbial Infection & Immunity, The Ohio State University, Ohio, USA

Department of Microbiology, Immunology and Pathology, Colorado State University, Colorado, USA

Department of Medicine, University of Massachusetts Medical School, USA

Department of Internal Medicine, Radbourd University Medical Center, Nijmegen, the Netherlands

5. Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of

circulating angiogenic factors Kumar NP, Moideen K, Sivakumar S, Menon PA, Viswanathan V, Kornfeld H, Babu S. J Infect. 2017 Jan;74(1):10-21. doi:

10.1016/j.jinf.2016.08.021. Epub 2016 Oct 4.



National Institutes of Health-NIRT-International Center for Excellence in Research, Chennai, India



LPD, NIAID, NIH, MD, USA




PUBLICATIONS

26

6. Modulation of dendritic cell and monocyte subsets in tuberculosis- diabetes co-morbidity upon

standard tuberculosis treatment Kumar NP, Moideen K, Sivakumar S, Menon PA, Viswanathan V, Kornfeld H, Babu S. Tuberculosis (Edinb). 2016 Dec;

101:191-200. doi: 10.1016/j.tube.2016.10.004. Epub 2016 Oct 11.



National Institutes of Health NIRT International Center for Excellence in Research, Chennai, India




LPD, NIAID, NIH, MD, USA

7. High prevalence and heterogeneity of diabetes in patients with TB in South India: A report

from the Effects of Diabetes on Tuberculosis Severity (EDOTS) Study Kornfeld H, West K, Kane K, Kumpatla S, Zacharias RR, Martinez-Balzano C, Li W, Viswanathan V. Chest. Volume 149,

Issue 6, June 2016, Pages 1501–1508.




Prof. M. Viswanathan Diabetes Research Center, Royapuram, India

8. Effect of standard tuberculosis treatment on naive, memory and regulatory T-cell homeostasis

in tuberculosis-diabetes co-morbidity Kumar NP, Moideen K, Viswanathan V, Kornfeld H, Babu S. Immunology. 2016 Sep;149(1):87-97. doi:

10.1111/imm.12632. Epub 2016 Jul 26.



National Institutes of Health - NIRT - International Centre for Excellence in Research, Chennai, India

Prof. M. Viswanathan Diabetes Research Centre, Chennai, India


Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA




Lectures

& Presentations RePORT India 7TH ANNUAL JOINT LEADERSHIP MEETING CATALYZING DISCOVERIES TOWARD TB ELIMINATION NEW DELHI | 15–17 FEB 2018


LECTURES & PRESENTATIONS

27

RePORT India Consortium

LECTURE

Gupta A. An Overview of the RePORT India Consortium. Presented at: Annual IeDEA Meeting; National

Institutes of Health; June 22, 2016; Rockville, MD, USA.

PRESENTATION

Hamilton CD, Ellner J, Swaminathan S, Christopher D, Gupta A, Sterling T, Rolla VC, Stoszek S. Regional

Prospective Observational Research for Tuberculosis (RePORT) Consortia using a Common Protocol to

Collect Specimens for Biomarker Research. Poster presented at: 45th Union World Conference on Lung

Health of the International Union Against TB and Lung Disease; October 28-November 1, 2014; Barcelona,

Spain.

Bhagwan Mahavir Medical Research Centre (BMMRC)/LEPRA Society/

University of Texas Health Science Center at Tyler

PRESENTATIONS

Devalraju KP, Neela VSK, Chaudhury A, Vankayalapati R,

Valluri VL. NK cells and Memory-like NK Cells as

Immunological Markers of Protection against Latent TB

Conversion in Household Contacts of TB Patients. Accepted

for oral presentation at: 5th Global Forum on TB Vaccines;

February 20-23, 2018; New Delhi, India.

Category Definitions

LECTURE: Individual presentation on

topic or field of expertise

PRESENTATION: Multiple authors,

includes poster and oral abstract

discussions

6

20

33

26

15

0

5

10

15

20

25

30

35

2014 2015 2016 2017 2018

LECTURES & PRESENTATIONS:

2013–JAN 2018


28

Neela VSK, Devalraju KP, Sumnalatha G, Chowdary A, Ansari MS, Vankayalapati R, Valluri VL. CD14+

CD16+ Cells as Immunological Marker for Protection in Household Contacts with Latent Tuberculosis

Infection. Accepted for poster presentation at: 5th Global Forum on TB Vaccines; February 20-23, 2018;

New Delhi, India.

Devalraju KP. Identify Potential Biomarkers for Development of Latent Tuberculosis Infection (LTBI) by

Longitudinal Follow-Up of HHC’s of TB Patients. Presented at: RePORT International 2016 Meeting; July 14-

15, 2016.

Cheekatla SS, Tripathi D, Venkatasubramanian S, Nathella PK, Paidipally P, Ishibashi M, Welch E, Tvinnereim

AR, Mitsuo I, Babu S, Kornfeld H, Vankayalapati R. NK-DC Crosstalk in Diabetes Enhances Il-6 Mediated

Inflammation during Tuberculosis Infection. Poster presented at: Keystone Symposium on Tuberculosis Co-

Morbidities and Immunopathogenesis (B6); February 28-March 3, 2016; Keystone, CO, USA.

Venkatasubramanian S, Paidipally P, Cheekatla SS, Welch E, Raghunath A, Tvinnereim AR, Nurieva R, Barnes

PF, Vankayalapati R. IL-21 Dependent Expansion of Memory-like NK Cells Enhances Protective Immune

Responses against Mycobacterium tuberculosis. Presented at: NK 2015—15th Meeting of the Society for

Natural Immunity; May 2-6, 2015; Montebello, Canada.

Byramjee Jeejeebhoy Medical College (BJMC)/National Institute for

Research in Tuberculosis (NIRT)/Johns Hopkins University (JHU)

LECTURES

Chandrasekaran P, TB Research in India. Presented at: 1st BRICS TB Research Network Meeting. September

14-15, 2017, Rio de Janeiro, Brazil.

Chandrasekaran P. Ongoing Research and Research Priorities for India on LTBI. Presented at: WHO Global

TB Programme Technical Consultation Meeting on Programmatic Management of Latent Tuberculosis

Infection (LTBI). August 31-September 1, 2017, Seoul, Republic of Korea.

Gupta A. TB in Pregnancy. Presented at: RePORT India meeting: Advancing TB Research; February 2, 2016;

CMC Vellore, India.

Gupta A. TB in Pregnancy. Presented at: RePORT India TB Workshop; March 5, 2015; Mumbai, India.

Mave V. RePORT India: Objectives and Future Directions. Presented at: TB Vaccine 4th Global Forum; 2015;

Shanghai, China.

Mave V. Therapeutic Drug Monitoring (TDM) of TB in Young Children: The Role of Hair Assays. Presented

at: IMPAACT Annual Meeting; June 2015; Washington DC, USA.

PRESENTATIONS

Dolla CK, Paradkar M, Gupte A, Thiruvenkadam K, Gupte N, Kukarni V, Balasubranian U, Hannah LE,

Dhanasekaran K, Bharadwaj R, Shivakumar SVBY, Gaikwad S, Meshram S, Kohli R, Lokhande R, Thomas B,

Kinikar A, Swaminathan S, Mave V, Gupta A, Chandrasekaran P. TB Infection among Household Contacts:

Preventive Therapy for All? Accepted for poster presentation at: 5th Global Forum on TB Vaccines; February

20-23, 2018; New Delhi, India.


29

Dhanasekaran K, Chandrasekaran P, Paradkar M, Marinaik SB, Gupte A, Dolla CK, Joseph B, Subramanyam

B, Sivaramakrishnan GN, Thiruvengadam K, Gupte N, Rajagopal S, Pradhan N, Selvaraju S, Kulkarni V,

Hannah LE, Nayakam R, Suryavanshi N, Shivakumar SVBY, Mave V, Thomas B, Bharadwaj R, Gaikwad S,

Meshram S, Lokhande R, Kinikar A, Daware R, Murali L, Swaminathan S, Gupta A for C-TRIUMPh Study

Team. Risk Factors Associated with Unfavorable Outcomes in a Cohort of Pulmonary TB Patients. Accepted

for poster presentation at: 5th Global Forum on TB Vaccines; February 20-23, 2018; New Delhi, India.

Paradkar M, Dhanasekaran K, Kinikar A, Kulkarni R, Bharadwaj R, Gaikwad S, Lokhande R, Meshram S, Dolla

CK, Selvaraju S, Murali L, Thiruvengadam K, Jain D, Rajagopal S, Kulkarni V, Pradhan N, Shalini J, Kohli R,

Nayagam R, Shivakumar SVBY, Suryavanshi N, Gupte A, Gupte N, Chandrasekaran P, Mave V, Gupta A for

the CTRIUMPh Study Team. Incidence of Mycobacterium tuberculosis Infection among Household Contacts of

Adult Pulmonary Tuberculosis Cases in India. Accepted for poster presentation at: 5th Global Forum on TB

Vaccines; February 20-23, 2018; New Delhi, India.

Selvaraju S, Thiruvenkadam K, Paradkar M, Marinaik SB, Bharadwaj R, Rajagopalan S, Gaikwad S,

Pattabiraman S, Kinikar A, Sivaramakrishnan GN, Meshram S, Hanna LE, Lokhande R, Dhanasekaran K,

Gupte A, John S, Gupte N, Thomas B, Kukarni V, Ayyanu S, Kohli R, Shivakumar SVBY, Swaminathan S,

Mave V, Gupta A, Chandrasekaran P for the CTRIUMPh Study Team. Incidence of Tuberculosis Disease

among the Household Contacts of Adult Pulmonary TB Patients in India—A Multicentric Cohort Study.

Accepted for poster presentation at: 5th Global Forum on TB Vaccines; February 20-23, 2018; New Delhi,

India.

Mave V, Chandrasekaran P, Paradkar M, Gupte A, Pradhan N, Sivaramakrishnan GN, Thiruvenkadam K,

Shivakumar SVBY, Kulkarni V, Dhanasekaran K, Subramanyam B, Selvaraju S, Murali L, Bharadwaj R, Gaikwad

S, Meshram S, Kinikar A, Hanna LE, Swaminathan S, Gupte N, Gupta A. Infection Free “Resistors” among

Household Contacts of Culture-Confirmed Adult Pulmonary TB Cases. Accepted for poster presentation at:

5th Global Forum on TB Vaccines; February 20-23, 2018; New Delhi, India.

Tornheim JA, Paradkar M, Valvi C, Gupte N, Madugundu A, Kulkarni V, Sreenivasamurthy S, Raja R, Pradhan

N, Shivakumar SVBY, Kohli R, Gupte A, Chandrasekaran P, Mave V, Pandey A, Gupta A. Gene Expression

Profiles of Pediatric Tuberculosis Patients and Exposed Controls from India. Accepted for oral presentation

at: 5th Global Forum on TB Vaccines; February 20-23, 2018; New Delhi, India.

Belgaumkar, V. Barriers to Contact Screening and Isoniazid Preventive Therapy among Pediatric Contacts of

Adults with Smear-Positive Tuberculosis. Presented at: 48th Union World Conference on Lung Health;

October 13, 2017; Guadalajara, Mexico.

DeLuca A, Dhumal G, Paradkar M, Suryavanshi N, Mave V, Kohli R, Shivakumar SVBY, Gupta A. Lack of TB

Knowledge among TST-positive Household Contacts of Pulmonary Cases: A Missed Opportunity. Presented

at: 48th Union World Conference on Lung Health, October 13, 2017; Guadalajara, Mexico.

Tornheim J, Paradkar M, Valvi C, Gupte N, Madugundu A, Kulkarni V, Sreenivasamurthy S, Raja R, Pradhan

N, Shivakumar SVBY, Kohli R, Chandrasekaran P, Pandey A, Mave V, Gupta A. Gene Expression Profiles of

Pediatric Tuberculosis Patients and Exposed Controls from India. Presented at: RePORT International

Meeting; September 13; 2017; Rio de Janeiro, Brazil.

Gupte A, Mave V, Meshram S, Lokhande R, Kadam D, Dharmshale S, Bharadwaj R, Kagal A, Pradhan N,

Deshmukh S, Atre S, Sahasrabudhe T, Barthwal M, Meshram S, Kakrani A, Kulkarni V, Raskar S, Suryavanshi

N, Shivakoti R, Chon S, Selvin E, Gupte N, Gupta A, Golub J. Trends in Glycated Hemoglobin Levels and

Implications for Diabetes Screening among Pulmonary Tuberculosis Cases Undergoing Treatment in India.

Presented at: RePORT International Meeting; September 13; 2017; Rio de Janeiro, Brazil.


30

Gupte A, Shrinivasa BM, Paradkar M, Danasekaran K, Pradhan N, Gomathy NS, Hannah LE, Kulkarni V,

Ramachandran G, Thomas B, Kohli R, Suryavarshini N, Thiruvengadam K, Dolla CK, Meshram S, DeLuca A,

Golub J, Shivakumar SVBY, Gupte N, Chandrasekaran P, Mave V, Gupta A. Hyperglycemia and Treatment

Outcomes in Adults with Newly Diagnosed Drug-sensitive Extra-pulmonary Tuberculosis in India. Presented

at: RePORT International Meeting; September 13; 2017; Rio de Janeiro, Brazil.

Shivakumar SVBY, Chandrasekaran P, Paradkar M, Danasekaran K, Kumar AMV, Ramachandran G, Thomas

B, Suryavarshini N, Kohli R, Thiruvengadam K, Gupte N, Kulkarni V, Hannah LE, Gomathy NS, Pradhan N,

Dolla CK, Gupte A, DeLuca A, Meshram S, Kagal AD, Golub J, Selvaraj K, Murali L, Swaminathan S, Mave V,

Gupta A. High Burden of Dysglycemia among Contacts of Tuberculosis Patients in India: Is it Time to Screen

Them All? Presented at: RePORT International Meeting September 13, 2017; Rio de Janeiro, Brazil.

Gupte A, Mave V, Meshram S, Lokhande R, Kadam D, Dharmshale S, Bharadwaj R, Kagal A, Pradhan N,

Deshmukh S, Atre S, Sahasrabudhe T, Barthwal M, Meshram S, Kakrani A, Kulkarni V, Raskar S, Suryavanshi

N, Shivakoti R, Chon S, Selvin E, Gupte N, Gupta A, Golub J. Trends in Glycated Hemoglobin Levels and

Implications for Diabetes Screening among Pulmonary Tuberculosis Cases Undergoing Treatment in India.

Presented at: JHU Center for TB Research Annual Scientific Meeting; June 2017, Baltimore, MD, USA.

Tornheim J, DeLuca A, Ganatra S, Radhika B, Gupta A, Udwadia Z. It Simply Won’t Work Here – Few

Eligible for the Newly Recommended Short Course MDR-TB Regimen in a Mumbai Private Clinic. Presented

at: American Thoracic Society 2017 International Conference; May 21, 2017; Washington, DC, USA.

Tornheim J. Paradkar M. CTRIUMPh Pediatric Biomarker Substudy. Session: The Future of MDR-TB

Treatment in Children. Invited Presentation. 2017 IMPAACT Annual Meeting; May 30, 2017; Washington,

DC, USA.

Mathad J, Alexander M, Bhosale R, Naik S, Shivakoti R, Mave V, Suryavanshi N, Gupte N, Kulkarni V, Pradan

N, Patil N, Gupta A. Impact of Immune Changes of Pregnancy and HIV Infection on Tuberculosis. Poster

Presentation. 6th Annual Regional Prospective Observational Research for Tuberculosis (RePORT) India

Joint Leadership Meeting; February 3, 2017; Hyderabad, India.

Gupte A, Meshram S, Selvaraju S, Gupte N, Shivakumar SVBY, Paradkar M, Kohli R, Thiruvengadam K,

Suryavanshi N, Chandrasekaran P, Mave V, Swaminathan S, Gupta A, Golub J, Checkley W. Host Factors

Associated with Poor Respiratory Health-related Quality of Life in Pulmonary Tuberculosis. Presented at:

RePORT India Annual Meeting; February 3, 2017; Hyderabad, India.

Chandrasekaran P, Thiruvengadam K, Gupte N, Luck EH, Mave V, Gupte A, Gupta A, Swaminathan S.

Household Contact Tracing of Adult Pulmonary TB Patients in India: Prevalence of TB Disease and Infection.

Presented at: 6th Annual Regional Prospective Observational Research for Tuberculosis (RePORT) India

Joint Leadership Meeting; February 3, 2017. Hyderabad, India.

Paradkar M, Kavitha D, Shiva Kumar SVBY, Khadse S, Khwaja S, Hari K, Rani N, Thiruvengadam K, Gupte N,

Raskar S, Jain D, Suryavanshi S, Kohli R, Kulkarni V, Pradhan N, Sathyamurthi B, Tornheim J, Gupte A,

DeLuca A, Mave V, Chandrasekaran P, Gupta A for the CTRIUMPH Study Team. Descriptive Baseline

Characteristics, Treatment Outcomes and Biorepository of Pediatric TB Cases in CTRIUMPh-RePORT India

Prospective Cohort. Presented at: 6th Annual Regional Prospective Observational Research for Tuberculosis

(RePORT) India Joint Leadership Meeting; February 3, 2017. Hyderabad, India.


31

John S, DeLuca A, Paradkar M, Nayagam R, Shivakumar SVBY, Gupte A, Gupte N, Thomas B, Suryavanshi N,

Kolhi R, Golub J, Kulkarni V, Pradhan N, Mave V, Chandrasekaran P, Gupta A. Alcohol Use Among Adult

Pulmonary and Extra-pulmonary TB Cases in the CTRIUMPH India Cohort. Presented at: 6th Annual

Regional Prospective Observational Research for Tuberculosis (RePORT) India Joint Leadership Meeting;

February 3, 2017. Hyderabad, India.

Tornheim JA, Ganatra S, DeLuca A, Banka R, Gupta A, Udwadia ZF. Impact of Drug Susceptibility Testing on

Drug Choice in a Tuberculosis Cohort with High Rates of Drug Resistance from the Private Sector in

Mumbai. Presented at: 6th Annual Regional Prospective Observational Research for Tuberculosis (RePORT)

India Joint Leadership Meeting; February 3, 2017. Hyderabad, India.

Mave V, Pradhan R, Kagal A, Bharadwaj R, Gupte N, Gupta A, Meshram S, Golub J. Third Anti-TB Drug in

Continuation Phase for TB patients: Is It the Need of the Hour for India? Presented at: 47th Union World

Conference on Lung Health; October 27, 2016; Liverpool, UK.

Mave V, Gupte N, Meshram S, Kagal A, Gupta A, Bharadwaj R, Pradhan R, Golub J. Xpert® MTB/RIF Assay

for Pulmonary Tuberculosis Diagnosis in Patients with Pre-Diabetes Mellitus and Diabetes Mellitus.

Presented at: 47th Union World Conference on Lung Health; October 27, 2016; Liverpool, UK.



Associated with Poor Respiratory Health-related Quality of Life in Pulmonary Tuberculosis.Presented at:

2016 IDSA Conference; October 27, 2016; New Orleans, LA, USA.

Chandrasekaran P, Mave V, Tiruvengadam K, Gupte N, Hannah LE, Meshram S, Swaminathan S, Gupta A.

Household Contact Tracing of Adult Pulmonary TB Patients in India: Prevalence of TB Disease. Presented at:

2016 IDSA Conference; October 27, 2016; New Orleans, LA, USA.

Shivakumar SVBY, Thiruvengadam K, Gupte N, Chandrasekaran P, Mave V, Hannah LE, Kulkarni V, Gupte A,

DeLuca A, Pattabiraman S, Sharma GN, Pradhan N, Subramaniyan B, Chandrakumar D, Thomas B,

Suryavanshi B, Paradkar M, Meshram S, Kagal A, Kohli R, Golub J, Ramachandran G, Swaminathan S, Gupta

A. TB Infection Prevalence, Incidence and Risk Factors among Child and Adult Household Contacts of Adult

TB Cases in India. Presented at: 2016 IDSA Conference; October 27, 2016; New Orleans, LA, USA.

Elf JL, Kinikar A, Khadse S, Mave V, Gupte N, Kulkarni V, Patekar S, Raichur P, Breysse P, Gupta A, Golub J.

The Association of Exposure to Air Pollution from Biomass Fuels, Kerosene, and Secondhand Tobacco

Smoke with TB in Adult Women and Children in Pune, India. Presented at: RePORT International; July 14,

2016; Durban, South Africa.



Associated with Poor Respiratory Health-related Quality of Life in Pulmonary Tuberculosis.Presented at:

RePORT International; July 14, 2016; Durban, South Africa.



Associated with Poor Respiratory Health-related Quality of Life in Pulmonary Tuberculosis. Presented at:

JHU Center for TB Research Annual Scientific Meeting; July 2016; Baltimore, USA.


32

Ogale YP, Elf JL, Lokhande R, Mave V, Roy S, Gupta A, Golub JE, Mathad J. Characteristics Associated with

Mobile Phone Access Among TB Patients in Pune, India. Poster presented at: 46th World Conference on

Lung Health of the International Union Against TB and Lung Disease; December 1-5, 2015; Cape Town,

South Africa.

Elf JL, Kinikar A, Khadse S, Mave V, Gupte N, Kulkarni V, Patekar S, Raichur P, Breysse P, Gupta A, Golub J.

The Association of Exposure to Air Pollution from Biomass Fuels, Kerosene, and Secondhand Tobacco

Smoke with TB in Adult Women and Children in Pune, India. Presented at: American Thoracic Society

International Conference; May 1, 2015; Denver, CO, USA.

Christian Medical College, Vellore (CMC-Vellore)/University of Cambridge-

University of Washington

LECTURES

Christopher DJ. Targeted LTBI Testing. Presented at: LTBI Knowledge Seminar; January 11, 2018;

Hyderabad, India.

Christopher DJ. LTBI Screening in High TB Prevalence Setting. Presented at: Qiagen Knowledge

Seminar; November 2, 2017; Bangalore, India.

Christopher DJ. LTBI Screening: A Clinician’s Perspective. Presented at: CME organized by Qiagen; April 5,

2017; New Delhi, India.

Christopher DJ. LTBI: To Screen or Not to Screen. Presented at The Three T’s of TB Prevention: Test,

Treat and Track Symposium. Asia Pacific Regional Conference; International Union against Tuberculosis;

March 23, 2017; Tokyo, Japan.

Christopher DJ. Large Thoracoscopic Pleural Biopsy Improves Yield of Xpert MTB/RIF for Diagnosis of

Pleural Tuberculosis. Presented at: BRONCOCON; CMC Vellore; March 2-4, 2017; Vellore, India.

Christopher DJ. Advances in the Management of Drug Resistant TB. Presented at: TB Symposium.

Convened by Krishna Medical College in collaboration with McGill University (Canada); December 21, 2016;

Manipal, India.

Christopher DJ. Healthcare Worker TB: A Panel Discussion. Presented at: TB Symposium. Convened by

Krishna Medical College in collaboration with McGill University (Canada); December 21, 2016; Manipal,

India.

Christopher DJ. Evolution of Drug Resistant TB in India. Presented at: Annual Update in Tuberculosis.

Convened by CMC Vellore. November 19, 2016; Vellore, India.

Christopher DJ. Screening for LTBI in Healthcare Personnel to Assess TB Risk- lessons from India.

Presented at: 5th Meeting of Asian Experts Community; August 26-28, 2016; Taipei, Taiwan.

Christopher DJ. TB Risk in Health Care Workers: Myth or Reality? Presented at: RePORT International

Meeting. July 14-15, 2016; Durban, South Africa.


33

Christopher DJ. From Lab to Clinic: Optimizing the Importance of New Diagnostics. Presented at:

Advancing TB Research – An Exploration of Opportunities. Convened by PD Hinduja Hospital and NIH

(USA); March 23-24, 2016; Mumbai, India.

Christopher DJ. Lessons from Healthcare –TB Research in India. Presented at: CMC Winter Symposium and

the 5th RePORT Leadership Group Meeting; February 12-13, 2016; Vellore, India.

Christopher DJ. Pleural Tuberculosis. Presented at: Association of Physicians of India Meeting. January 29-31,

2016; Hyderabad, India.

Christopher DJ. TB in Healthcare Workers. Presented at: National Update in Respiratory Medicine.

Convened by PD Hinduja Hospital; November 27-29, 2015; Mumbai, India.

Christopher DJ. Road for TB Elimination in India. Presented at: 4th Meeting of Asian Experts Community;

August 7-9, 2015; Bali, Indonesia.

Christopher DJ. Newer Diagnostics in TB. Presented at: Institute of Thoracic Medicine, MMC, CME

Program for the PG Students of Southern States; September 2014; Chennai, India.

Christopher DJ. Relevance of TST and IGRA in Current Day Practice. Presented at: ASHRAICON

Conference 2014; July 27, 2014; Ahmedabad, India.

PRESENTATIONS

Dinakaran S, Christopher DJ, Gupta R, Prince J, Isaac B, Thangakunam B. Large Thoracoscopic Pleural Biopsy

Improves Yield of Xpert MTB/RIF for Diagnosis of Pleural Tuberculosis. Presented at: BRONCOCON;

CMC Vellore; March 2-4, 2017; Vellore, India.

Christopher DJ , Balamugesh T, Dhabi P. The Prevalence of Active and Latent Tuberculosis Infection in

Patients with Type 2 Diabetes Mellitus in a Tertiary Care Hospital of South India. Presented at: Winter

Symposium RePORT Leadership Group Meeting; February 12-14, 2016; Vellore, India.

Christopher DJ, Balamugesh T ,Rohit KO, James P, Gupta R. Diagnostic Yield of Various Microbiologic and

Histopathologic Tests in TB Pleural Effusion Diagnosed with Thoracoscopy and Outcomes of Such Patients

on 6 Months Follow Up. Presented at: Winter Symposium RePORT Leadership Group Meeting; February

12-14, 2016; Vellore, India.

Christopher DJ, Mitra S, Saroini JS, Balaji V, Gupta M, Therese M, Yadav B, Jeyaseelan L. Burden of Diabetes

Among Patients with Tuberculosis: Ten-Year Experience from an Indian Tertiary Care Teaching Hospital.

Presented at: 45 Annual Union World Conference on Lung Health. October 28-Nov 1, 2014; Barcelona,

Spain.

Christopher DJ, Denkinger C, Thangakunam B, Sarojini JS, Pai M, Schumacher S. Point-of-Care

Implementation of Xpert: Evaluating the Impact of Product and Process Innovation in TB Diagnosis.

Presented at: 45 Annual Union World Conference on Lung Health. October 28–Nov 1, 2014; Barcelona,

Spain.


34

Jawaharlal Institute of Postgraduate Medical Education & Research

(JIPMER)/ Boston Medical Center (BMC)

LECTURES

Hochberg, NS. Indo-US TB Cohort: Study Design and Preliminary Results. Presented at: TB Research Unit

(TBRU) Investigators Meeting. September 2017; Boston, MA, USA.

Hochberg, NS. Updates in Tuberculosis: The Era of Sea Changes. Medicine Grand Rounds. Presented at:

Carney Hospital. March 2017.

Hochberg, NS. Indo-US TB Cohort: Study Design and Preliminary Results. Invited speaker, JIPMER.

February 8, 2017; Puducherry, India.

Hochberg, NS. Malnutrition and TB in India: Intersection and Implications. Presented at: Northeastern

World TB Day Symposium.

Hochberg, NS. Tuberculosis: The Fundamentals and the Sea Changes. Presented at: MPH Course: Global

Health Priorities & Approaches. Tufts University School of Medicine. Boston, MA, USA.

PRESENTATIONS

Chua A, Mowry WB, Sahu S, Roy G, Ellner JJ, Horsburgh Jr CR, Pleskunas J, Sarkar S, Hochberg NS, Reddy

D. Does the Form of Tobacco Product Used by Smokers Influence Pulmonary Tuberculosis Severity?

Accepted for poster presentation at: ATS 2018; San Diego, CA, USA.

Schenk NM, Sahu S, Roy G, Ellner JJ, Horsburgh Jr CR, Pleskunas J, Sarkar S, Hochberg NS, Reddy D.

Influence of Type of Tobacco Product on Chest X-ray findings in Pulmonary Tuberculosis Patients in India;

Accepted for poster presentation at: ATS 2018; San Diego, CA, USA.

Hoyt K, White L, Sarkar S, Pleskunas J, Zhou T, Noyal J, Muthuraj M, Vinod K, Roy G, Ellner JJ, Horsburgh Jr

CR, Hochberg NS. Effect of Malnutrition on Tuberculosis Mycobacterial Burden and Chest Radiographic

Findings. Accepted for poster presentation at: Union Regional Conference, North America 2018; Chicago,

IL, USA.

Svadzian A, Sahu A, Pleskunas JA, Sarkar S, Roy G, Ellner JJ, Hochberg NS, Reddy D. Association between

Wood Fuel Usage and Disease Severity among Pulmonary Tuberculosis Cases. Poster presented at:

American Society of Tropical Medicine & Hygiene Meeting; November 2016; Atlanta, GA, USA.

Stigma as a Barrier to Tuberculosis Care: A Literature Review. Poster presented at: Evans Department of

Medicine Research Days, Boston University School of Medicine; October 2016; Boston, MA, USA.

Roy G, Sivaprakasam A, Kubiak R, Govindarajan S, Salgame P, Ellner J, Hochberg N, Sarkar S. Description of

New Pulmonary Tuberculosis Cases in Southern India. Poster presented at: Evans Department of Medicine

Research Days, Boston University School of Medicine; October 2016; Boston, MA, USA.

Svadzian A, Sahu A, Pleskunas JA, Sarkar S, Roy G, Ellner JJ, Hochberg NS, Reddy D. Association between

Wood Fuel Usage and Disease Severity among Pulmonary Tuberculosis Cases. Poster presented at: Evans

Department of Medicine Research Days, Boston University School of Medicine; October 2016; Boston, MA,

USA.


35

Conversion among Pulmonary Tuberculosis Cases in India. Poster presented at: Evans Department of

Medicine Research Days, Boston University School of Medicine; October 2016; Boston, MA, USA.

Predictors of 2 Month Sputum Conversion among Tuberculosis Patients in India. Poster presented at: Evans

Department of Medicine Research Days, Boston University School of Medicine; October 2016; Boston, MA,

USA.

Prolonged Cough among Tuberculosis Patients In Tamil Nadu and Pondicherry, India. Poster presented at:

Evans Department of Medicine Research Days, Boston University School of Medicine; October 2016;

Boston, MA, USA.

Reddy D, Sahu S, Roy G, Ellner JJ, Horsburgh Jr CR, Pleskunas JA, Sarkar S, Hochberg NS. Association

between Biomass Fuel, Tobacco Use and Two-month Sputum Smear Conversion among Pulmonary

Tuberculosis Cases in India. Poster presented at: American Thoracic Society Conference; May 2016; San

Francisco, CA, USA.

Roy G, Sivaprakasam A, Kubiak R, Govindarajan S, Salgame P, Ellner J, Hochberg N, Sarkar S. Description of

New Pulmonary Tuberculosis Cases in Southern India. Poster presented at: 46th Union World Conference

on Lung Health of the International Union Against TB and Lung Disease; December 1-5, 2015; Cape Town,

South Africa.

Sarkar S, Fernandes P, Lakshminarayanan S, Kubiak R, Horsburgh CR, Ravikumar T, Ellner J, Hochberg N.

Age and Gender Distribution of Latent Tuberculosis Infection Cases in a Household Contact Study, India.

Poster presented at: 46th Union World Conference on Lung Health of the International Union Against TB

and Lung Disease; December 1-5, 2015; Cape Town, South Africa.

Reddy, D, Sahu S, McIntosh A, Kubiak R, Roy G, Ellner J, Sarkar S, Hochberg N. Association Between Latent

Tuberculosis Infection and Indoor Air Pollution among Household Contacts of Pulmonary Tuberculosis

Cases. Poster presented at: 46th Union World Conference on Lung Health of the International Union

Against TB and Lung Disease; December 1-5, 2015; Cape Town, South Africa.

MV Diabetes Research Centre (MVDRC)/ University of Massachusetts

PRESENTATIONS

Kornfeld H. Sugar, Fat and Consumption. Invited seminar: Boston University School of Medicine; January 16,

2016; Boston, MA, USA.

Kornfeld H. Tuberculosis: The Rise of Comorbidities. Medical Grand Rounds, University of Massachusetts

Medical School; June 4, 2015; Worcester, MA, USA.

Kornfeld H. TB and Diabetes. Invited seminar: Singapore Immunology Network; February 27, 2015;

Singapore.

Kornfeld H. TB and Diabetes. Keystone Symposium on Granulomas in Infectious and Non-Infectious

Disease, January 22-27, 2015, Santa Fe, NM, USA.

Kornfeld H. The Effects of Diabetes on TB Susceptibility. Invited seminar: No.4 People’s Hospital of

Nanning; January 12, 2015; Nanning, China.


36

Kornfeld H. Sugar, Fat, and Consumption. Invited seminar: University of Texas, Health Science Center at

Tyler; August 22, 2014; Tyler, TX, USA.

Kornfeld H. Determinants of TB Severity. Invited seminar: Shenzhen-Hong Kong Institute of Infectious

Diseases; Shenzhen, China.

ABSTRACTS

Kumar NP, Moideen K, Sivakumar S, Menon P, Viswanathan V, Kornfeld H, Babu S. Effect of Standard

Tuberculosis Treatment on Circulating Levels of Pro-inflammatory Cytokines in Tuberculosis-diabetes Co-

morbidity. Accepted for poster presentation at: Keystone Symposia -Tuberculosis: Translating Scientific

Findings for Clinical and Public Health Impact; April 15-19, 2018; Whistler, BC, Canada.

Kumar NP, Moideen K, Sivakumar S, Menon P, Viswanathan V, Kornfeld H, Babu S. Effect of Anti-

tuberculosis Treatment on the Systemic Levels of Matrix Metalloproteinases and Tissue Inhibitors of MMP in

Tuberculosis–Diabetes Co-morbidity. Accepted for poster presentation at: 5th Global Forum on TB

Vaccines; February 20-23, 2018; New Delhi, India.

Moideen K, Kumar NP, Bethunaickan R, Sivakumar S, Menon PA, Viswanathan V, Shruthi BS, Kornfeld H,

Babu S. Altered Systemic Levels of Neutrophil and Mast Cell Granular Proteins in Tuberculosis-Diabetes

Co-morbidity and Changes Following Treatment. Accepted for poster presentation at: 5th Global Forum on

TB Vaccines; February 20-23, 2018; New Delhi, India.

Cheekatla SS, Venkatasubramanian S, Tripathi D, Paidipally P, Welch E, Tvinnereim AR, Vankayalapati R. IL-

21 Is Essential for the Optimal Control of Mycobacterium tuberculosis Infection. Presented at: American

Association of Immunologist Meeting; May 8-12, 2015; New Orleans, LA, USA.

Cheekatla SS, Tripathi D, Venkatasubramanian S, Paidipally P, Welch E, Tvinnereim AR, Kornfeld H,

Vankayalapati R. IL-6 regulates Pro- and Anti-Inflammatory Cytokine Production and Mortality of

Mycobacterium tuberculosis Infected Type 2 Diabetic Mice. Presented at: American Association of

Immunologist Meeting; May 8-12, 2015; New Orleans, LA, USA.

Tripathi D, Venkatasubramanian S, Cheekatla SS, Paidipally P, Welch E, Tvinnereim AR, Vankayalapati R.

Liver NK1.1 Cells and IL-22 Promote Pancreatic Islets Allograft Survival in Type 1 Diabetic Mice. Presented

at: American Association of Immunologist Meeting; May 8-12, 2015; New Orleans, LA, USA.

Tripathi D, Venkatasubramanian S, Cheekatla SS, Paidipally P, Welch E, Tvinnereim AR, Vankayalapati R.

CD4+CD25+Foxp3+ Cells from JNK-/- Mice Prolong Pancreatic Allograft Survival in Type 1 Diabetic Mice.

Presented at: American Association of Immunologist Meeting; May 8-12, 2015; New Orleans, LA, USA.

Venkatasubramanian S, Dhiman R, Paidipally P, Cheekatla SS, Tripathi D, Welch E, Tvinnereim AR, Brenda

Jones B, Theodorescu D, Barnes PF, Vankayalapati R. A Rho GDP Dissociation Inhibitor Produced by

Apoptotic T-cells Inhibits Growth of Mycobacterium tuberculosis. Presented at: American Association of

Immunologist Meeting; May 8-12, 2015; New Orleans, LA, USA.


37

PD Hinduja Hospital/Johns Hopkins University (JHU)

PRESENTATIONS

Chawla PK, Lokhande RV, Naik PR, Dherai AJ, Udwadia ZF, Mahashur AA, Soman R, Patel J, Ashavaid TF.

Therapeutic Drug Monitoring of Rifampicin & Isoniazid and Implications of Acetylator Genotype on Plasma

Levels. Presented at: 15th International Congress on Therapeutic Drug Monitoring and Clinical Toxicology

(IATDMCT); September 27, 2017; Kyoto, Japan.

Udwadia ZF, Tornheim JA, Ganatra S, DeLuca A, Banka R, Gupta A. Impact of Drug Susceptibility Testing on

Drug Choice in a Tuberculosis Cohort with High Rates of Drug Resistance from the Private Sector in

Mumbai. Presented at: 2016 IDSA Conference; October 27, 2016; New Orleans, LA, USA.

Tornheim J, Ganatra S, Deluca A, Banka R, Rodrigues C, Gupta A, Udwadia Z. Linezolid Experience among

MDRTB Patients in Mumbai. Presented at: ERS International Congress, European Respiratory Society;

September 14, 2016; Milan, Italy.

Grants

& Substudies RePORT India 7TH ANNUAL JOINT LEADERSHIP MEETING CATALYZING DISCOVERIES TOWARD TB ELIMINATION NEW DELHI | 15–17 FEB 2018

GRANTS & SUBSTUDIES

38

RePORT INTERNATIONAL SUPPLEMENTAL FUNDED PROJECTS | AWARDED

Title Partners CRDF # Start Date Investigators

1. Validation of Transcriptional

Signature to Predict Active TB

Disease among Advanced HIV

Patients

BMC,

BJGMC,

JHU,

RePORT

Brazil

RICC 2017

Mave V, Rolla V,

Salgame P, Kadam D,

Andrade B, Gupta A,

Meshram S, Kulkarni V,

Ellner J

2. Molecular Signatures of

Tuberculosis-Diabetes Interaction

(MSTDI) study

JHU,

UMass,

BJGMC,

NIRT,

MVDRC

RICC 2017

Kornfeld H, P

Chandrasekaran, Gupte

A, Mave V, Bharadwaj R,

Golub J, Andrade B,

Paradkar M, Luke H,

Kulkarni V, Gupte N,

Shivakumar SVBY, Gupta

A

3. Biomarkers for TB Diagnosis and

Treatment Response BJGMC

NIRT

Emory

JHU

23737 2016

Rengarajan J, Hanna LE,

Mave V, Chandrasekaran

P, Thiruvengadam K,

Toidi A, Gupte N,

Kulkarni V, Gupta A and

CTRIUMPH team

4. Impact of HIV and Diabetes

Mellitus on TB Drug Resistance

and Recurrence

BJGMC

NIRT

JHU

MVDRC

UMass

23738 2016

Mave V, Devi U,

Chandrasekaran P,

Mathema B, Vishwanathan

V, Kornfeld H, Kreiswirth

B, Golub J, Gupte N,

Shivakumar SVBY, Gupta

A

5. MDR-TB and HIV at RePORT

Sites India

BJGMC

NIRT

JIPMER

JHU

BMC

23723 2016

Horsburg R,

Chandrasekaran P, Mave

V, Gupta A, Sarkar S

6. Validation and Fine Tuning of the

Computer Aided Diagnosis of

Pulmonary Tuberculosis

Model for the Indian Subcontinent

CMC 23734 2016

Christopher DJ,

Thangakunam B, Lal B,

Agrawal A

7. Extracranial Involvement as

Detected by Positron Emission

Tomography Scan in Patients with

Tubercular Meningitis

CMC 23721 2016 Thangakunam B,

Christopher DJ

8. Inflammatory Biomarkers as a

Triage Test for Screening

Symptomatic TB

JIPMER

Rutgers

BMC

23732 2016 Ellner J, Salgame P,

Sarkar S, Pleskunas J

9. Characterization of Monocyte

Responses in Pulmonary TB

Patients with or without Type 2

Diabetes

NIRT-NIH

– ICER

MVDRC

23722 2016 Kumar P

10. Effect of Malnutrition on Latent

TB JIPMER

Rutgers

BMC

23719 2016

Hochberg NS, Negi VS,

Mahalakshmy T, Johnson

WE, Salgame P, Pleskunas

J

GRANTS & SUBSTUDIES

39

RePORT INTERNATIONAL SUPPLEMENTAL FUNDED PROJECTS | AWARDED

Title Partners CRDF # Start Date Investigators

11. Determining Barriers to TB Care JIPMER

BMC

BU

23730 2016

Sabin L, Sarkar S,

Hochberg NS,

Fernandes P, Pleskunas J,

Amsaveni

12. TH17 Cell Subsets as Potential

Risk Markers of Latency and

Active TB Infection in Household

Contacts

BMMRC

UT 23725 2016

Devalraju KP, Neela

VSK, Valluri VL,

Vankayalapati K

13. Comparison of Available Purified-

Protein Derivative (PPD)

Tuberculin Skin Test (TST)

Antigen Solutions in Detecting

Latent Tuberculosis Infection in

India

CMC

BJGMC

JIPMER

BMMRC

NIRT

JHU

BMC

61783 2015

Christopher DJ,

DeLuca A, Ellner J, Gupta

A, Horsburgh B, Kadam

D, Kulkarni V, Lakshmi V,

Amsaveni,


V, Jones F, Hochberg N

GRANTS & SUBSTUDIES | AWARDED

Title Partners Grant

Source

Start Date/

Duration Investigators

1. Tuberculosis: Learning the

Impact of Nutrition (TB LION) JIPMER

BMC

Rutgers

Tufts

NIRT

Warren

Alpert

Foundation

2018-2023

Hochberg NS, Parija S,

Chandrasekaran P,

Ellner JJ, Johnson WE,

Wanke C, Sarkar S, Negi

VS, Joseph N, Rajkumari N,

Mahalakshmy T, Reddy D,

Saravanan N, Harisankar,

Tripathy S

2. Therapeutic Outcomes with

Second-Line Drug Exposures in

a Cohort of South African and

Indian Patients with Drug

Resistant TB: A

Pharmacokinetic-

Pharmacodynamic Assessment

Hinduja

PHRU

JHU

DBT/South

Africa MRC 2017

Ashavaid TF, Variava E,

Rodrigues C, Udwadia ZF,

Gupta A, Martinson N

3. Predictors of Resistance

Emergence Evaluation in MDR-

TB Patients on Treatment -

(PREEMPT)

JIPMER

NIRT

BJGMC

Brazil

Vanderbilt

Rutgers

CDC

JHU

BMC

Hinduja

NIH/NIAID:

R01

7/1/2017-

6/30/2022

Horsburgh R, Sterling

TR, Pelloquin C, Alland D,

Ciegelski P, Collins J,

Chandrasekharan P, Ellner

J, Gupta A, Mave V, Rolla

V, Kritski A, Sarkar S

GRANTS & SUBSTUDIES

40



Source

Start Date/


4. Transcriptomic and

Metabolomic Analysis of

Microbiologically Confirmed

Pediatric Tuberculosis Patients

and Uninfected Household

Contacts

BJGMC

JHU

Ujala

Foundation

Wyncote

Foundation

BWI-CTU

C-TRIUMPH

2017

Tornheim JA, Paradkar

M, Dutta N, Bader J,

Kulkarni V,

Balasubramanian U,

Bharadwaj R, Raja R,

Sreenivasmurthy S,

Karakousis P, Mave V,

Pandey A, Gupta A

5. The Role of Innate Immunity in

the Acquisition of Sterile

Protection Against TB Infection U Colorado,

JHU, BJMC NIH R21 2017

Weinberg A, Segano Z,

Mave V, Gupte N, Paradkar

M, Suryavanshi N, Kulkarni

V, Balasubramanian U,

Bharadwaj R, Gupta A

6. Association of Lipid Mediators

of Inflammation with TB

Treatment Outcomes

JHU, NIRT,

BJGMC

CTRIUMPH

and Gilead

Foundation

2017

Shivakoti R,


V, Kulkarni V, Gupte A,

Gupte N, Shivakumar

SVBY, Nimkar S, Dalli J,

Natarajan, S,

Karunaianantham R, Gupta

A

7. IFN-γ Independent Inhibition of

MTB Growth in Human

Macrophages.

BMMRC

UT

NIH/NIAID:

R01AI12331

0-01A1

2017 Vankayalapati K, Valluri

V and others

8. Validation Study of TruNAT-

MTB-Rif in EPTB

CMC/NIRT/Hi

nduja/

AIIMS

ICMR 2017

Christopher DJ, Singh M,

Gomathi, Rodrigues C,

Singh U

9. Validation Study of TruNAT-

MTB-Rif in Pediatric TB

CMC/NIRT/Hi

nduja/

AIIMS

ICMR 2017

Christopher DJ, Singh M,

Gomathi, Rodrigues C,

Singh U

10. Measuring TB Drugs in Hair as a

Tool to Monitor Adherence,

Exposure and Response

BJGMC

NIRT

JHU

NIH/NIAID:

R21 2016-2018

Mave V, Dooley K,

Ramachandran G, Gupta A,

Bacchetti, Sushant M,

Gupte N, Gandhi M

11. The Role of Monocyte

Subpopulation in HIV+LTB+

Individuals and Development of

Active TB BMMRC

UT

NIH:

R21AI12717

8-01

Indo-US

Vaccine

Program,

RePORT

India Cohort

2016-2018 Vankayalapati K, Valluri

V, and others

12. Role of Iron Deficiency in

Resistance of Women of Child-

Bearing Age to Tuberculosis

JIPMER

BMC NIH 2016-2017

Ellner J, Salgame P, Sarkar

S, Pleskunas J, Amsaveni,

Hochberg NS

GRANTS & SUBSTUDIES

41



Source

Start Date/


13. Studying T cell Memory

Responses for Understanding

Protective Immune Response in

Tuberculosis (TB) CMC, NIRT,

Saint Louis

University

American

Society of

Tropical

Medicine and

Hygiene/

Burroughs

Wellcome

Fund)

2016 Christopher DJ,

Chatterjee S, Balamugesh T

14. Impact of Immune Changes of

HIV and Stages of Pregnancy on

TB

BJGMC

NIRT

JHU

NIH/NICHD

:

R01

2015-2019

Gupta A, Mathad J,

Bhosale R, Alexander M,

Mave V, Gupte N, Padhan

N, Kulkarni V, Hannah LE,

Babu S

15. Impact of Pregnancy on

Tuberculosis

JIPMER

BMC

NIH/NIAID

R01 2015-2018

Ellner J, Sarkar S,

Hochberg N, Horsburgh

CR, Salgame P, Savic R,

Dartois V, Joseph NM,

Jacob SE, Jayalakshmy R,

Plakkal N, Ramachandran

G, Sasirekha R, White LF

16. D4GDI-mediated Immune

Responses in LTBI+HIV+

Individuals

BMMRC

UT

NIH:

R21AI12025

7-01

Indo-US

Vaccine

Program,

RePORT

India

2015-2017 Vankayalapati K, Valluri

V and others

17. Residual Respiratory Impairment

Following Pulmonary

Tuberculosis: The Lung Health

Sub-Study

BJGMC

NIRT

JHU

UJALA/

Gilead

Foundation/

RePORT

India

2015-2017

Gupte A, Gupta A,

Meshram S, Kadam D,

Mandar, Gupte N,

Chandrasekaran P, Salvi S,

Golub J, Selvaraju S

18. Targeting Mycobacterium

Tuberculosis Persisters By

Enhancing Stringent Response-

Specific Cellular Immunity

JHU, BJMC NIH R21 2015

Karakousis P, Gupta A,

Mave V, Kulkarni V, Dutta

N

19. Understanding of Tuberculosis

Infection and Preventive

Therapy Among Skin-Test

Positive Household Contacts of

Tuberculosis Cases

BJGMC

NIRT

JHU

NIH CFAR

and D43 2015

Deluca A, Suryavanshi N,

Mave V, Kadam D,

Chandrasekaran P,

Shivakumar SVBY, Pardeshi

G, Thomas B, Kolhi R,

Gupta A

20. T-regs Mediated Immune

Responses in LTBI+HIV+

Individuals

BMMRC

UT UT 2015

Vankayalapati K, Valluri

V and others

21. Compare Drug Levels in Newly

Diagnosed or Relapsed PTB/

EPTB Following Daily ATT vs

DOTS Regimen

CMC

Internal fluid

research

grant


Balamugesh T

GRANTS & SUBSTUDIES

42



Source

Start Date/


22. Impact of Personal Exposure to

Black Carbon on Pulmonary

Tuberculosis Severity

JIPMER

BMC

Potts

Memorial

Foundation

2014-2018 Hochberg NS, Reddy D,

Sahu S, Sarkar S

23. Yield of TB using GeneXpert

(Xpert MTB-Rif) by Induced

Sputum Compared to Standard

Sputum Samples

CMC

Internal fluid

research

grant


Balamugesh T

24. Multicenter Phase II/III Double-

Blind, Randomized, Placebo

Controlled Study to Evaluate the

Efficacy and Safety of VPM1002

in the Prevention of TB

Recurrence in Pulmonary TB

Patients after Successful TB

Treatment in India.

RePORT India

Sites

Serum

Institute 2017 - 2020 RePORT India PIs

GRANTS & SUBSTUDIES | NOT AWARDED


Source

Start Date/


1. RePORT India TB

Transmission Training

Program (RITP)

RePORT India

Consortium

NIH Fogarty

D43 2017

Gupta A, Christopher DJ,

Bollinger R, Deluca A, Golub J

2. Developing a Rapid Point-of-

Care TB Diagnostic

RePORT

International

NIH/NIAID:

R01 2017

Walt D (Tufts PI), Rushdy A

(Broad Institute co-PI), Rolla V,

Santos M, Kristi A, Sterling T, Li

Y, Mave V, Cristopher DJ, Gupta

A, Pim A, Walzl G, Hamilton C,

Duffy D, Gillette M

3. Research and Interventions

for HIV, Alcohol, Tobacco

and Tuberculosis in India and

South Africa (The HATT

Consortium)

BJGMC

NIRT

JHU

NIH/NIAAA:

R01 2017

Gupta A, Chander G, Heidi H,

Thomas B, Kadam D, Suryavanshi

N, Chandrasekaran P, Mave V,

Gupte N

4. Bio-markers for Risks of

Development of LTBI and TB

Disease in a Cohort of

Childhood Contacts of

Sputum Positive TB Patients.

CMC

RePORT

India

Supplemental

Funding

2017 Christopher DJ, Rose W

5. Impact of Air Pollution on

Inflammation and Anti TB

Immunity

BJGMC

NIRT

JHU

RePORT

India

Supplemental

Funding

2016-2017

Shivakoti R, Gupta A,

Chandrasekaran P,

Chandrakumar D, Golub J, Mave

V, Babu S, Elf J, Hannah LE,

Kulkarni V, Gupte N

GRANTS & SUBSTUDIES

43



Source

Start Date/


6. Characterizing the Host

Inflammatory Response, and

its Association with

Treatment Outcomes and

Lung Health in Adult


Undergoing Treatment in

India

BJGMC

NIRT

JHU

RePORT

India

Supplemental

Funding

2016-2017

Gupte A, Chandrasekaran P,

Gupta A, Babu S, Mave V, Gupte

N, Kornfeld H

7. Does Tubercular Infection

Adversely Affect

Cardiovascular Risk? JIPMER BCM

RePORT

India

Supplemental

Funding

2016

Kar S, Sarkar Si, Negi VS,

Prasanna MD, Roy G, Premarajan

KC, Hochberg N,

Lakshminarayanan S

8. Impact of Malnutrition on

Latent Tuberculosis Infection

JIPMER

BMC

Rutgers

OHSU

Tufts

NIH/R01 2016

Hochberg NS, Salgame P, Wanke

C, Johnson WE, Ellner JJ, Parija S,

Negi VS, Joseph NM, Rajkumari

N, Mahalakshmy T, White LF,

Lewinsohn D

9. Geographical and Genotypic

Distribution of TB Cases

Under RePORT India – Tools

for Understanding

Epidemiology

JIPMER

BMC

BU

RePORT

India

Supplemental

Funding

2016

Sarkar S, Roy G, Mahalakshmy T,

Lakshminaraya S, Joseph NM,

Jenkins H, Amsaveni, Hochberg

NS

10. Determining Barriers to TB

Care JIPMER

BMC BU SPH Pilot 2016

Fernandes P, Sabin L, Sarkar S,

Pleskunas J, Amsaveni, Hochberg

NS

11. Novel Serum Based

Biomarkers for Diagnosis of

TB and Treatment Monitoring

in HIV-infected and

Uninfected Children

BJGMC

NIRT

DTTC,

Capetown

JHU

India SA RFA 2016

Valvi C, Hesseling AC,

Chandanwale A, Kulkarni R,

Paradkar M, Mave V, Gupte N,

Chandrasekaran P, Shivakumar

SVBY, Danasekaran K,

Thiruvenkadam K

12. Pediatric TB Biomarkers for

Diagnosis and Treatment

Response BJGMC

NIRT

JHU

NIH/NIAID:

R01 2016

Karakousis P, Paradkar M,

Tornheim JA, Gupta A,

Chandrasekaran P, Bader J, Mave

V, Gupte N, Kulkarni V,

Bharadwaj R, Valvi C,

Shivakumar SVBY, Hannah LE,

Pandey A

13. Biomarkers for Treatment

Response and Disease

Recurrence in Pulmonary and

Extrapulmonary Tuberculosis

Disease

IGIB

BJGMC

SA

NIRT

JHU

India SA RFA 2016

Gokhale R, Kana B, Swaminathan

S, Chandrasekaran P, Mave V,

Gupta A, Shivakumar SVBY

14. Novel Blood Biomarker to

Predict Progression to Active

TB Disease Among Recently

Exposed Adult and Pediatric

Household Contacts of TB

Patients in India and South

Africa

BJGMC

NIRT

SA

JHU

India SA RFA 2016

Chandrasekaran P, Scriba T,

Mave V, Paradkar M, Shivakumar

SVBY, Gupte N, Gupta A,

Danasekaran K, Khan S,

Thiruvengadam S, Tripathy S,

Prasad K

GRANTS & SUBSTUDIES

44



Source

Start Date/


15. Memory-like NK Cells and

Household Contacts of TB

Patients.

BMMRC

UT

NIH:

1R21AI12717

7-01

Vankayalapati K, Valluri V and

others

16. Annual Screening of

Healthcare Personnel Using

TST & QGFT and

Identification of Bio-markers

& the Role of Pet Scan

CMC

RePORT

India

Supplemental

Funding

2016 Christopher DJ, Balamugesh T

17. Radiological Treatment

Response in Pulmonary

Tuberculosis CMC

RePORT

India

Supplemental

Funding

2016 Balamugesh T, Christopher DJ

GRANTS & SUBSTUDIES | PENDING


Source

Start Date/


1. Effect of Helminths

on Tuberculosis

Severity

JIPMER

BMC

Rutgers

NIRT

NIH

NIH R21

2018

Hochberg NS, Salgame P, Babu S,

Ellner JJ, Johnson WE, Joseph NM,

Mahalakshmy T, Nutman T,

Rajkumari N, Parija S

2. Characterization of

Genomics and

Metabolomics among

Individuals

Emory

JHU

BJGMC

NIRT

PHRU

McGill

NIH R01 2018

Gandhi N, Shah S, Brust J, Gupta

A, Mave V, Bharadwaj R,

Chandrasekaran P, Hanna LE,

Martinson N, Sun Y, Gwinn M,

Schurr E, Jones D

3. Innate Immune

Responses in

Household Contacts

BMMRC/LEPRA

BJMC

NIRT

JHU

UT

NIH/NIAID:

R01 2017

Vankayalapati K, Valluri V, Gupta

A, Mave V, Kadam D, Bharadwaj R,

Hanna LE, Shivakumar SVBY,

Prudhula, Chandrasekaran P, Gupte

N

4. Progression of

Tuberculosis

Infection to Disease

Among HIV-Infected

and HIV Seronegative

Individuals – A

Prospective Cohort

Study in South India

and South Africa

CMC

BMMRC/LEPRA

JIPMER

NIRT

PHRU

UWITS

Indo-South

Africa 2016

Valluri VL, Martinson N,

Christopher DJ, Variava E, Sarkar S,

Priyadarsini P, Bhavna G, Ziyaad W,

Melissa C, Prudhula DK, Sanjeev

NV

Agenda RePORT India 7TH ANNUAL JOINT LEADERSHIP MEETING CATALYZING DISCOVERIES TOWARD TB ELIMINATION NEW DELHI | 15–17 FEB 2018


45

7th ANNUAL JOINT LEADERSHIP MEETING

CATALYZING DISCOVERIES TOWARD TB ELIMINATION

DAY 1: THURSDAY, FEBRUARY 15 | STATE OF THE CONSORTIUM

POSTER SETUP & REGISTRATION | 8:30–9:00 AM

SESSION 1: WELCOME | Jyoti Logani, Moderator

9:00–9:10 am Lighting Ceremony | DBT/ICMR/NIH

9:10–9:55 am Sponsor Welcome

Alka Sharma, Adviser (DBT)

Sudha Srinivasan, Program Officer / Roxana Rustomjee, Senior Scientist (NIH/DAIDS)

Sanjay Mehendale, ADG (ICMR) / R.R. Gangakhedkar, Scientist G (ICMR)

Remarks by Director ICGEB

Dinakar M Salunke, Director (ICGEB)

Remarks by RePORT International Advisory Board Member

Gagandeep Kang, Executive Director (THSTI)

9:55–10:10 am State of TB in India

DJ Christopher, RePORT India Chair (CMC)

10:10–10:25

am

Update on ITRC

Sanjay Mehendale, ADG (ICMR)

10:25–10:55

am

State of the RePORT India Consortium & Central Biorepository

Amita Gupta, RePORT India Chair (JHU) & Luke Elizabeth Hanna, Biorepository Head (NIRT)

TEA BREAK | 10:55–11:10 AM

SESSION 2: SITE PRESENTATIONS | Vidya Mave & Padma Chandrasekaran, Moderators

11:10–11:15

am

Meeting Objectives, Agenda Overview | Samyra Cox

11:15–11:45

am

Site108: Hinduja Hospital | Zarir Udwadia

11:45–12:15

pm

Site 104/107: BMMRC/Texas | Vijaya Valluri & Krishna Vankayalapati

12:15–12:45

pm

Site 103: MVDRC/UMass | Vijay Viswanathan & Hardy Kornfeld

GROUP PHOTO | 12:45–1:00 PM

LUNCH BREAK | 1:00–2:00 PM

YOUNG INVESTIGATOR POSTER SESSION

SPONSOR MEETING | DBT/ICMR/NIH (Closed Meeting)

PI MEETING (Closed Meeting)

SESSION 2: SITE PRESENTATIONS | Vijay Viswanathan & Krishna Vankayalapati, Moderators

RePORT India New Delhi, India

15–17 Feb 2018

46

2:00–2:30 pm Site 102: JIPMER/BMC/Rutgers | Gautam Roy, Sonali Sarkar, Padmini Salgame, & Jerry Ellner

2:30–3:00 pm Site 106: BJGMC/JHU | Vidya Mave & Amita Gupta

3:00–3:30 pm Site 105: NIRT | Padma Chandrasekaran

3:30–4:00 pm Site 101: CMC Vellore | DJ Christopher

TEA BREAK | 4:00–4:15 PM

SESSION 3: PI & WORKING GROUP BREAKOUT SESSIONS

4:15–5:30 pm PI Meeting with Sponsors (closed meeting)

4:15–5:30 pm Clinical Epi Working Group | Balamugesh Thangakunam

4:15–5:30 pm Behavioral Science Working Group | Nishi Suryavanshi

4:15–5:30 pm Operations Working Group | Shri Vijay Bala Yogendra Shivakumar

4:15–5:30 pm Data Management Working Group | Jane Pleskunas, Nikhil Gupte, SAS CHRD

4:15–5:30 pm Lab Quality Assurance & Basic Science Working Group (Lab Staff & Basic Science WG Members)

| Luke Elizabeth Hanna & Vandana Kulkarni

47



DAY 2: FRIDAY, FEBRUARY 16 | COLLABORATIONS & OPERATIONS

SESSION 1: SUB-STUDIES & COLLABORATIONS | Sudha Srinivasan & DJ Christopher,

Moderators 9:00–9:15 am Welcome & Day 2 Objectives

Jyoti Logani & Sudha Srinivasan

9:15–9:55 am BJGMC/JHU Fogarty Program

Introductory Remarks | Bob Bollinger & Andrea Deluca

Aarti Kinikar

Anita Basavaraj

Geeta Pardeshi

Gauri Dhumal

9:55–11:10 am Review of RePORT India-related Studies (5-7 min Presentations Each)

MDR Pilot & PREEMPT | Bob Horsburgh

Validation of Transcriptional Signature to Predict Active TB Disease among Advanced HIV

Patients | Padmini Salgame & Vandana Kulkarni

Comparison of Available PPD TST Antigen Solutions in Detecting Latent TB Infection in

India I DJ Christopher

Extra Cranial Involvement as Detected By Positron Emission Tomography Scan In Patients

With Tubercular Meningitis | Balamugesh Thangakunam

PRACHITi | Jyoti Mathad

TH17 Cell Subsets as Potential Risk Markers of Latency and Active TB Infection in

Household Contacts | Prudhula Kamakshi

Biomarkers for Tuberculosis Diagnosis and Treatment Response | Jyothi Rengarajan

Q&A

TEA BREAK | 11:10 – 11:25 am

11:25–12:45

pm

Review of RePORT India-related Studies (cont’d) (5-7 min Presentations Each)

VPM | Vidya Mave

Impact of HIV and Diabetes Mellitus on TB Drug Resistance and Recurrence | Vidya Mave

Molecular Signatures of TB-Diabetes Interaction (MSTDI) | Hardy Kornfeld

Characterization of Monocyte Responses in Pulmonary TB Patients with or without Type

2 Diabetes | Pavan Kumar

Effect of Malnutrition and Parasites on Latent TB Progression | Natasha Hochberg

Determining Barriers to TB Care | Sonali Sarkar & Natasha Hochberg

The Association of Tobacco and Biomass Fuel with Pulmonary Tuberculosis | Divya Reddy

Q&A



SESSION 2: OPERATIONS DISCUSSIONS


15–17 Feb 2018

48

1:45–2:00 pm Summary: Operations Progress, Challenges, & Next Steps

Shri Vijay Bala Yogendra Shivakumar

2:00–2:15 pm Discussion, Questions, & Action Items | Shruthi BS, Moderator

2:15–2:45 pm Summary: Data Management Progress, Challenges, & Next Steps

Jane Pleskunas | Nikhil Gupte | SAS CHRD

2:45–3:00 pm Discussion, Questions, & Action Items | Kannan Thiruvengadam, Moderator

3:00–3:15 pm Summary: Lab Quality Assurance Progress, Challenges, & Next Steps

Vandana Kulkarni & Saranathan Rajagopal

3:15–3:30 pm Discussion, Questions, & Action Items | S Amsaveni, Moderator

TEA BREAK | 3:30–4:00 pm

SESSION 3: COMMON PROTOCOL IMPLEMENTATION & POLICIES |

Sonali Sarkar & Amita Gupta, Moderators

4:00–4:30 pm Lessons Learned from Parent Protocols – Study Coordinator Panel and Q&A

4:30–4:45 pm Review of Common Protocol Clarifications & FAQs

Vidya Mave 4:45–5:00 pm Protocol Deviations

Vaishali Adkar

5:00–5:30pm Facilitated Discussion, Questions, & Action Items

SPONSORED DINNER FOR ALL PARTICIPANTS

49



DAY 3: SATURDAY, FEBRUARY 17 | SCIENTIFIC TALKS

WELCOME & SCIENTIFIC PRIORITIES

9:00–9:05 am Welcome & Day 3 Objectives | Samyra Cox

9:05–9:55 am RePORT India Overview & Scientific Priorities | EC Chairs, Nishi Suryavanshi, Balamugesh

Thangakunam/Sonali Sarkar, Padmini Salgame/Krishna Vankayalapati

SESSION 1: EXTENDING BEYOND ULTRA: WILL NEXT GENERATION SEQUENCING &

HOST BIOMARKERS TRANSFORM TB DIAGNOSTICS? | Jerry Ellner & Bala Thangakunam,

Moderators

9:55–10:00 am Xpert EXTEND & XPERT ULTRA | Jerry Ellner

10:00–10:05 am What is Still Needed in TB Diagnostics? | Bala Thangakunam

10:05–10:20 am Systems Immunology Analysis of Mtb Infection for Prediction & Diagnosis of Tuberculosis |

Purvesh Khatri

10:20–10:35 am Next Generation Sequencing from Sputum | Vedam Ramprasad

10:35–10:50 am Transcriptional Signatures for Discriminating Active TB from Latent Infection in Individuals from

South India | Evan Johnson

10:50–11:00 am Biomarkers Predicting Risk of Progression to TB Disease | Padmini Salgame

11:00–11:10 am The Devil is in the Details - Standardizing Methods for RNAseq as a Biomarker for Pediatric

Tuberculosis | Jeff Tornheim

11:10–11:30 am Panel Discussion/Q&A

TEA BREAK | 11:30–11:45 AM

SESSION 2: HUMAN IMMUNITY TO TB | Hardy Kornfeld & Vijaya Valluri, Moderators

11:45–12:00 pm Understanding the Host-Mycobacterium Tuberculosis Crosstalk by Global Phosphoproteome

Analysis of Macrophage Proteins | Nisheeth Agarwal

12:00–12:15 pm Building Capacity for Human Immunology in India | Anmol Chandele

12:15–12:30 pm Lysosomal Control of Intracellular Mtb | Varadha Sundaramurthy

12:30–12:45 pm Alcohol Enhances Type I Interferon-α Production and Mortality of Young Mice Infected with MtB

| Buka Samten

12:45–1:00 pm Longitudinal Cytokine Studies in TB/Diabetes Comorbidity | Subash Babu

1:00–1:15 pm Panel Discussion/Q&A




15–17 Feb 2018

50

SESSION 3: DESIGNING STUDIES & INTERVENTIONS AIMED AT

UNDERSTANDING AND BLOCKING TB TRANSMISSION | Roxana Rustomjee,

Moderator

Padmini Salgame, Palwasha Khan, & Neel Gandhi, Co-Chairs

2:15–2:30 pm Zero TB Cities Chennai | Srikanth Tripathy

2:30–2:45 pm Introductory Remarks

Microbiology & Immunology | Bavesh Kana

Epidemiology, Spatial Mapping & Measurement | Neel Gandhi

Interventions | Palwasha Khan/Sriram Selvaraju

2:45–3:15 pm Panel Discussion 1: Microbiology & Immunology | Bavesh Kana & Padmini Salgame, facilitators

Rajesh Gokhale

Urvashi Singh

Purvesh Khatri

Evan Johnson

Kalpana Sriraman

3:15–3:45 pm Panel Disucssion II: Epidemiology, Spatial Mapping & Measurement | Neel Gandhi & Vidya

Mave, Facilitators

Aarti Kinikar

Chitra Iravatham

Bob Horsburgh

Anirvan Chatterjee

3:45–4:15 pm Interventions | Palwasha Khan, Sriram Selvaraju, Thuli Mthinaye, Facilitators

Dina Nair

Amita Gupta

Banurekha Velayutham

Natasha Hochberg

Purvesh Khatri

TEA BREAK | 4:15–4:30 PM

4:30–4:45 pm TB Transmission Summary & Next Steps I Roxana Rustomjee

4:45–5:00 pm Meeting Action Items | Samyra Cox & Vaishali Adkar

5:00–5:30 pm Closing Remarks | Sponsors & EC Chairs

ADJOURN | 5:30 PM

Speaker Biographies RePORT India 7TH ANNUAL JOINT LEADERSHIP MEETING CATALYZING DISCOVERIES TOWARD TB ELIMINATION NEW DELHI | 15–17 FEB 2018


SPEAKER BIOGRAPHIES

51

Vaishali Adkar, MS, MBA

Sr. Project Manager, Government and Public Health Services, PPD

Ms. Adkar has 11 years of clinical research management & coordination experience within CRO

&pharmaceutical industries. She has worked as a Clinical Project Manager, Clinical Research Manager / Clinical

Research Data Manager / Sr. Clinical Research Specialist and Clinical Research Associate (monitor/auditor) with

clinical research management/coordination, data management, monitoring, regulatory, drug safety and quality

management/audit experience in the area of oncology, endocrinology, medical device, infectious disease, vaccine,

immunology, alternative and complementary medicine.

Nisheeth Agarwal, PhD Associate Professor, Vaccine and Infectious Disease Research Center, Translational Health Science

and Technology Institute (THSTI)

Dr. Agarwal currently works at the Vaccine and Infectious Disease Research Center

(VIDRC), Translational Health Science and Technology Institute. Identifying and

characterizing new drug targets, understanding the mechanisms of drug-induced phenotypic

tolerance and genetic resistance in M. tuberculosis, and the host response to M. tuberculosis infection.

Subash Babu, PhD, MBBS National Institutes of Health-National Institute for Research in Tuberculosis, International Center

for Excellence in Research (NIH-NIRT-ICER)

Dr. Babu currently works at the NIH-NIRT-ICER, National Institutes of Health. His lab is

involved in three major areas of research: (1) Host response to helminth infection and

pathogenesis of helminthic disease; (2) Immune responses in pulmonary and

extrapulmonary tuberculosis and (3) Modulation of immune responses in tuberculosis by coinfections and

comorbidities such as helminth infections and type 2 diabetes mellitus. Our larger group comprising of our

center at Chennai and the Helminth Immunology Section in the Laboratory Parasitic Diseases, NIAID, NIH is

the world’s leading authority on basic and clinical research on filarial infections. We have also contributed to

most of the mechanistic understanding of the immunological convergence of helminth infections and tuberculosis

as well as more recent data on the interaction between diabetes and tuberculosis.

VV Banurekha, PGDPH Scientist D, National Institute for Research in Tuberculosis.

D. Banurekha is working as Scientist in the Department of Clinical Research at the

ICMR -National Institute for Research in TB, Chennai since 2007. She completed her

medical under-graduation at the Madras Medical College and Masters in Public Health at

the National Institute of Epidemiology, ICMR School of Public Health, Chennai. She has

a Post Graduate Diploma in Bioethics. At the National Institute for Research in TB she

is involved in Clinical trials and Operational research studies focusing on the diagnosis,

treatment and prevention of TB.

SPEAKER BIOGRAPHIES

52

Anita Basavaraj, MD. Associate Professor, Department of Medicine, BJGMC

Dr. Basavaraj has done her MBBS from Nagpur University with Honors in Surgery (1987).

Thereafter she did her MD in Medicine (1990) and her Diplomat of National Board (D.N.B.) in

1992.She has done her post graduate Diploma in geriatric Medicine (P.G.D.G.M.) winning the

university Gold Medal by virtue of standing first in the country (2012), which is a distant

education venture run by Indira Gandhi National Open University (IGNOU). Dr. Basavaraj is at present working

as Associate Professor in The Department Of Medicine and Unit In charge at B.J.Medical College and Sassoon

General Hospital, Pune ,India. She has special interest in HIV medicine which she learned and practiced in Grant

Medical Government Medical college and J.J.Hospital, Mumbai, before coming to Pune. She was pioneer in

starting HAART in PLHIV at SGH in 1998 and was given the responsibility of starting and nurturing the first HIV

OPD at SGH on 9th April 1999 which later in 2004 merged into NACO’s ART center which today caters to

care and follow up of over 30,000 PLHIV. She was awarded and underwent Fellowship for HIV studies at the

New York Presbyterian hospital and Weill Cornell Medical center in New York City, USA(2004).she was

awarded and felicitated by the first President of Zambia, Mr. Kenneth Kaunda for outstanding work for care and

treatment of patients with HIV and AIDS. She has participated in BJGMC-JHU,CTU, projects since last 12 years,

monitoring PEP, toxicities and adverse events. She manages BJGMC-JHU undergraduate students activities and

monthly HIV videoconferencing. She has as a research guide studied lyphadenopathy in PLHIV, fever in

PLHIV,TB-HIV co-infection, Pulmonary manifestations of PLHIV, Cardiac toxicities, ART toxicities, psychosocial

aspects and CD4 as surrogate marker in PLHIV. She heads the Gastroenterology services at BJ and performs

and overviews upper and lower GI therapeutic and diagnostic video endoscopies. She also heads the Geriatric

services at B.J. and is the Programme In-Charge for PGDGM since last 8 years. She has designed a syllabus for

geriatric curriculum for MUHS.

Basavaradhya S. Shruthi, MDS

Study Manager, Prof M Viswanathan Diabetes Research Centre

Bob Bollinger, MD, MPH Professor of Medicine and Public Health, Johns Hopkins University

Dr. Bollinger is Professor of Medicine and Public Health at Johns Hopkins University. He

is Founding Director of the JH Center for Clinical Global Health Education, Associate

Director for Medicine of the JH Center for Global Health, Director of the JHU Fogarty

India Program, and course instructor for the Global Health Intersession Course for JH

medical students. Dr. Bollinger has more than 35 years of experience in international public health, clinical

research, and education. His research interests include identifying biological and behavioral risk factors for HIV

transmission; characterizing the clinical progression and treatment of HIV and related infections; and

implementing science research projects to optimize healthcare capacity and delivery in resource-limited settings.

He served as a member of the US Presidential Advisory Council for HIV/AIDS (PACHA), and a member of the

PACHA International Sub-committee, and is a current member of the Institute of Medicine Forum on Public-

Private Partnerships for Global Health and Safety. He established and has sustained programs in countries

throughout Africa, South and Central America, Southeast Asia, and the Middle East. In 1991, he initiated an

ongoing, NIH-funded Indo-US HIV research program in Pune, India, involving the National AIDS Research

Institute/ICMR and the BJ Medical College. He has served as Principal Investigator for many NIH-supported

studies and clinical trials in Pune, including the SWEN study, which changed World Health Organization (WHO)

guidelines for treatment of infants born to HIV/positive mothers to prevent mother-to-child transmission. Under

his leadership of the Hopkins Fogarty International Program, short-term and degree training has been provided

to more than 100 visiting scientists at JHU, and in-country training has been provided to more than 2000 Indian

scientists. His commitment to clinician education has been honored with the Johns Hopkins Department of

SPEAKER BIOGRAPHIES

53

Medicine David M. Levine Excellence in Mentoring Award. He is author of more than 180 peer-reviewed

research publications and 15 book chapters, including the first and largest studies of risk factors for HIV

transmission in India, the cloning and sequencing of the first HIV viruses from India, the only studies

characterizing the primary immune response to HIV in India, and the demonstration of increased risk of HIV

acquisition with recent HSV infection and lack of circumcision.

Anmol Chandele, PhD Assistant Professor, ICGEB-Emory Vaccine Center

Dr. Chandele is Assistant Professor at the ICGEB-Emory Vaccine Center, International

Center for Genetic Engineering & Biotechnology, New Delhi. Her lab is a unique

partnership between Emory Vaccine Center, Atlanta and ICGEB, New Delhi. As an

immunologist, for the past few years she has worked extensively to build capacity for

human immunology research in India by mentoring graduate students, research scholars

and senior research scientists. She has also collaborating with clinicians, epidemiologists and basic researchers

from several institutions in India and USA for capacity building, technology transfer and basic research, with

special emphasis on immunology of dengue virus infections in India. In the RePORT meeting, she will share my

experiences in my talk titled 'Capacity building for human immunology research in India.'

Padmapriyadarsini Chandrasekaran MBBS, DNB, MS (CR) Deputy Director, Department of Clinical Research, National Institute for Research in Tuberculosis

Executive Committee Member, RePORT India

Dr. Chandrasekaran is a clinician by training and is currently Deputy Director (medical) in the

Department of Clinical Research at the National Institute for Research in Tuberculosis (NIRT)

(formerly known as the Tuberculosis Research Centre), Chennai. She has a Short-term

Fellowship in HIV epidemiology from University of California, Los Angeles and a Masters

Degree in Clinical and Translational Research from Tufts University Boston, USA. Over the last 16 years, she is

involved in multiple clinical studies involving HIV and TB coinfected adults and children at NIRT. She is the

Principle investigator of multiple collaborative, multicentric projects, both at national and international level. She

has more than 45 publications in peer reviewed national and International journals and 3 book chapters to her

credit. Her current research interests include Treatment and prevention strategies for TB, Nutritional

supplement for TB, Pediatric HIV-TB and Management of Non-tuberculous Mycobacteria in lungs.

Anirvan Chatterjee, PhD Postdoctoral Fellow, IIT Bombay; Consultant, The Foundation for Medical Research

During his PhD studies, (under the mentorship of Dr. Nerges Mistry, FMR) Dr. Chatterjee

focused on the genetic variability of MDR TB strains in Mumbai, and explored transmission

patterns. They undertook the largest molecular epidemiology study of MDR-TB in India.

Following that he moved over to WGS of M.tb strains from Mumbai (this during his PDF at

Oxford University), and observed that even hyper-endemic locales like Mumbai can have

clonal outbreaks of TB. Detecting such outbreaks has far reaching implications in public health. Currently his is

at IIT Bombay discovering new viruses from the environment using genomics and metagenomics. He is actively

involved with efforts to mobilize a WGS-based TB diagnostic system in Mumbai. He began his research career

working exclusively in the wet lab, and now works to develop a computational framework for microbial analysis.

He is hoping to contribute to efforts to translate basic research for public health.

SPEAKER BIOGRAPHIES

54

Andrea DeLuca, MHS Research Associate; Johns Hopkins University

Ms. DeLuca is a Senior Research Associate faculty member in the Department of

International Health at the Johns Hopkins Bloomberg School of Public Health and the

Project Director for the CCGHE-directed Byramjee Jeejeebhoy Government Medical

College (BJGMC)-JHU Fogarty Training Program in Pune, India. Ms. DeLuca’s research

focuses on capacity building and advocacy for HIV-TB policy change. She has more than 10 years of managing

multi-country projects, with an emphasis on ethics and quality of program and research implementation. Ms.

DeLuca received undergraduate degrees in biology and creative writing from Pacific Lutheran University and a

master of health science in international health, disease prevention and control from Johns Hopkins Bloomberg

School of Public Health.

Devasahayam (DJ) Christopher, DNB, FRCP Chief Pulmonary Physician, Professor of Pulmonary Medicine & Associate Director (HR), Christian

Medical College, Vellore

India Chair, RePORT India

Dr. Christopher heads the department of pulmonary medicine at the Christian Medical

College, Vellore; a well-known referral hospital in Southern India. His basic medical training

was from India and he has had advanced training in United Kingdom and Australia. He holds

the clinical title of ‘professor of pulmonary medicine’. He is a recipient of prestigious training fellowships; the

Raj-Nanda and the British thoracic society fellowship for training in interventional pulmonology, in the UK,

International fellowship of the American association of respiratory care awarded by the American Association of

Respiratory Care and the Senior training fellowship for training in Interventional Pulmonology in Marsielle. He is

a Fellow of the Indian Chest Society, Royal college of Physicians & Surgeons, Glasgow and the American College

of Chest Physicians and the Asia Pacific Society of Respirology. He is the Zonal Chairman of the Indian Chest

Society and past president of the Indian Association of Respiratory care. Dr Christopher’s research awards

include; ‘the rising star of global healthcare’ by the Grand challenges, Canada to work on a point of care test for

extra-pulmonary TB and the First place in the CMC research day award. He is the chair of the RePORT India.

His major research interest is in the area of 'TB point of care diagnostics' & ‘TB risk in healthcare workers’ and

his group has performed the largest study in ‘healthcare workers TB infection risk’, in India. Apart from

Tuberculosis, his research interests include; Interventional pulmonology, Asthma, COPD and Pleural

diseases. He is in the advisory boards of journals and reviews articles for National and International

journals. He authored 10 chapters in books and has more than 110 publications in various National and

International journals. He has been an invited speaker at numerous National and International conferences,

CMEs and Workshops.

Kamakshi Prudhula Devalraju (M.Tech) Research Coordinator, Bhagwan Mahavir Medical Research Centre

Common Protocol Co-Chair, RePORT India

Ms. Devalraju is the site coordinator for BMMRC and a co-chair for the common protocol,

which involves establishment of cohorts, She is responsible for collection and shipment of

samples across various sites in India for future TB research. Ms. Devalraju is an M.tech in

Biotechnology who is pursuing a PhD in the biotechnology at Jawaharlal Nehru Technological University

Hyderabad (JNTU) as an external candidate. She is the Research Coordinator at Bhagwan Mahavir Medical

Research Centre- BMMRC. She has more than 7 years of experience in various immunological and molecular

biological techniques. Her research interests include development of biomarkers for early detection of TB in

house hold contacts of TB patients. For her PhD, she is studying the immune factors responsible for activation

SPEAKER BIOGRAPHIES

55

of latent TB in HIV+ individuals. At Dr. Vijaya Lakshmi’s lab, she handles screening of study subjects, enrolment

into research, PBMC cultures, immuno-phenotyping. she also have an USD 50000 grant by NIH-NIAID for one

year to study the role of “TH17 cells as potential risk markers for latency and active tb infection in household

contacts". She has co-authored manuscripts on TB and Leprosy and have 3 manuscripts under review on HIV.

Samyra Cox, MPH Research Program Manager, Johns Hopkins Center for Clinical Global Health Education

US Secretariat, RePORT India

Ms. Cox is responsible for managing Indo-JHU research projects under Dr. Amita Gupta at

the Johns Hopkins Center for Clinical Global Health Education. She serves as the Executive

Committee Secretariat of the RePORT India consortium and is a collaborator on the

CTRIUMPh and Common Protocol studies. She also plays a project management, data analysis, and writing role

on a number of other BJGMC-JHU collaborative studies related to CDC Shepherd (neonatal sepsis), the AIDS

Clinical Trials Group (ACTG), and the International epidemiology Database to Evaluate AIDS (IeDEA). Ms. Cox

is a public health professional with over seven years of project management and grant writing experience at

international development non-profits. She has been supporting complex TB research and implementation

projects since 2013 and has worked extensively on multi-million dollar grants from institutional donors. Prior to

CCGHE, Ms. Cox worked for Partners In Health in collaboration with Harvard Medical School and Brigham and

Women’s Hospital writing grants for global health programs in Haiti, Russia, Navajo Nation, and Rwanda. She

received a Bachelor of Arts (BA) in International Relations from New York University (NYU) and a Master of

Public Health (MPH) with a Certificate in Epidemiology for Public Health Professionals from the Johns Hopkins

Bloomberg School of Public Health.

Gauri Dhumal, MSc Program Manager, BJGMC-JHU Fogarty HIV-TB Training Program

Ms. Dhumal is Program Manager for the BJGMC-JHU Fogarty HIV-TB Training Program. The

Fogarty Program is a five-year partnership with the Byramjee Jeejeebhoy Medical College in

Puna, India, designed to establish a cadre of highly trained faculty to build institutional

capacity for, and lead, HIV and tuberculosis research. Ms. Dhumal is an anthropologist with a

public health background and more than 9 years of expertise in research, project

management, clinical trial, epidemiology and teaching. She is author of 6 national and

international publications, and has presented research findings at national and international

conferences. She serves on the editorial board of the anthropological journal An Asian Man. She has contributed

in the book “Maharshtratil Adivasi” which is in Marathi. She also contributed anthropological expertise for

Marathi Vishwa kosh. Her key competencies are anthropology, epidemiology, research, project management,

budget development and proposal writing, monitoring and control, qualitative and quantitative data analysis and

report writing. Ms. Dhumal attended the University of Pune, Pune, Maharashtra, India, where she completed her

BSc in zoology, her MSc in anthropology and she is rank holder of University of Pune, and currently pursuing a

PhD in anthropology.

Jerrold J. Ellner, MD Professor, Boston University School of Medicine


Dr. Ellner is Professor at Boston University School of Medicine. He has studied the

immunopathogenesis of TB and TB in HIV through research collaborations in Uganda and

Brazil. His research group was the first to show that TB accelerated the course of HIV

SPEAKER BIOGRAPHIES

56

infection by activating viral replication in latently infected cells. He was one of the principal architects of the

Uganda-Case Western Reserve University Research Collaboration, a founding member of the Academic Alliance

for AIDS Prevention and Care in Africa which developed the Infectious Diseases Institute at Makerere

University, and the founding director of the TB Research Unit at Case Western Reserve University. He

currently is PI of the TB Research Unit on Paucibacillary TB (South Africa, Brazil), RePORT India Collaboration

with JIPMER in Pondicherry and RePORT South Africa. Dr. Ellner has authored more than 300 research

publications on TB and has trained a number of current academic leaders in infectious diseases.

Neel Gandhi, MD Assistant Professor, Department of Medicine, Department of Epidemiology & Population Health,

Emory University

Dr. Gandhi is Associate Professor in the Departments of Epidemiology, Global Health and

Infectious Diseases at Emory University’s Rollins School of Public Health and Emory School

of Medicine. He has been in clinical research in Tuberculosis and HIV co-infection since

1998. Since 2002, Dr. Gandhi has led a research team focused on epidemiology and clinical

research studies to improve care for TB patients co-infected with HIV. In 2006, Dr Gandhi was the lead author

on a study describing high rates of mortality in patients with extensively drug-resistant tuberculosis (XDR TB)

and HIV co-infection in the rural town of Tugela Ferry. This study has been credited for uncovering a rapidly

expanding multidrug-resistant (MDR) TB and XDR TB epidemic in South Africa. Since the discovery of the drug-

resistant TB epidemic in South Africa, Dr. Gandhi’s research group has focused on characterizing the

epidemiology, and improving diagnosis and treatment of MDR and XDR TB. His research group has

demonstrated that transmission of drug-resistant TB strains, in healthcare and community settings, is major

factor in driving the rapid expansion of the epidemic. They have also shown that MDR TB treatment outcomes,

among HIV co-infected individuals, can be improved to rates similar to those without HIV, if antiretroviral

therapy is given concurrently. His research group is now investigating the risk of developing resistance to

bedaquiline, as well as drug-drug interactions with antiretroviral therapy, among pre-XDR and XDR TB patients.

In addition to NIH funding for the South African studies, Dr. Gandhi is also collaborating with colleagues at

Emory and in TB Research Unit (TBRU) ASTRa, to understand adaptive and innate immune responses and their

relationship to outcomes following Mtb exposure, including active TB disease, prolonged latent TB infection, and

clearance or resistance to infection. Dr. Gandhi’s group has collaborated with the US CDC and Kenya Medical

Research Institute to establish a study site in Kisumu, Kenya, and with the DeKalb County Board of Health for a

study site in Atlanta for these studies.

Raman R. Gangakhedkar Scientist G, ICMR

SPEAKER BIOGRAPHIES

57

Rajesh S. Gokhale, PhD Staff Scientist at National Institute of Immunology

Dr. Gokhale is presently a Staff Scientist at National Institute of Immunology (NII). He was

the Director of CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB) for more

than seven years. During his tenure he established the IGIB’s South Delhi Campus and also

led interdisciplinary initiatives in translational genomics research towards resolving complex

diseases. He is trained as a chemical biologist from Indian Institute of Science (IISc),

Bangalore and Stanford University, USA and was a Wellcome Trust Senior Research Fellow,

UK and also the International HHMI Fellow, USA. The thematic focus of his laboratory is to elucidate

complex interplay between metabolic reprogramming and immunity in the context a pathogenic disease

Tuberculosis and autoimmune skin disorder Vitiligo. These studies should define how metabolic imbalances

drive disease pathogenesis and through this develop novel therapeutic strategies that will tackle the underlying

causes, rather than just the symptoms. He is recipient of several awards including Infosys Prize, Shanti

Swaroop Bhatnagar Prize and IIT Bombay Distinguished Almuni Award. He is on the editorial board of Journal

of Biological Chemistry, Section Editor of Tuberculosis and the Advisory Board of Natural Product Reports.

He has Co-founded Vyome Biosciences (VYOME), a biopharmaceutical company developing best in class

drugs for dermatology care utilizing genomics knowledge.

Amita Gupta, MD, MHS Associate Professor of Medicine and Public Health, Johns Hopkins University; US Chair, RePORT

India

Dr. Amita Gupta, MD, MHS is Associate Professor of Medicine in the Division of

Infectious Diseases with a joint appointment in International Health at the Johns Hopkins

Bloomberg School of Public Health. She is also Deputy Director of the Center for Global

Health Education, mission of which is to train healthcare workers in low-income countries evidence based

clinical prevention and management of infectious diseases. Dr. Gupta has 20 years of experience in international

public health and clinical research and 15 years of working in HIV, TB, and other infectious diseases in India. She

is a clinical trialist and epidemiologist who focuses on the prevention and treatment of pediatric and adult

HIV/AIDS, TB and malnutrition with special interest in HIV and TB in pregnant women. She actively mentors

postdoctoral investigators in this field some of whom have now become independent investigators.

Additionally, she has been instrumental in raising more than $6.5 million dollars in philanthropic support for

Indo-US research and educational capacity.

Nikhil Gupte, PhD Research Associate, Johns Hopkins School of Medicine; Deputy Director, BJGMC-JHU Clinical

Research Site

Data Management Working Group Co-Chair, RePORT India

Dr. Gupte has a PhD (2003) in Biostatistics from Johns Hopkins University with more than 20

years of experience in public health and clinical research in developing countries. For the last

20 years I have been involved in clinical, behavioral, and laboratory research related to HIV/AIDS and TB

prevention and treatment in the capacity of a Biostatistician. In addition, he has more than 15 years of

experience in clinical data management. He a lead statistician for several clinical trials on HIV/TB epidemiological

studies and clinical trails in India and South Africa, and he has published extensively in peer-reviewed journals. I

have spearheaded several analysis from the AIDS Clinical Trial Group. Currently, he is Data Management

Director and Deputy Director for the Johns Hopkins/BJ Medical College Clinical Trials Unit in Pune, India where

several AIDS Clinical Trial Group (ACTG) and International Maternal, Pediatric, Adolescent AIDS Clinical Trials

SPEAKER BIOGRAPHIES

58

(IMPAACT) studies are being conducted. He is an active member of the RePORT India consortium and

currently serve as the consortium’s Data Management Co-Chair.

Luke Elizabeth Hanna, PhD Scientist E, Department of Clinical Research, National Institute for Research in Tuberculosis,

Indian Council of Medical Research

Central Biorepository Head, RePORT India

Dr. Hanna is Scientist E, Department of Clinical Research, National Institute for

Research in Tuberculosis, Indian Council of Medical Research. She has a background in

Immunology with 20 years of working experience in the broad area of immunology of infectious diseases

including tuberculosis, HIV and lymphatic filariasis. She is trained in several immunological, molecular and

virological techniques including flow cytometry, neutralization antibody assays, virus culture, real-time PCR,

multiplex PCR, molecular cloning, sequencing, drug resistance genotyping, etc. She has undertaken a number of

research studies on HIV pathogenesis and immune response to HIV/TB co-infection, and has published more

than 50 articles in peer reviewed journals. She is actively involved in several TB and HIV-TB clinical trials and is a

resource person and trainer in Good Clinical and Good Laboratory Practices.

Natasha Hochberg, MD, MPH Assistant Professor of Medicine and Public Health, Boston University

Dr. Hochberg is an Assistant Professor of Medicine (Section of Infectious Diseases) and

Assistant Professor of Epidemiology at Boston University Schools of Medicine and Public

Health. She is also the co-director of the Travel Clinic at Boston Medical Center. She is PI

for the TB LION study (TB Learning the Impact of Nutrition), and co-investigator for

RePORT India (JIPMER site) and an R01 for TB in pregnancy.

C. Robert Horsburgh, Jr., MD, MUS Professor of Medicine and Public Health, Boston University

Dr. Horsburgh’s career has been dedicated to understanding and preventing mycobacterial

diseases, particularly drug-resistant tuberculosis and tuberculosis in HIV-infected persons.

He is an experienced TB clinician and his research has focused on TB clinical and

epidemiologic research and clinical trials. He served as Chairman of the infectious Diseases

Society of America’s TB Committee, Chairman of the Steering Committee of the U.S.

Tuberculosis Trials Consortium (TBTC), Chairman of the Steering Committee of the U.S. Tuberculosis

Epidemiologic Studies Consortium (TBESC) and Co-Chair of the “Access and Appropriate Use Work Group” of

the Gates Foundation’s Critical Path to TB Drug Regimens Initiative. He is a member of the U.S. Advisory

Committee for the Elimination of Tuberculosis (ACET), which advises CDC on tuberculosis control and

elimination strategy. In addition, he is Co-Chairman of the Drug-Resistance Working Group of the IUATLD,

Chair of the MDR/XDR-TB Working Group of the TBTC, and Chairman of the Steering Committee of Research

Excellence to Stop TB Resistance (RESIST-TB), an international organization that advocates for clinical trials of

Drug-resistant TB (http://www.resisttb.org/). He recently became President-Elect of the North American Region

of the International Union Against Tuberculosis and Lung Disease.

http://www.resisttb.org/

SPEAKER BIOGRAPHIES

59

Chitra Iravatham Director - Dr. Iravatham’s Clinical Laboratory (referral lab for TB) since 2000.

Trained in Mycobacterial techniques from TRC, NTI and JALMA. Headed TB lab in State

TB Center under RNTCP. Gold member, European Respiratory society; Member,

IUATLD, IPAQT & Indian TB association. Dr. OA Sarma oration award at Natcon 2017.

Three Gold medals for best paper in State TB conferences. International presentations in

ERS and IUATLD. Pilot study on identifying TB HOT spot and Transmission pattern. Pilot

study on strain pattern in local urban setting. Pilot study on geniturinary TB and its

association with infertility in women. Molecular identification of Non tuberculous mycobacteria. Pilot study on

response to second line drugs in MDR patients.

Area of interest is TB epidemiology and diagnostics

W. Evan Johnson, PhD Associate Professor of Medicine, Biostatistics, and Bioinformation

Dr. Johnson is Associate Professor of Medicine and Biostatistics at Boston University. His

research interests include applications in precision genomic medicine, metagenomics,

infectious disease diagnostics, batch effects, genomic data analysis, tumor heterogeneity and

cancer research.

Bavesh Kana PhD Professor, University of the Witwatersrand

Professor Bavesh Kana is the head of the University of the Witwatersrand (Wits) node of

the DST/NRF Centre of Excellence for Biomedical TB Research, Johannesburg, South

Africa, where he studies tuberculosis with a focus on identifying new drug targets and

biomarkers to monitor treatment response and risk of disease recurrence. He obtained his

PhD at Wits and has worked in several US institutions including the University of

Pennsylvania, Texas A&M University, the Public Health Research Institute and Harvard Medical School. Prof.

Kana was also appointed as an Early Career Scientist of the Howard Hughes Medical Institute (2012-2016) and

was selected as one of the 200 top young South Africans by the Mail and Guardian newspaper. His current work

attempts to address fundamental questions regarding pathogenesis and clinical manifestation of TB disease, with

a specific focus on identification and characterization of differentially culturable tubercle bacteria in the sputum

of TB infected individuals. In addition, he studies remodelling of the mycobacterial cell wall to identify new drug

targets. He is also involved in the development of next-generation diagnostic verification reagents for quality

assurance and verification of tuberculosis molecular diagnostics. Some of the reagents developed in his

laboratory are now being deployed in over 20 countries.

Gagandeep Kang, MD, PhD Executive Director, Translational Health Science and Technology Institute, Department of

Biotechnology, Government of India

Prof. Kang is Executive Director of the Translational Health Science and Technology

Institute, Department of Biotechnology, Government of India. She also is Professor of

Microbiology and Head of the Wellcome Trust Research Laboratory (WTRL), and Division

SPEAKER BIOGRAPHIES

60

of Gastrointestinal Sciences at Christian Medical College (CMC), Vellore. Over the past 20 years, Prof. Kang has

built a strong inter-disciplinary research and training program, where young faculty and graduate students are

mentored before embarking on independent research careers. She leads a multi-disciplinary research team that

conducts comprehensive and complementary studies in the description, prevention and control of diarrheal

disease using state-of-the-art tools in the laboratory, hospital and the field. Prof. Kang is an Associate Editor for

PLoS Neglected Tropical Diseases and Tropical Medicine and International Health, and serves on the editorial

board of Nature Scientific Reports as well. She is a Council Member of the International Society for Infectious

Diseases and an Independent Director of the Biotechnology Industry Research Assistance Council. Her

expertise in vaccines is underlined by her membership of the National Technical Advisory Group on

Immunization, the WHO's Global Advisory Committee on Vaccine Safety, and the WHO's Immunization and

Vaccine Implementation Research Advisory Committee, as well as chairing the WHO SEAR's Immunization

Technical Advisory Group.

Palwasha Y Khan Epidemiologist

Pasha Khan is a clinical epidemiologist and completed clinical training as specialist in HIV

medicine and Sexual Health in the UK in 2017 with a period of research training in Malawi

investigating Mycobaceterium tuberculosis transmission funded by the Wellcome Trust with

LSHTM (2012-2015). She is leading the baseline transmission survey, which is part of the

impact evaluation of Zero TB Karachi with IRD.

Purvesh Khatri, PhD Assistant Professor, Stanford University

Dr. Khatri is an electronics and communications engineer turned software developer

turned computational systems immunologist. He is an assistant professor in Institute for

Immunity, Transplantation and Infection and Division of Biomedical Informatics Research

in Department of Medicine at Stanford University. His research focuses on developing

methods for reusing and repurposing public data for translational medicine inexpensively

and faster than traditional translational approaches. His lab leverages heterogeneity present across independent

cohorts to better understand human immune system to develop novel diagnostics and therapies for

inflammatory diseases including autoimmune and infectious diseases, organ transplant, vaccination, and cancer.

Aarti Avinash Kinikar MD, MRCP Professor of Paediatrics and Neonatology

Dr Kinikar is Professor of Paediatrics and Neonatology at BJ Government Medical College,

Pune , India. She completed her MD at Grant Medical College Mumbai in 1988 and then

trained in UK for 5 years. She completed her MRCP (UK) -Paediatrics in 1995 and

Diplomat National Board - Paediatrics in 2005. Recipient of the prestigious Dr Dahanukar

– Best Medical Teacher Award in 2013 from Maharashtra University of Health Sciences, Nashik. Has been

awarded provisional patent for developing low cost indigenous Bubble CPAP during H1N1 pandemic in Pune,

India.She has been a Fogarty Scholar for HIV (2007) and TB (2014) Research at John Hopkins University,

Baltimore, USA. She has been the subject Principal Investigator (PI) for various Indo- US (NIH) clinical research

trials in Paediatric TB and HIV since 2000 in collaboration with John Hopkins University, Baltimore USA

( IMPAACT Network). She has several national and international research publications to her credit and

presented research papers at various National and International Conferences. She is a member on various State

SPEAKER BIOGRAPHIES

61

level Expert Committee’s on pediatric infectious diseases and also a National Master Trainer for various

National Health Programms. She has been an undergraduate and postgraduate teacher in Paediatrics and guided

several MD students for the past 20 years .She has mentored undergraduate students doing short term

research projects under ICMR,MUHS and also mentored students coming from Hopkins since 2000 at BJGMC,

Pune. Her area of research interest has been Paediatric Infectious Diseases – HIV,TB, Measles, Polio. She is also

heading the Thalassemia center and the Nutrition Rehabilitation center at BJ Government Medical College and

Sassoon Hospital, Pune.At Sassoon General Hospital, Pune she has been instrumental in establishing Pediatric

and Neonatal ICU, Thalassemia Unit, Nutritional Rehabilitation unit for Malnourished children, Human Milk

Bank, Early Intervention and Nutrition Clinic , dedicated HIV and TB OPD’s, etc over the past 17 years through

government funds and generous contributions from voluntary donors. This work was appreciated by the

Hospital and the Government , especially patient care during the H1N1 pandemic in Pune. Recently (2017) she

was awarded “BMJ South Asia Award for Best Maternal & Child Team of the Year” for pionieering work in

Human Milk banking.

Hardy Kornfeld, MD Professor of Medicine at the University of Massachusetts Medical School

US Co-Chair, RePORT INdia

Dr. Kornfeld is Professor of Medicine at the University of Massachusetts Medical School. A

graduate of Boston University School of Medicine, he completed internal medicine

residencies at University Hospital (Boston) and St. Luke’s Hospital (New York) followed

by subspecialty training in infectious diseases (St. Luke’s), pulmonary medicine (Boston University) and a

postdoctoral fellowship in molecular virology at the Harvard School of Public Health. Dr. Kornfeld is a physician-

scientist, practicing pulmonary and critical care medicine alongside research projects. His laboratory studies

macrophage cell death in TB and mechanisms of TB susceptibility in mouse models of diabetes. Clinical projects

include the Effects of Diabetes on Tuberculosis Severity study in Chennai (collaboration with Dr. Vijay

Viswanathan), an observational study of lung function in HIV/TB patients with IRIS (collaboration with the

Aurum Institute, South Africa) and he is developing a clinical trial proposal to test metformin as adjunctive

therapy in HIV/TB.

Vandana Kulkarni, MSc Laboratory Manager, BJGMC Clinical Research Site

Ms. Kulkarni has a master’s degree in microbiology and has completed the Professional

Development Program for Quality Assurance and Regulatory Affairs in Biopharmaceutical

Industry. She is Laboratory Manager at Byramjee Jeejeebhoy Government Medical College

Clinical Research Site (BJMC-CRS) in collaboration with Johns Hopkins University,

Baltimore, USA, where she has worked since September of 2004. During the last 14 years,

she has worked in the research laboratory providing lab support to NIH-funded ACTG and IMPAACT trials as

well other studies. She is responsible for the overall lab operations of the research which includes evaluates

personnel competency and proficiency as well as waste management, vendor development, and maintenance

contracts. her work profile also includes writing and revising all laboratory standard operating procedures

(SOPs), for training staff in new methodologies as required, and for ensuring that laboratory and staff operate

under Good Clinical Laboratory Practices. Additionally, my responsibilities include method/instrument

validations, periodic EQA evaluations and methodology improvements to ensure that quality control and quality

assessment programs are established and maintained, overseeing the specimen repository, coordination of

international shipping and documentation, responsible for lab readiness for annual audit to the Division of AIDS,

NIAID, NIH. Her prior experience includes quality control, microbiological testing, antibiotic and vitamin assays,

and toxicity and sterility testing in the pharmaceutical industry.

http://bwictu.jhu.edu/about-us/

SPEAKER BIOGRAPHIES

62

N. Pavan Kumar, PhD Post-doctoral Fellow, National Institutes of Health-National Institute for Research in Tuberculosis,

International Center for Excellence in Research (NIH-NIRT-ICER)

Dr. Pavan received his Bachelor’s Degree from the University of Madras in 2005 and

Master’s degree from Loyola College in 2007. Soon thereafter he began working at the

National Institute of Allergy and Infectious Diseases (NIAID) / National Institute for

Research in Tuberculosis (NIRT) International Center for Excellence in Research (ICER) program and formally

he began his doctoral studies in 2010, he got awarded PhD in Immunology at the National Institute for Research

in Tuberculosis (University of Madras affiliate) in 2015. Between 2007 and 2010, Pavan’s research was related to

elucidating the immune responses in both lymphatic filariasis and in tuberculosis. During his doctoral program

(PhD granted in 2015) his work focused exclusively on characterizing the T cell responses in pulmonary and

extra-pulmonary tuberculosis and how these responses are influenced by other co-morbidities (e.g. helminth

infection, diabetes mellitus). For the past 3 years, as a post-doctoral fellow, Pavan has been extending his work

on the immunology of tuberculosis with particular emphasis on the role played by Type 2 diabetes in altering the

responses to M. tuberculosis. He is on reviewer in various international reputed journals. He is the author or

coauthor of over 50 papers almost all of his publications have been in internationally recognized journals, some

of which include PLoS Pathogens, Nature, J Immun, J Infect Dis, Infect Immun, Immunology and PLoS NTD and

Pavan has received Bill and Melinda Gates Foundation Global Health Travel Award in 2011, 2013 and 2017 for

attending Keystone Symposia held in United States and Canada. He was also awarded with National Post-

doctoral Fellowship from Science and Engineering Research Board, Department of Science and Technology,

Government of India.

Jyoti Logani, MSc, PhD Scientist E, DBT


Dr. Logani working as Scientist E, in the Department of Biotechnology (DBT), Ministry of Science & Technology,

GOI. She has been working with the Medical Biotechnology Division of DBT since her joining in 2010. She is the

Programme officer for the Vaccine Development and TB R& D programmes of the Department. She has been

coordinating research activities in the area of Vaccine Research & Development through- Vaccine Grand

Challenge Programme (VGCP) & Indo-US Vaccine Action Programme (VAP). She is also involved in the

implementation of activities for the National BioPharma Mission: Industry-Academia Collaborative Mission for

Accelerating Discovery Research to Early Development for Biopharmaceuticals - “Innovate in India (I3)

Empowering biotech entrepreneurs &accelerating inclusive innovation” Mission being implemented by

Biotechnology Industry Research Assistance Council (BIRAC) - a Public Sector Undertaking of Department of

Biotechnology and Wold Bank. She obtained her M.Sc. from Post Graduate Institute of Medical Education &

Research (PGIMER) Chandigarh and Ph.D. degree from Department of Pediatrics AIIMS, New Delhi, India.

Before joining the department she has worked on ‘Evaluation of immune responses during Rotavirus infection’

and published research articles in national and international journals.

Jyoti Mathad, MD, MSc Instructor of Medicine, Weill Cornell Medical College

Dr. Mathad is an Assistant Professor of Medicine and Obstetrics & Gynecology in the the

Center for Global Health at Weill Cornell Medical College. She is also a faculty member at

the Johns Hopkins Center for Clinical Global Health Education. Her primary research

interests include the immune changes of pregnancy and how they affect the development of

tuberculosis (TB) in TB-endemic countries, such as India. Since 2010, she has been conducting research in Pune,

India, on the performance of immune-based latent TB diagnostics in pregnant women with and without HIV. She

SPEAKER BIOGRAPHIES

63

is now leading the PRACHITi study there, which is investigating the impact of pregnancy and HIV on the immune

response to M. tuberculosis. She is an investigator in the International Maternal, Pediatric, and Adolescent AIDS

Clinical Trials network (IMPAACT), and she is also the principal investigator on a study of the immune changes

of pregnancy and TB in Port-au-Prince, Haiti. Dr. Mathad completed her undergraduate studies in biology at

Cornell University and received her medical degree from Albany Medical College. She completed her internal

medicine residency at the University of Maryland, where she was chief resident. She returned to New York to

complete her fellowship in infectious diseases at Weill Cornell, where she also completed her masters in clinical

epidemiology.

Vidya Mave, MD, MPH Assistant Professor of Medicine, Johns Hopkins University

Executive Committee Member & Common Protocol Co-Chair, RePORT India

Dr. Mave is Director and Clinical Research Site (CRS) Leader of the Baltimore-

Washington-India Clinical Trials Unit (BWI-CTU) and Assistant Professor at the Johns

Hopkins School of Medicine. Based in Pune, India, at BJGMC, Dr. Mave directs operations

for the Indo-JHU clinical research enterprise. She runs the Pune-based Clinical Trials Unit

that is a part of the NIH-funded UM1 Baltimore-Washington India Clinical Trials Unit (BWI-CTU). The CTU is a

collaborative research partnership among BJGMC in Pune, India, Johns Hopkins School of Medicine in Baltimore,

Maryland, and Whitman Walker Health in Washington, DC, that conducts phase I, II, and III clinical trials of

therapeutic drug interventions for HIV and co-morbid infections, including TB and hepatitis, in adults (including

pregnant women) and children. The BWI-CTU is part of the world’s largest HIV therapeutic trial networks (the

AIDS Clinical Trials Group [ACTG] and the International Maternal Pediatric and Adolescent AIDS Clinical Trial

Network [IMPAACT]). She also leads several investigator initiated infectious disease studies funded by the NIH,

CDC, the British MRC, the Indian government, and private foundations. Dr. Mave’s research interests includes

comorbidities (diabetes, HIV) and the use of novel tools (Hair PK, whole genome sequencing, host biomarkers)

to study TB treatment outcomes. She also has initiated cohorts of antimicrobial resistance in India. In addition,

Dr. Mave has mentored more than 16 pre- and postdoctoral trainees from Hopkins and trainees participating in

the BJGMC-JHU HIV-TB Fogarty Research Training Program in India. Dr. Mave has more than 12 years of

combined experience in clinical practice, education, and research in infectious diseases and has published more

than 40 peer-reviewed research articles. Dr. Mave received an MD in medicine from Karnatak University,

Dharwad, India, and an MPH from Tulane University. She completed her internal medicine training at St.

Barnabas Hospital in New York, followed by a post-doctoral fellowship in infectious diseases at Tulane

University and Long Island Jewish Medical Center. Dr. Mave is board certified in internal medicine and infectious

diseases by the American Board of Internal Medicine.

Sanjay Mehendale, MBBS, MD, MPH Director and Scientist G, Indian Council of Medical Research, Government of India

Dr. Mehendale is Director (and Scientist G) of the Indian Council of Medical Research,

Department of Health Research, Govt. of India, New Delhi. He served as Director of the

National Institute of Epidemiology, Indian Council of Medical Research, Chennai from 2010

to 2015. His research career started began with a tenure of six years in the Division of

Epidemiology at the National Institute of Virology, ICMR in Pune, where he conducted field-based studies

related to dengue fever, Japanese encephalitis, hepatitis, measles, and hemorrhagic fevers. In 1992, he headed the

Division of Epidemiology and Biostatistics in the newly formed National AIDS Research Institute, ICMR at Pune,

India, and conducted pioneering cohort studies in high-risk populations that provided initial estimates of HIV

incidence, prevalence and an understanding about associated risk factors. He then led several clinical trials on

female-controlled HIV prevention options such as vaginal microbicides and female condoms. He was the

Principal Investigator of two pioneering HIV vaccine trials in India. Under his leadership, Clinical Trials Unit grant

SPEAKER BIOGRAPHIES

64

(NIH Grant No. 5U01AI069417) was awarded to National AIDS Research Institute. He is a recipient of many

national and international research grants, and was the Principal Investigator for the NIH-funded online bioethics

training program (NIH Grant No. 5R25TW007093-09) at NIE, Chennai. He is a member of many national and

international committees and joint working groups, and has served as Chairperson as well as Member of several

scientific committees, expert committees and ethics committees. Dr. Mehendale has published more than 180

papers in national and international journals.

Thuli Mthinaye, MPH Scientist & Project Manager, South African Medical Research Council, Pretoria, South Africa

Ms. Mthinaye has been involved in the conduct of clinical trials since 1994. She has grown with the Medical

Research council and presently is the unit manager supervising 50+ staff, the Principal investigator of two

projects, and co-investigator of 4 projects. She excels in clinical trial management and has been involved in

pharmacokinetic studies, early bacterial activity studies, and also operational research.

Dina Nair, MBBS, PGDPh, MHscPH Scientist C (Medical), Department of Clinical Research, National Institute for Research in

Tuberculosis

Dr. Dina Nair is currently working as Scientist in the Department of Clinical Research at

the ICMR -National Institute for Research in TB, Chennai since 2007. She is a graduate

from the Government Medical College, Thiruvananthapuram and has completed her

Masters in health sciences in public health from Annamalai University. At the National

Institute for Research in TB she is involved in Clinical trials and Operational research

studies focusing on the diagnosis, treatment and prevention of TB. Her priority research areas are in the field of

drug-resistant TB and pediatric TB. She has over 30 scientific publications in National and International journals.

Geeta Shrikar Pardeshi, MD Professor, Department of Community Medicine, Vardhman Mahavir Medical College and Safdarjung

Hospital

Dr. Pardeshi is Professor of Community Medicine at Vardhman Mahavir Medical College

and Safdarjung Hospital. She has led research projects related to Reproductive and Child

Health, Sanitation and Infectious diseases. Her research interests include TB epidemiology,

and the association of co-morbidities with clinical presentation and treatment outcomes in

tuberculosis.

Jane Pleskunas, MPH Senior Research Study Coordinator, Boston Medical Center

Data Management Working Group Co-Chair, RePORT India

Ms. Pleskunas is a Senior Research Study Coordinator at Boston Medical Center (BMC). In

her role since 2015, she is the lead data manager and coordinates clinical, laboratory and

operational procedures on protocols based at JIPMER Hospital in Pondicherry, India. Jane is

also the Data Management Working Group Co-Chair of the RePORT India Consortium. Prior

to her role at BMC, Jane worked at Novartis Vaccines in Global Medical Affairs.

SPEAKER BIOGRAPHIES

65

Vedam L Ramprasad, PhD Chief Operating Officer, Medgenome

Dr. Ramprasad is COO of Medgenome. He holds a master’s degree and a PhD from BITS,

PILANI. After his post doctoral training be worked for 6 years as a Scientist (molecular

genetics) at Vision Research Foundation, Sankara Nethralaya, Chennai, India and then

went on to work for 4 years at Spinco Biotech, India, handling Affymetrix and Illumina

technologies. He also worked as Principal Scientist at SciGenom Labs, Cochin, for a year.

He has 17 peer reviewed publications to his credit.

Divya Reddy, MD, MPH Assistant Professor, Albert Einstein College of Medicine/Montefiore Medical Center

Dr. Reddy is Assistant Professor at Albert Einstein College of Medicine/Montefiore Medical

Center. She received her medical degree from Padmashree Dr. DY Patil Medical College in

Mumbai, India. Her interest in tuberculosis research and its global impact lead her to pursue

a master’s degree in public health, which strengthened her background in study design, data

analysis and interpretation. During her fellowship in pulmonary and critical care medicine at

Boston University, she actively sought TB-related epidemiological projects under the

mentorship of Drs. Saukkonen, Ellner, Hochberg and Horsburgh. In collaboration with the Centers for Disease

Control and Prevention (CDC), she is studying the utility of Alanine transaminase Kinetics as a biomarker for

TB treatment related Hepatotoxicity. She has been working very closely with Drs. Ellner and Hochberg in the

Infectious diseases Division at Boston University to establish the Regional Prospective Observational Research in

Tuberculosis (RePORT) cohort (4000 Pulmonary TB cases and 8820 household contacts in 4 yrs) in

Pondicherry, India, in collaboration with Jawarharlal Institute of Postgraduate Medical Education and Research

(JIPMER). She is particularly interested in looking at the association of air pollution and tobacco use with

Tuberculosis within this cohort. She plans to use her experience thus far to develop translational research

projects looking at transcriptomic biomarkers with diagnostic, therapeutic and prognostic utility for TB infection

and disease under the mentorship of Drs. Jacqueline Achkar and Simon Spivack at Albert Einstein College of

Medicine.

Jyothi Rengarajan, PhD Associate Professor, Emory University

Dr. Rengarajan is an Associate Professor of Infectious Diseases at the Emory Vaccine

Center at Emory University in Atlanta where her laboratory focuses on the pathogenesis

and immune response to tuberculosis (TB) in animal models and humans. Her research

interests include understanding the mechanisms by which Mycobacterium tuberculosis

evades and modulates host immunity with the goal of identifying new targets for immune

therapeutics and vaccines. She conducts patient-based research studying human immunity to

latent and active TB in Atlanta as well as through international collaborations, to identify correlates of

protection and biomarkers of infection and disease. Jyothi is also involved in a Tuberculosis Research Unit

(TBRU) grant which seeks to identify antigen-specific T cell signatures associated with clearance or persistence

of Mtb in humans and nonhuman primates.

Dr. Gautam Roy Professor and Head, Department of Preventive and Social Medicine, JIPMER


SPEAKER BIOGRAPHIES

66

Roxana Rustomjee, MbChB, MMed, FCPhM, FRCP, PhD Senior Scientist, Tuberculosis Clinical Research Branch Therapeutics Research Program,

DAIDS/NIAID/NIH/DHHS


Dr. Rustomjee is currently a senior scientist at the Tuberculosis Clinical Research Branch

Therapeutics Research Program Division of AIDS/NIAID/NIH/DHHS and previously chief

specialist scientist, Office of TB and HIV Research Strategic Health Innovation Partnerships

South African Medical Research Council prior to being Senior Director of Clinical Strategy,

in the BioSciences Division of Emergent Biosolutions. Qualified as a medical doctor, she has been the recipient

of a Medical Research Council, Ford Foundation and Fogarty International Foundation scholarships and holds a

PhD in Epidemiology (Columbia University NY) and additionally a Fellowship in Public Health Medicine; Master

of Medicine in Public Health and Diploma in Health Service Management from the Nelson R Mandela School of

Medicine in KwaZulu Natal, SA. She is a fellow of the Royal College of Physicians, Edinburgh University UK. She

has played a leadership role in TB and HIV research and programme management with special expertise in public

health interventions and product development strategy of TB and/or HIV vaccines diagnostics and treatment.

She has extensive experience in research management including laboratories. As principal investigator of

multicenter research networks and as the South African lead in a global vaccine development initiative she has

accrued an impressive national and international network.

Padmini Salgame, PhD Professor of Medicine, Rutgers-New Jersey Medical School

Basic Science Working Group Co-Chair, RePORT India

Dr. Salgame is tenured Professor in the Department of Medicine, Division of Infectious

Diseases and the Centre for Emerging Pathogens at Rutgers-New Jersey Medical School.

Dr. Salgame is the Director of the MD/PhD Program and the Graduate Medical Research

Program at NJMS. She is also Program Director on a recently awarded T32 training grant. Dr. Salgame’s

research program has been continually funded by the National Institutes of Health. The core interests of her

laboratory are investigations of the host immune response to tuberculosis and in identifying biomarkers for risk

of progression to tuberculosis disease and treatment failure. She has several international collaborators and

conducts research studies in Brazil, India, South Africa and Uganda. Dr. Salgame has published extensively in

leading scientific journals and has presented her research work at several National and International meetings.

She has served on several NIH study section panels. She is on the Editorial Board of Infection and Immunity and

is Associate editor for PLOS Pathogens. Dr. Salgame has mentored masters, graduate and MD/PhD students, as

well as Postdoctoral researchers.

Dinakar M. Salunke, MSc, PhD Director, International Centre for Genetic Engineering and Biotechnology

Dr. Slunke is Director of International Centre for Genetic Engineering and Biotechnology.

He is an eminent immunologist and a structural biologist. He is the recipient of Shanti Swarup

Bhatnagar Prize for Science and Technology in the category of biological sciences (year 2000)

and Fellow of all major science academies in India. Salunke joined National Institute of

Immunology (NII), Delhi in year 1988 as staff scientist and worked until 2015[4] at (NII),

Delhi.[5] Since Nov 2015 Dr. Salunke is nurturing International Centre for Genetic Engineering and

Biotechnology as its Director. Previously he headed the newly established Regional Centre for Biotechnology, an

institution of education, training and research as its first Executive Director (year 2010-2015). He has also

served as Executive Director (additional charge) of Translational Health Science and Technology Institute

(THSTI), Delhi (year 2010-2011). For more than 3 decades, he has extensively worked in the field of

SPEAKER BIOGRAPHIES

67

immunology involving structural biology of immune recognition, molecular mimicry and allergy. Dr. Salunke has

received several medals, awards and fellowships both in India and overseas. He has been awarded coveted Shanti

Swarup Bhatnagar Prize for Science and Technology (Category –Biological Sciences,[6] Year 2000) from Council

of Scientific and Industrial Research (CSIR). He is fellow[7] of all the 3 major science academies in India e.g.

Indian Academy of Sciences (IAS), Bangalore; Indian National Science Academy (INSA), Delhi; National Academy

of Sciences, India (NASI), Allahabad. He was recently elected as Fellow of The World Academy of Sciences

(TWAS).

Buka Samten, MD, MS Associate Professor, University of Texas Health Science Center at Tyler

Dr. Samten currently holds an Associate Professor of Microbiology and Immunology

position at the University of Texas Health Science Center at Tyler, Texas. His research has

focused on understanding T cell immune responses against tuberculosis infection using

human primary immune cells isolated from the peripheral blood samples of tuberculosis

patients. He has shown that defects in cellular proteins contributes to the compromised T cell immune

responses against tuberculosis infection. Recently, he has shown that early secreted antigenic target of 6 kD

(ESAT-6) of Mycobacterium tuberculosis has the potential to suppress Th1 immune responses. His current

research focuses on dissecting the molecular mechanisms of interaction between immune cells and virulence

factors of Mycobacterium tuberculosis during tuberculosis infection.

Rajagopal Saranathan, PhD Lab Manager, Central Biorepository, National Institute for Research in Tuberculosis

Dr. Saranathan is Lab Manager at the Central Biorepository at the National Institute for

Research in Tuberculosis. His research interests include medical microbiology and

molecular epidemiology, genomics and virulence mechanisms in nosocomial pathogens.

His doctoral research was focused on exploring antibiotic resistance mechanisms in a

nosocomial pathogen, Acinetobacter baumannii. He is currently working on TB biomarker

research.

Amsaveni S, MVSc, PG Diploma Project Coordinator, JIPMER

Sonali Sarkar, MD Additional Professor, Department of Preventive and Social Medicine, JIPMER


Dr. Sarkar is an Additional Professor in the Dept. of Preventive and Social Medicine in

JIPMER, which is a Institute of National Importance in India. She is a co-investigator in

JIPMER for the site and common protocols under RePORT India consortium. She is also

the site principal investigator for RO1 grants by NIH, USA for projects titled ‘Impact of

pregnancy on Tuberculosis’ and Predictors of Resistance Emergence Evaluation in Multidrug Resistant-

Tuberculosis Patients on Treatment “PREEMPT” and other studies under the RePORT supplemental funding.

She is a member of the India TB Research Consortium constituted by ICMR, spearheading TB research in the

country. She is an active academician as undergraduate and postgraduate teacher, guide and mentor and also the

Chief Editor of International Journal of Medicine Public Health and Editor of Internal Journal of Advanced

Medical and Health Research.

SPEAKER BIOGRAPHIES

68

Dr. Sriram Selvaraju, MBBS, MPH Scientist C, National Institute for Research in Tuberculosis

Dr. Selvaraju is working in the Epidemiology unit of National Institute for Research in

Tuberculosis. He is involved in the conduct of TB prevalence surveys, monitoring and

evaluation of the TB control program and involved in teaching research methodology to

medical college faculty. He is also interested in understanding the transmission dynamics of

TB and design interventions for preventing the spread of TB.

Dr. Alka Sharma Adviser, DBT

Shri Vijay Bala Yogendra Shivakumar, MD Project Coordinator, JHU-India

Interim Coordinator, RePORT India

Dr. Shivakumar is a clinician and project coordinator for C-TRIUMPH at Johns Hopkins

University, India office. He recently joined the CCGHE team as an overall project

coordinator for C-TRIUMPH for both Chennai and Pune. His research interests are TB

infection transmission and its progression to disease. Dr. Shivakumar joined National

Institute for Research in TB in Chennai as a clinician and study coordinator for C-TRUIMPH,

an epidemiological study recruiting a cohort of TB patients and their household contacts and following their

health over a period of 2 years. This study includes multiple sample collection and storage for creating a TB

repository in developing multiple sub studies looking at bio-markers and factors influencing TB infection and

disease outcomes. After graduating medicine from Armenia, he underwent his clinical trainings in India to obtain

his medical license for the country. He worked as junior doctor and medical officer in department of medicine

both in urban and rural setting hospitals of the country.

Manjula Singh Scientist E, Indian Council of Medical Research


Dr. Singh works at the Division of Epidemiology and Communicable Diseases (ICMR), Indian Council of Medical

Research. She does research in Dermatology, Gynaecology and Infectious Diseases.

Urvashi Singh, MBBS, MD, PhD Professor and Chief of Tuberculosis Detection, Department of Microbiology, All India

Institute of Medical Sciences

Dr. Singh currently works at the Department of Microbiology, All India Institute of

Medical Sciences. Her research interests include Obstetrics, Gynaecology and

Infectious Diseases. She works on understanding the epidemiology and pathogenesis

of tuberculosis in India, molecular insights into spread of multidrug resistant tuberculosis in India, designing novel

SPEAKER BIOGRAPHIES

69

rapid detection methods for multidrug resistant tuberculosis, and rapid detection of rifampicin resistance and

spoligotypes from stained sputum smears. Her clinical work includes TB co-infections and co-morbidities &

other mycobacterial diseases, paediatric tuberculosis, and molecular diagnostics to aid clinical diagnosis and

treatment.

Sudha Srinivasan PhD, MPH Tuberculosis Clinical Research Branch, Therapeutics Research Program, Division of

AIDS/NIAID/NIH/DHHS


Dr. Sudha Srinivasan is a program officer at the TB clinical research branch at the Division

of AIDS at the National Institutes of Allergy and Infectious Diseases at the National

Institutes of Health. She manages a portfolio of grants and cooperative agreements in the

HIV/TB area. She is also the project officer for RePORT International and RePORT India, for the RePORT

consortium. She also serves as the project officer for projects for the H3 Africa Consortium, an Africa centered

genomics capacity building initiative. Dr. Srinivasan is a geneticist by training, but with over a couple decades of

professional experience in managing international projects and programs in public health (both private and public

sector).

Kalpana Sriraman PhD Research Officer, The Foundation for Medical Research

Dr. Sriraman is a Research Officer at The Foundation for Medical Research, Mumbai.

Kalpana has a diverse research experience in the fields of molecular biology,

biotechnology and mammalian biology. She completed her PhD from Indian Institute of

Technology-Madras and has more than 6 years of research experience in molecular

biology post her PhD. Her recent work focuses on understanding molecular changes associated with rapid

acquisition of multi-drug resistance in Mycobacterium tuberculosis and how that may be used to predict

patient’s response to tuberculosis treatment. She is also currently engaged in a Tata Trusts-India Health Fund

sponsored study on understanding mechanisms underlying infectiousness and hence transmission of tuberculosis

bacteria. The study primarily focus on understanding effect of early phase treatment with an aim to get insights

into infectiousness mechanisms.

Varadharajan Sundaramurthy, PhD Assistant Professor, National Center for Biological Sciences, Tata Institute of Fundamental

Research

Dr. Sundaramurthy is Assistant Professor, National Center for Biological Sciences, Tata

Institute of Fundamental Research. His research is looking at the host-pathogen

interface and forces that have shaped the contours of pathogenesis. The broad goal of

his lab is to understand the contours of these interactions at multiple levels by studying

the modulation of critical host pathways by pathogens and exploiting the potential of this knowledge for drug

discovery. In particular, he’s interested in understanding the modulation of host trafficking pathways by two very

different pathogens, namely Mycobacterium and Plasmodium, the causative agents of the deadly diseases

tuberculosis (TB) and malaria. Towards this, he is applying a combination of chemical genetics, quantitative image

analysis and high content screening tools together with conventional cell and molecular biological approaches.

SPEAKER BIOGRAPHIES

70

Nishi Suryavanshi, PhD Clinical Research Site Coordinator, JHU-Pune

Behavioral Science Working Group Co-Chair, RePORT India

Dr. Suryavanshi is Clinical Research Site Coordinator aor the BJGMC-CRS in Pune, India,

and a member of the faculty at the Johns Hopkins Center for Clinical Global Health

Education. Dr. Suryavanshi is a behavioral scientists whose research involves women’s

empowerment, reproductive health, and HIV and tuberculosis research in clinical settings

as well in urban and rural community settings. Dr. Suryavanshi has established extensive networks with regional

nongovernmental organizations (NGOs) and has developed and co-developed various behavioral projects

addressing health topics including stigma and tuberculosis, disclosure of HIV among children, infant feeding

patterns among HIV positive mothers, empowerment of women in low resource settings, and gender based

violence. During the past 12 years, she has overseen the clinical research studies related to HIV/AIDS in India.

As a clinical research site study coordinator her role includes developing patient education materials, informed

consent agreements, and treatment adherence and retention strategies. Dr. Suryavanshi was recently awarded a

CDC grant to enhance the capacity of outreach workers catering to HIV-infected pregnant women for the

uptake of PMTCT services using mHealth platform. She has presented her work at national and international

conferences, and has published study findings in peer reviewed journals. Dr. Suryavanshi attended the University

of Pune, Pune, Maharashtra, India, where she earned her BSc in zoology, her MSc in medical anthropology, and

her PhD in anthropology. Additionally, she is a graduate of the Johns Hopkins University Summer Institute of

Epidemiology and Biostatistics, where she studied the ethical issues related to human subjects research in

developing countries.

Sunita Taneja, MBBS, PhD Deputy Director, CHRD, SAS

Dr. Taneja is a community health researcher with vast experience in field and clinical trials.

Her research interests are vaccines, diarrheal diseases, child nutrition and micronutrient

deficiencies. Her skills include protocol development, coordinating field, laboratory and data

management activities and data analysis. In addition to being a Principal Investigator or

Coinvestigator on several trials, she also coordinates all activities of the data management

centre at CHRD, SAS.

Balamugesh Thangakunam, MD Professor, Department of Pulmonary Medicine, Academic Officer, Principal’s Office, Christian

Medical College, Vellore

Clinical Epi & Chex Xray Working Group Co-Chair, RePORT India

Dr. Thangakunam is currently works at the Department of Pulmonary Medicine, Christian

Medical College Vellore. His research interests include Pulmonology, Respiratory

Medicine, and Infectious Diseases. He is author of more than 70 articles, and is a recipient of ICMR’s Smt. Kamal

Satbir Award for significant contributions in bio-medical research 2006. He has worked in UK and trained in

Cardiopulmonary Exercise testing & Endobronchial ultrasound. He received training in interventional

pulmonology in University of Heidelberg, Germany.

Kannan Thiruvengadam Biostatistician, National Institute for Research in Tuberculosis (NIRT)

SPEAKER BIOGRAPHIES

71

Jeff Tornheim, MD, MPH Assistant Professor, Johns Hopkins School of Medicine

Dr. Tornheim, is Assistant Professor in the Division of Infectious Diseases here at Johns

Hopkins University School of Medicine. His research explores the application of new

diagnostic technologies to improved health outcomes in the treatment of drug resistant

tuberculosis among both adult and pediatric patients in India. Dr. Tornheim recently completed his infectious

diseases fellowship at Johns Hopkins, during which he worked with Drs. Amita Gupta, Vidya Mave, Bob Bollinger

of Johns Hopkins, and with Dr. Zarir Udwadia at the Hinduja Hospital in Mumbai. His interest in clinical

outcomes for underserved populations led him to practice in physician training environments in Bolivia, Peru,

South Sudan, Kenya, Uganda, Rwanda, South Africa, and the United States. Dr. Tornheim completed a clinical

fellowship in infectious diseases in June 2017. Prior to that he completed residencies at Yale University in both

internal medicine and pediatrics. He received an MD/MPH from Mount Sinai School of Medicine, with his thesis

evaluating the impact of water policy on rates of pediatric diarrhea in Bolivia. After completing undergraduate

studies in International Development and Economics at Brandeis University he moved to East Africa where he

engaged in health system strengthening for returning refugees to South Sudan and worked with the Centers for

Disease Control and Prevention (CDC) on the epidemiology of pneumonia and diarrhea in Western Kenya. At

the same time he worked at the Bureau of TB Control for the Department of Health and Mental Hygiene and

was actively engaged in the operations of an East Harlem free clinic. As a Fogarty International Clinical Scholar,

he spent 2 years in rural Bolivia establishing and managing operations for a Chagas Disease treatment program.

Srikanth Tripathy, MBBS, MD Scientist G & Director in Charge, National Institute for Research in Tuberculosis (NIRT)

Dr. Tripathy has been a physician working for the Indian Council of Medical Research

(ICMR) since 1986 involved with research on TB in HIV infected individuals in the Pune

region. He has also been involved in research related to leprosy, TB, and HIV in the Agra

region in north India. Prior to becoming NIRT Director, Dr. Tripathy worked as the Head of

the HIV Laboratory.

Zarir Udwadia, MBBS, MD, MRCP, DNB Consultant Chest Physician, Hinduja Hospital


Dr. Udwadia is a consultant chest physician at the Hinduja Hospital, Mumbai with a

special interest and expertise in drug-resistant tuberculosis. About 8000 patients pass

through his busy clinics annually, including difficult MDR cases referred by colleagues from across India. He has

been invited to give guest orations before the BTS, ERS, ATS, IUATLD, ACCP, Harvard School of Public Health

and the Royal Society of Medicine, London. He has over 140 PubMed publications and 7000 citations to his

credit and is co-author of "Principles of Respiratory medicine" published by Oxford International. He was the

sectional-editor for Tuberculosis for the journal Thorax. His publication of the first Indian patients with Totally

Drug Resistant TB attracted intense media and medical interest from across the globe, and featured on the front

pages of the WSJ, NY Times, Time, BBC and CNN, and served to galvanize great change in the community. This

lead to an invitation to give a TED talk on MDR-TB in 2016, which has been viewed over 100,000 times.

SPEAKER BIOGRAPHIES

72

Vijaya Valluri, PhD Scientist, Bhagawan Mahavir Medical Research Centre

India Co-Chair, RePORT India

Dr. Valluri is a Scientist at Bhagawan Mahavir Medical Research Centre (BMMRC) in

Hyderabad, India focused on immunologic and genetic aspects of mycobacterial diseases,

leprosy, and tuberculosis (TB). Her work has involved evaluating the efficacy of BCG vaccine

and investigating in vitro correlates of protection in the context of these diseases. Dr. Valluri is the RePORT

India Principal Investigator for BMMRC and serves as a co-chair for the consortium’s Executive Committee.

Over the past six years, Dr. Valluri has collaborated with University of Texas scientist, Dr. Ramakrishna

Vankayalapati, to study the role of NK (natural killer) cells, monocytes and T regulatory cells in conferring

protection to TB. Earlier in her career, she received the Young Scientist award from the Ministry of Science and

Technology and completed fellowships both within India and abroad. Dr. Valluri has an MSc in Genetics and a

PhD in Immunogenetics from Osmania University in Telangana, India.

Krishna Vankayalapati, PhD Chair, Pulmonary Immunology and Margaret E. Byers Cain Chair for Tuberculosis Research,

University of Texas Health Science Center at Tyler

Executive Committee Member & Basic Science Working Group Co-Chair, RePORT India, RePORT

India

Dr. Vankayalapati received his PhD degree from Osmania University, India. He joined the

University of Texas Health Science Center at Tyler in 1999 after completion of his first

postdoctoral fellowship at the Toronto General Hospital, University of Toronto. He was promoted to

Instructor in 2001, Assistant Professor in 2004, Associate Professor in 2007, and Professor in 2013. He is

currently serving as Chair, Department of Pulmonary Immunology and Margaret E. Byers Cain Chair for

Tuberculosis Research.

Vijay Viswanathan, MD, PhD, FRCP Head & Chief Diabetologist, MV Hospital for Diabetes; Prof M Viswanathan Diabetes Research

Centre, WHO Collaborating Centre for Research Education and Training in Diabetes


Dr. Vijay Viswanathan is a Diabetologist, General Physician and Internal Medicine in Adyar,

Chennai and has an experience of 28 years in these fields. He practices at MV Hospital for

Diabetes in Adyar, Chennai, MV Centre For Diabetes in Velachery, Chennai, and MV Hospital for Diabetes &

Diabetes Research Centre in Royapuram, Chennai. He completed MBBS from Stanley Medical College &

Hospital , Chennai in 1988,MD - Internal Medicine from Kasturba Medical College in 1991 and FRCP from Royal

College Of Physician, London in 2010. He is a member of Indian Medical Association (IMA).

73

Acknowledgements

Planning Committee & Event Coordination Vaishali Adkar, PPD

Nandita Chopra, US National Institutes of

Health, Delhi

DJ Christopher, CMC Vellore

Samyra Cox, Johns Hopkins University

Amita Gupta, Johns Hopkins University

Gail Jessop, Johns Hopkins University

Hardy Kornfeld, UMass Medical School

Jyoti Logani, Department of Biotechnology,

Government of India

Roxana Rustomjee, US National Institutes of

Health/National Institute of Allergy and

Infectious Diseases/Division of AIDS

Dinakar M Salunke, ICGEB

Sudha Srinivasan, US National Institutes of

Health/National Institute of Allergy and

Infectious Diseases/Division of AIDS

Chengappa Uthappa, US National Institutes of

Health, Delhi

Vijaya Valluri, Bhagawan Mahavir Medical

Research Centre

Conference Manual Managing Editor

Samyra Cox, Johns Hopkins University

Data Tables

Shri Vijay Bala Yogendra Shivakumar, Nikhil Gupte, JHU Pune; Jane Pleskunas, Boston Medical Center; Karthik

Jutur, PPD

Design

Molly Bowen, Johns Hopkins University

Special Thanks Department of Biotechnology, Government of India, graciously hosted the event.

Department of Biotechnology, US National Institutes of Health, Indian Council of Medical Research, and the

Indo-U.S. Vaccine Action Program provide support, guidance, and sponsorship to the consortium.

RePORT India study coordinators and data managers provided valuable contributions to the presentations and

conference manual.

RePORT India investigators and external speakers delivered excellent presentations during the event.

ICGEB leadership shared their beautiful campus with our group.

Documents

RePORT India...RePORT INDIA OVERVIEW 2 Parent Protocol data and samples at their respective India-based institutions. Below are the CRUs and their Parent Protocols: 1. BMMRC and U